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ABSTRACT
Breast cancer overall is the second most common cause of cancer related death
in women, with one in eight women being diagnosed during their lifetime. Breast cancer
itself is divided into subtypes based on the expression levels of the hormone receptors
including the estrogen receptor (ER) and the progesterone receptor (PR), as well as
expression of the growth factor receptor epidermal growth factor receptor 2 (HER2).
ER+ breast cancer is the most common breast cancer diagnosis, and these tumors are
defined as being initially dependent on activation of the receptor for growth. Based on
this, targeted endocrine therapies (ETs) have been designed to inhibit the ER to block
the growth of these tumor cells. Overall, ETs are highly effective as they are associated
with better outcomes and lower rates of recurrence than non-targeted therapies.
However, long term recurrence rates in these patients still remain high and are relatively
unchanged during the 5 years a patient undergoes ET compared to the following 5
years of no treatment. This suggests that in a subset of patients that experience
recurrence, ET alone may be insufficient to prevent cancer recurrence.
Tumor initiating cells (TICs) are one cell type thought to contribute to recurrence
in ER+ breast cancer. This is thought to be due to the persistence of these cells during
ET, as they express relatively low levels of the ER and are hence intrinsically resistant
to their anti-ER effects. Thus, although TICs make up a relatively small percentage of
the tumor cell population, they remain within the tissue and overtime can recapitulate
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formation of a heterogeneous, aggressive tumor. TICs in ER+ breast cancer were
shown to be dependent on NOTCH signaling, and it was illustrated that ET increases
activation this pathway. Hence ET is thought to select for TICs by increasing NOTCH
signaling. To prevent this, pharmaceuticals that inhibit NOTCH activation like γsecretase inhibitors (GSIs) were developed for clinical use in combination with ETs. The
hypothesis being ET will inhibit growth of the ER-dependent bulk tumor cells, and the
GSI will inhibit TIC-survival. Preclinical results were promising, however the side effect
profiles in patients made the use of GSIs in the clinic sub-optimal. Ultimately these
findings indicated there was still a need for therapeutics that prevent TIC-survival in
ER+ breast cancer.
In a recent biomarker clinical trial, we identified a reported transcriptional
repressor, DAXX, as a potential new target to prevent TIC-survival. Additional
experiments indicated that DAXX was dependent on ER activation for its protein
expression, thus under ET conditions, DAXX protein was depleted. Further, DAXX was
shown to be required for ER restriction of TIC-survival and NOTCH signaling, and under
ET conditions, overexpression of DAXX is sufficient to have the same effect. Together
these findings suggested that DAXX was a bonafide repressor of TICs. Moreover, a
therapeutic regimen that includes ET + a DAXX promoting agent may improve
outcomes in patients with high risk of recurrence. We have illustrated that ET + partial
agonists of the ER are sufficient to increase DAXX protein levels and decrease TICsurvival, without stimulating ER-dependent bulk tumor cell proliferation. Further, we
have demonstrated both DAXX and the ER were required for these anti-TIC effects.
Overall our results suggest that combination therapy of ET + a DAXX promoting agent
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represents a novel strategy to prevent TIC-survival, and ultimately improve outcomes in
a subset of ER+ breast cancer patients.
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CHAPTER ONE
REVIEW OF LITERATURE
ANATOMY AND DEVELOPMENT OF HUMAN BREAST TISSUE
The breast tissue in both males and females is an endocrine organ that comprises 3
main compartments, which include mammary epithelial cells, adipose tissue, and
connective tissue [1, 2]. From birth until puberty, these mammary glands are essentially
identical in both sexes, and consist of a tree-like structure of ducts [3, 4]. However,
differences between male and female breast tissue begin to arise when females enter
puberty and undergo Thelarche, or the onset of breast development [3, 4]. This is
categorized by a surge in the production of the steroid hormones estrogen and
progesterone by the ovaries in combination with pituitary release of somatotropin,
(human growth hormone), resulting in mammary gland formation within the female
breast. The resulting mammary gland is comprised of a network of ducts and 15-20
lobes that are divided into 4 lobules [1, 2]. It is these lobes that produce milk in adult
females following pregnancy, while the ducts carry milk to the nipple [1, 2]. Complete
breast development occurs during pregnancy in which the mammary gland enlarges
due to cell proliferation and differentiation in response to hormones estrogen,
progesterone, prolactin, somatotropin from the mother as well as hormones secreted by
the placenta of the developing fetus [5]. Following birth of the baby, the mammary gland
promotes milk production [5]. Conversely during menopause, there is a reduction in
mammary gland size and volume due to atrophy of the ducts and lobules and deposition
1

2

of fat and stromal tissue [6]. This is due to a decrease in estrogen and progesterone
levels within the female host, leading to cell death of the mammary epithelial cells [6].
Stem cells located in the breast are thought to be essential for the process of mammary
development during both puberty and pregnancy [7, 8]. It is these stem/progenitor cells
that give rise to two distinct epithelial cell types including luminal cells (ductal and
alveolar subtypes) and myoepithelial cells (basal subtype) [7, 8]. Evidence of progenitor
mammary stem cells has been shown in mice as serial dilutions of transplanted
mammary epithelial cells are able to give rise to the entire mammary gland [8]. Further,
it has been shown in vitro that human mammary glands contain progenitor cells and
they are able to give rise to both the luminal and myoepithelial cell subtypes [9-11].
Although the exact mechanism is still highly debated, there is evidence that cancers,
including breast cancer, arise from abnormal functioning of these progenitor cells [1216]. This can be due to genetic mutations or environmental insult to the relatively small
amount of progenitor cells that exist within the mammary gland.
BREAST CANCER AND ITS RISK FACTORS
Breast cancer is the second most common cause cancer-related death amongst
women worldwide [17]. The American Cancer Society estimates there will be 252,710
cases of invasive breast cancer this year [18]. Overall, nearly 1 in 8 women will be
diagnosed with breast cancer in their lifetime [17]. Breast cancer itself can form from
any of the major tissues of the breast. These include the breast lactiferous ducts (ductal
carcinoma) or the lobules (lobular carcinoma), with ductal carcinoma representing about
80% of breast cancer diagnoses, and lobular representing 10% [20]. Additionally the
grade and stage of a new breast cancer diagnosis is determined via histopathology,
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where grade indicates the amount of disorganization occurring within the individual
tumor cells, and stage indicating the degree of invasiveness of the disease [21].
A number of risk factors are associated with breast cancer. These include and
are not limited to patient age, time of menarche, time of first birth, obesity, alcohol and
tobacco use, physical activity, and family history (genetic risk factors) [22]. For example,
high use of alcohol (2-5 drinks/day) increases ones risk of breast cancer by 1.5 times
[22]. Further, post-menopausal patients that are overweight or obese have a higher risk
of breast cancer [22]. This is thought to be due, in part, to the higher amounts of
estrogen that are reported in these patients, produced by the excessive adipose tissue
both within the mammary gland and systemically [22].
Age and environmental factors are a large contributor to the development of
breast cancer, however there are also clear genetic factors/relationships that exist in the
development of the disease. In less than 5% of women, the development of breast
cancer is associated with mutations in two highly penetrant tumor suppressor genes:
Breast Cancer Associated 1 (BRCA1) and 2 (BRCA2) [23, 24]. Mutations in either of
these genes leads to a lifetime risk of breast cancer development approaching 80%
[25]. As the BRCA1/2 genes encode for proteins that normally contribute to DNA repair
during the cell cycle, loss of function of these genes leads to improper DNA repair
leading to accumulation of mutations within the affected cell, facilitating its
transformation into a cancer cell [23, 24]. Other genetic mutations detected in breast
cancer include TP53, PTEN, PALB2, PMS2 CDH1, MSH6, ATM, and BARD1
[breastcancer.org].
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SUBTYPES OF BREAST CANCER
Breast cancer is not considered a single disease, but rather a group of diseases
or subtypes that occur within the same tissue. Currently there are 18 subtypes of breast
cancer that have been defined based on their cell of origin and include tubular,
medullary, mucinous and papillary carcinoma [26]. However, breast cancer is typically
divided into five main distinct molecular subtypes, each with their own distinct biological
features and thus course of treatment and associated clinical outcomes [27]. These 5
molecular subtypes include:
I. HER2+ Breast Cancer
II. Triple Negative Breast Cancer
III. Normal-like Breast Cancer
IV. Luminal A Breast Cancer
V. Luminal B Breast Cancer
HER2+ BREAST CANCER
Approximately 15-25% of newly diagnosed breast cancer are considered
Epidermal Growth Factor Receptor 2 positive (HER2+). They are defined as having an
overexpression or gene amplification of ERBB2 on chromosome 17q12, causing an
increased transcript expression of the gene by up to or greater than twenty-fold
compared to normal breast tissue [28, 29]. Overexpression of HER2 is sufficient to drive
oncogenesis and is considered a true proto-oncogene in breast cancer [29]. These
tumors however are negative for overexpression of the estrogen and progesterone
hormone receptors, and thus are not dependent on their activation for growth [30].

5

HER2+ tumors tend to be of high histological grade upon diagnosis, with 71% of
patients having mutations in TP53 [31, 32]. Due to these features they are associated
with early relapse, high rates of recurrence, and high rates of metastasis [30]. This is
reflected in poor overall prognosis in patients that have metastatic HER2+ disease, with
a survival probability of 0.55 (55%) 20 years after diagnosis [33]. As HER2
overexpression does not occur in normal, healthy tissues, it is considered an ideal
candidate for targeting this subtype of breast cancer. First line therapies designed to
target HER2 include the monoclonal humanized, antibody trastuzumab and the
EGFR/HER2 tyrosine kinase inhibitor, lapatinib [33]. Although these therapies improve
clinical outcomes, 10-15% of women acquire resistance during therapy, with most of
these being patients diagnosed with metastatic disease when treatment is initiated [34,
35].
TRIPLE NEGATIVE BREAST CANCER
The Triple Negative Breast Cancer (TNBC) subtype comprises nearly 15-20% of
all breast cancer diagnoses [30]. These tumors are defined as lacking the estrogen and
progesterone receptors, while also expressing wild type or normal levels of HER2 [30].
Thus, therapies that target the hormone receptors or HER2 are ineffective against these
tumors [30]. TNBC tumors are also referred to as basal-like tumors, as they express
markers associated with basal cells or myoepithelial cells including cytokeratins (CKs)
5, 6, 14, and 17, p-cadherin, fascin, and caeolins 1 and 2 [36-38]. Although most of
these tumors are basal-like, there exists a defined small subset that exhibit luminal,
mesenchymal, stem-like, and/or androgen receptor positive properties [36, 39] These
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TNBC tumors are highly proliferative, metastatic, and have a high rates of TP53 (85%)
and BRCA1 (75%) mutations [30, 32, 40].
TNBC has the worst prognosis of the breast cancer subtypes due to the lack of
targeted therapy. Current therapeutic regiments include chemotherapeutic agents that
target rapidly dividing cells [41]. These therapeutics are associated with many adverse
side effects due to off targeting of rapidly dividing, healthy tissues including hair follicles
(alopecia), bone marrow (host immunity inhibition or bone marrow failure), and
gastrointestinal tissues (gastrointestinal disturbances) [41]. Use of poly-ADP-ribose
(PARP) inhibitors in the targeting of basal-like TNBC are currently being investigated
and show promise [42, 43]. The rationale being inhibition of PARP targets tumor DNA
repair, resulting in accumulation of damaged DNA, leading to cell cycle arrest in G2/M
phase of the cell cycle and subsequent apoptosis [42]. Conversely, further classification
of TNBC subtypes has led to the use of other targeted therapeutics in the treatment of
the different subtypes of the disease. For example, the immunomodulatory subtype of
TNBC is classified by its high levels of immune cell trafficking and signaling within the
tumor microenvironment [36, 45]. Thus recent attempts have been made to alter the
immune cell populations within the tumor to potentially treat the disease [36].
Additionally, the mesenchymal and stem-like TNBC subtypes are classified by their high
expression of mesenchymal markers including TWIST, SNAI2 (SLUG) and ZEB1 as
well as the claudin-low gene signature (Claudin 3, 4, 7) [36]. As these tumors exhibit
sensitivity to the inhibition of the mechanistic target of rapamycin (mTOR), use of the
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Phosphatidylinositol 3 Kinase (PI3K)/mTOR inhibitor NVP-BEZ235 is currently being
investigated [45].
NORMAL-LIKE BREAST CANCER
As suggested by its name, normal-like breast tumors share gene expression
patterns to that of normal cells that make up the breast tissue including adipose and
myoepithelial cells [37]. However, like TNBC, Normal-like breast cancer tumors lack
detectable overexpression of the common targets in breast cancer, namely the hormone
receptors and HER2 [31]. Because of this, some consider it to be a part of the TNBC
subtype, as these tumors tend to express basal cell markers [31, 37]. Others do not
consider it a subtype at all, instead hypothesizing it could be the Luminal A subtype that
has been contaminated with normal breast cells during histopathological and gene
expression analysis [46, 47]. As normal-like breast cancer is not an extensively studied
subtype of breast cancer, its clinical significance, potential targeted therapies, and
pathogenesis are unclear [48]. The clinical prognosis of this subtype tends to be better
than that of TNBC basal-like tumors, but these tumors do not typically respond to
neoadjuvant chemotherapy [28, 48].
ESTROGEN RECEPTOR+ BREAST CANCER
Nearly 75% of breast cancer diagnoses express the Estrogen Receptor (ER)
and/or the Progesterone Receptor (PR) and thus are considered ER+ breast cancer
[47]. These tumors are initially dependent on ER signaling for their growth, and typically
overexpress a number of ER-responsive genes [47]. These include PGR and luminal
epithelial cell markers such as GATA3, E-cadherin and pS2 [47]. Further, gene
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expression analysis of these ER+ breast cancer tumors led to the classification into two
separate luminal subtypes which are referred to as Luminal A and Luminal B breast
cancer [49]. This was then validated by independent groups [50, 51].
Luminal A. Luminal A Breast Cancer is the most common subtype of breast
cancer diagnoses overall, accounting for nearly 60% of all new cases [52]. It is
classified as being ER alpha positive (ERα+) and having low/normal levels of HER2
and/or low Ki67 staining (a marker of cell proliferation) [47, 52]. Being of their Luminal
origin, these tumors express CKs 8 and 18, as well as other ER-responsive genes
including Forkhead Box A1 (FOXA1), X-box binding protein 1 (XBP1), GATA binding
protein 3 (GATA3) and low expression of basal markers such as CKs 5 and 6 [52].This
subtype of breast cancer has the best prognosis compared to any other subtype of
breast cancer [33]. Patients with this subtype of breast cancer typically present with
tumors of low histological grade, and lower rates of metastasis when compared to the
more aggressive basal-like subtype [53]. Common mutations that occur in this subtype
include those associated with kinase signaling cascades like PI3KCA (49%) and
MAPK3K1 (14%), maintenance of genome integrity (TP53, 12%), and cell differentiation
(GATA3, 14%) [TCGA Research Network: http://cancergenome.nih.gov/].Targeted
therapies for Luminal A Breast Cancer are designed to inhibit activation of ERα, and are
commonly referred to as Endocrine Therapies (ETs) [33]. One problem of clinical
concern however is the high rates of resistance within this subtype, with nearly 50% of
patients with metastatic disease developing resistance during the course of ET [54, 55].

9

Luminal B. The Luminal B subtype of breast cancer accounts for approximately
15% of new breast cancer diagnoses [56]. Similar to the Luminal A subtype, Luminal B
tumors are derived from the ducts of the luminal epithelium within the mammary gland
and are associated with high expression of the ERα and its target genes [56]. Thus,
these tumors also lack expression of basal markers such as CKs 5 and 6, but tend to
express epithelial markers including CKs 8 and 18, FOXA1 and GATA3 [57]. The
distinct difference that separates Luminal B from Luminal A tumors is their high
proliferative index, which is associated with high levels of Ki67 expression and/or high
expression of HER2 within the tumor tissue [30]. Due to this increased proliferative rate,
Luminal B tumors tend to be more aggressive than Luminal A tumors [58]. Current
treatment strategies include combination therapies consisting of ETs and anti-HER2
therapies in the form of trastuzumab or lapatinib [35, 59]. The addition of chemotherapy
to the regiment has also been explored [60]. Specifically, in a subset of patients that
reported low ER expression and a high recurrence score as determined by the 21-gene
OncotypeDX gene-based analysis, were shown to benefit by addition of chemotherapy
[59]. This combination treatment strategy however has only resulted in modest success
in outcomes, as the five-year disease free survival remains around 50% [30, 31]. This is
thought to be due, in part, to the 81% rate of recurrence patients treated with antihormonal or anti-HER2 therapies [30, 31].
Models of ER+ Breast Cancer. Four principle ER+ cell lines currently exist and
are used consistently in studies modeling ER+ Breast Cancer. These include ZR-75,
T47D, MCF-7, and BT-474 cell lines [61].
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The ZR-75 cell line was derived and characterized in 1978 from a postmenopausal 63-year-old female with metastatic ductal carcinoma [62, 63]. It was
derived from an ascites three months after initiation of tamoxifen and is responsive to
hormones that include estrogen and insulin [62, 63]. The cells are epithelial in
morphology and express epithelial markers including E-cadherin [63]. They are ERα+,
PR+, glucocorticoid receptor positive and androgen receptor + [63]. Their growth is
stimulated by estrogen, and inhibited by therapeutics that inhibit ER-activation such as
tamoxifen or fulvestrant [63]. Their growth is also stimulated by insulin and inhibited by
androgens and glucocorticoids [62].
The BT-474 cell line is an ERα+, PR+, HER2+ epithelial cell line derived from a
60 year-old female with ductal breast carcinoma [64]. Thus, these cells are a model of
Luminal B Breast Cancer [64]. Their growth is stimulated by estrogen, and targeted
therapies against either the ER or HER2 inhibit their growth [64].
The T47D cell line was derived and characterized from a 54 year-old female with
invasive ductal breast carcinoma in 1979 [65, 66]. They are ERα+, PR+, androgen
receptor+, and glucocorticoid receptor+ and are epithelial in morphology [65]. Unlike
other ER+ cell lines, T47D cells have increased ER expression under estrogen-rich
conditions, while estrogen-free medium results in decreased expression of ER [66].
Long-term estrogen deprivation of this cell line results in permanent loss of ER, which
occurs in roughly 1/4 of ER+ breast cancer patients following ET [66, 67]. Additionally,
they express a mutant TP53 [65].
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The MCF-7 cell line is an ER+, PR+ cell line derived from the pleural effusion of
69 year-old female with adenocarcinoma of the breast [68, 69]. These cells are
epithelial in morphology, are responsive to estrogen, and their growth is inhibited by
antiestrogens that block ER activation [69, 70]. This is the most widely used ER+ Breast
Cancer cell line in modeling the disease in vitro.
Although these ER+ cell lines are of significant value in studying ER+ Breast
Cancer, they possess significant limitations due in part to their lack of heterogeneity,
which is compounded following clonal selection of multiple passages of these cells [71].
Patient-derived xenografts (PDXs) are a relatively new model for investigating ER+
Breast Cancer [72]. These are tumor lines originally derived from human patient
samples that are propagated and maintained in murine hosts, thus eliminating the
selection pressures of cell culture [72]. Their gene expression profile matches that of
human ER+ Breast Cancer tumors and importantly both ET-sensitive and ET-resistant
clones exist [73-75]. Additionally they tend to be more heterogeneous than the above
mentioned cell lines, thus better modeling the human disease [73-75].
The ER in ER+ Breast Cancer. The relationship between hormones and breast
cancer was first reported at the end of the 19th century, in which removal of a breast
cancer patient’s ovaries resulted in regression of their tumor [76]. Confusion resulted
however when only 1 in 3 women reported reduction in breast tumor growth following
this oophorectomy therapy [77, 78]. This discrepancy became clear when the ER was
discovered in 1962 [79]. Following its discovery, the ER was used as a predictor of
response to ovarian ablation, with patients containing ER+ tumors responding better
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than ER- tumors [79]. Research over the last 50 years however has led to an enriched
understanding of the structure, function, and isoforms of the ER, which has had vast
clinical implications.
Structure and function of the ERs. The ERs are members of the nuclear
receptor superfamily, a group that contains the thyroid receptor, vitamin D receptor,
retinoic acid receptor, glucocorticoid receptor, androgen receptor, progesterone
receptor and mineralocorticoid receptor [80]. Two isoforms of the ER have been
categorized, ERα, which was cloned from MCF-7 cells in 1985, and ERβ, which was
amplified from rat prostate tissue by polymerase chain reaction (PCR) and later cloned
from human tissue [81-83]. These two isoforms are distinct, with ERα encoded on
chromosome 6 and ERβ encoded on chromosome 14 [84]. Although these two
receptors share similar domains with each other, they are in fact structurally distinct
proteins (Figure 1). The receptors themselves contain 6 major domains that are labeled
as domains A-F. Within the A/B domain is the activation function 1 (AF1) site, which is
responsible for the constitutive activation of the ER [85]. In terms of homology when
comparing ERα and ERβ, this is one of the least conserved regions, which is supported
by reports that ERβ has low AF1 activity [86]. Conversely, the C domain, which contains
the DNA binding domain, is highly conserved between the two isoforms. Thus, these
receptors tend to recognize similar DNA target sequences (5′- GGTCAnnnTGACC-3)
known as estrogen response elements (EREs) within the genome [87]. The D domain,
or hinge region has relatively low levels of conservation between ERα and ERβ
isoforms [85]. This region contains one of the nuclear localization signals that exist in
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both ER isoforms [85]. The E domain of the ERs contain the ligand binding domain, the
AF2 domain, and dimerization domain of the receptors, which share 53% amino acid
sequence homology [80, 85]. A number of ligands are sufficient to bind this region
leading to activation of AF2 and propagation of ER signaling [80]. Under normal
conditions in humans, the primary ligand that binds both ERs is estrogen, specifically its
active form 17β-estradiol (E2) [88].

FIGURE 1: STRUCTURE OF ERS Α AND Β. Pictorial representation of the ER
isoforms. Amino acid number (AA#) refers to the amino acid position within the
polypeptide chain and its association with each domain of the receptor. Each isoform
contains 4 major components, the activation function 1 (AF1), DNA binding, Hinge, and
activating function 2 (AF2, Ligand binding) domains. AF1 is a constitutive activating
function and contributes to the transcriptional activity of the ER. The hinge domain
contains the nuclear localization signal of the ERs. Ligands, including E2, bind the AF2
region allowing ligand-dependent activation of transcription. The homology % is the
comparison of similarity between the alpha and beta ERs as reported by Ogawa et al.
1998 [85].
The affinity of E2 for the ER varies slightly between the isoforms, with ERα and
ERβ having KD values of 0.6nM and 0.24nM, respectively [88]. More obvious
differences arise when comparing the individual receptor affinities to other ligands
including antagonists used for ET and partial agonists like natural plant-derived
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phytoestrogens [88]. Affinities of the individual receptors for specific ligands are
summarized in Table 1. These values were determined as a concentration of a binding
competitor to reduce the specific radio-ligand binding by 50% [88]. Interestingly,
although affinity for E2 is similar by relative binding affinity assessment, ERβ tends to
have a higher affinity for antiestrogens as well as phytoestrogens compared to ERα
[88]. Although it is ultimately unknown, this may have distinct consequences in terms of
how patients respond to currently used therapeutics, and also may provide rationale for
use of non-standard therapies in subsets of patients.
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Table 1: Ki (nM) of various compounds for ERs
Compound

ERα

ERβ

E2

0.13

0.12

4-OHT (Tamoxifen)

0.1

0.04

ICI 164,384

0.2

0.08

0.04

0.05

2.6

0.3

(Fulvestrant)
Diethylstilbestrol
(DES)
Genistein
(phytoestrogen)

During the process of ER activation and downstream signaling, phosphorylation
at one or more specific serine/threonine residues can occur [89, 90]. ER
phosphorylation at mainly serine residues are typically associated with ligandindependent signaling, thus creating a cross-talk between the ER and other cell
signaling pathways [89, 90]. A number of enzymes and ligands are known to cause ER
phosphorylation and include cyclinA-CDK2, E2, 4-OHT, ICI (Fulvestrant), epidermal
growth factor (EGF), phorbol 12-myristate 13-acetate (PMA), insulin-like growth factor
(IGF), Mitogen-activated protein kinase (MAPK), cyclin dependent kinase 7 (CDK7)
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casein kinase II, PI3K, AKT, and protein kinase A (PKA) [80]. Each compound and
associated phosphorylation sites on ERα are represented in Figure 2. As depicted in
Figure 2, although phosphorylation of the ER occurs in the absence of E2, reports in
MCF-7 cells have shown that it is enhanced by the ligand [91]. As high levels of ER
phosphorylation are associated with less dependence on ligand association for ER
activation, it is hypothesized that ligand-independent phosphorylation of ERs is a
mechanism of therapeutic resistance in ER+ breast cancer. This is supported by the
association that patients with high MAPK activity are associated with a poor response to
ET [92].

FIGURE 2: ERΑ PHOSPHORYLATION SITES. Pictorial representation of the
phosphorylation sites of ERα and the enzymes/ligands that induce their
phosphorylation. The AF1 located S104, S118, S167 are substrates of a number of
different enzymes. The DNA binding domain of C can be phosphorylated at S236 by
PKA, while Y537 within the AF2 region can be phosphorylated by SRC family kinases
as reported by Pearce et al. 2004 [79].
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The primary function of the ERs is to regulate transcription in the presence of its
ligand, E2 [93]. This activity is mediated by the AF1 and AF2 regions of the ER, and the
overall effects (repression or activation of transcription) are dependent on the cellular
environment and the gene promoter [93, 94]. The process of regulation is not carried
out solely by E2 association with the ligand binding domain to activate AF2, but requires
the interaction of the ER with a number of coregulators to activate, enhance, or repress
transcription of ER-target genes [95, 96]. Further, it has been shown through ERα
binding of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) that
the ER can regulate gene expression without directly binding to DNA [97]. These ERassociated coregulators include the coactivators like steroid receptor coactivators 1-3
(SRC1-3), p300, activating protein 1 (AP-1) and CREB-binding protein (CBP), and
corepressors including nuclear receptor corepressor (NCoR) and silencing meditator for
retinoid thyroid hormone receptor (SMRT) [96]. These coactivators and corepressors
that interact with the activated ER can bind with other receptors, or the ER exclusively,
for example, the protein repressor of estrogen receptor activity (REA) [98]. Thus, there
are three distinct models in which the ER can regulate gene expression represented in
Figure 3. The classical ERE-pathway, in which activated ERs dimerize following
dissociation of heat shock proteins, recognize EREs on the promoter of their target
gene, and activate transcription [99]. The non-classical pathway in which the activated
ER associates with other transcription factors such as AP-1 and forms a complex at AP1-directed sites of gene targets to regulate their expression [100]. Finally, the ER can
regulate gene expression without associating with DNA, but instead by binding and
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trapping proteins such as NF-κB and preventing them from activating their target genes
[97]. Interestingly, which DNA sequences, cofactors, or proteins the ER associates is
dependent on the confirmation of the ER following ligand binding within the E domain,
as well as the relative abundance of cofactors within the specific tissue of interest [101104]. Thus, ligands bind the ER, but the associated changes in gene expression are
dependent on the structural changes in the AF2 region which in turn determines what
cofactors then associated with the ER [85]. Whether ERα and ERβ recruit different
cofactors is still largely unknown. Because the AF2 regions of the two receptors do have
high homology (Figure 1), it is postulated that the activated ERs recruit similar cofactors,
however differences in cofactor affinity have been reported between ERα and ERβ [85].
These include studies indicating that SRC-3 has a much higher affinity for activated
ERα than ERβ [105]. Further, because differences in ligand affinity and differences in
receptor confirmation following ligand binding have been reported when comparing the
two receptors, it is speculated that there are in fact differences in cofactor recruitment
when comparing ERα and ERβ [106, 107].
ER signaling in normal breast tissue and Breast Cancer. Transcript
expression of both ER isoforms is detectable in a variety of tissues of both female and
male origin, not just the female breast and ovary tissues [88, 108]. These tissues
include the brain, liver, bone, gastrointestinal tract and the prostate [88, 109]. Mouse
knockout studies have begun to delineate which ER isoform (α, β or both) is required for
proper function of each respective tissue [110]. In the breast, transcript levels of ERα
and ERβ are relatively similar, however only loss of ERα causes a failure of full
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mammary gland development [110, 111]. Specifically, the mammary glands of adult
ERα knockout (KO) female mice look like those of a male mouse or a female prior to
starting puberty, suggesting ERα is required for full mammary gland proliferation and
differentiation [110].

FIGURE 3: MODELS OF ER REGULATION OF GENE TRANSCRIPTION. Depicted
are three distinct models exist in which the ER regulates gene transcription. These
include the classical model in which the ER is activated by its ligand E2, dimerizes with
another activated ER and associates directly at DNA promoter regions that contain ERE
sites to activate gene transcription. The cofactor model represents another model in
which the ER can activate or repress transcription based on the cofactor it associates
with. For example association with AP-1 is associated with activation of gene transcript
expression, whereas association with REA is associated with repression of gene
transcript expression. Finally, the ER can regulate transcription independent of DNA
association by associating with other transcription factors like NF-κB and preventing
them from activating their target genes.
As alluded to previously, the process of mammary gland maturation is complex,
involving a number of hormones. These include gonadotropin-releasing hormone
(GnRH), insulin-like growth factor 1 (IGF-1), estrogen, progesterone, and prolactin
[112]. Prior to puberty, male and female breast tissues are nearly identical [4, 5]. At the
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onset of puberty in females however, there is a surge of pulsatile release of GnRH by
the hypothalamus, which in turn induces the pituitary gland to release follicle-stimulating
hormone (FSH) and luteinizing hormone (LH) [113, 114]. FSH and LH then travel
through the systemic circulation to stimulate the ovaries to produce estrogen and
progesterone [113, 114]. In parallel with this, growth hormone (GH) and IGF-1 levels are
produced by the pituitary and reach their peak levels during puberty [115]. It is this
surge of GH that induces the breast epithelial cells to express the ERs, allowing it to
respond to the surging levels of estrogen and progesterone secreted by the ovaries
[116, 117]. GH appears to be required for proper mammary gland development, as loss
of GH prevents full breast development [116]. Ductal cells within the breast, now
induced to express the ER by GH, then respond to E2 levels resulting in an induction of
growth at the tips of their ducts, known as the terminal end buds (TEBs) [112, 118].
Overtime, these TEBs elongate and penetrate the fat pad of the breast, leading to a
mature, dense network of mammary ducts [112, 118]. Thus following puberty, the
lobules of the breast that are capable of milk production post-pregnancy have a mature
connection system composed of the branching ducts all the way to the nipple [119]. If
there is a drop in GH and/or estrogen levels either artificially or during menopause, this
lack of hormonal signal leads to atrophy of these ER+ cells ultimately leading to atrophy
of the ductal system and deposition of fat and connective tissue [7, 116]. This rise and
fall in hormone levels continues throughout the adult life of females in which surges of
GnRH, GH, and estrogen influence the makeup of the mammary gland until the female
reaches menopause [112]. At this point, hormone levels permanently drop, leading to
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atrophy of the breast tissue and an inability for the patient to achieve pregnancy [7].
Overall, breast proliferation and differentiation during puberty requires a complex
temporal rise in hormones, with E2 and the ER being required for this to properly occur
[110].
Although progesterone affects normal breast development during puberty, it does
not appear to be required for adult mammary gland development. This has been
demonstrated in experiments in which PR KO mice only showed delay in gland
development [120]. The hormone does however play a significant role in terminal breast
differentiation, which occurs during and just after pregnancy in women as they prepare
for breastfeeding [6]. During late pregnancy, ER and PR signaling are several hundredfold higher than during menstrual cycle levels [121]. This causes an induction of
prolactin release from the anterior pituitary and it is the action of progesterone and
prolactin that is required for the full development of the lobules within the breast [122].
This was demonstrated in PR or prolactin receptor (PRLR) KO mice, which still
developed full mammary ducts, but failed to reach full lobular development following
pregnancy [120, 122]. Additionally, as expression of the PR requires activation of the
ER, inhibition of the ER had a similar effect on perturbing lobular development [110].
Together these findings indicate that terminal lobular development during and following
pregnancy requires the PR and its ligand, which is regulated by the ER.
Work from a multitude of groups have shown that breast development during
pregnancy requires the ER, and terminal development requires the ER and PR [112122]. More recently, research has turned to why this relationship between breast
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proliferation and the hormone receptors goes awry, and its clinical consequences.
Pathogenesis of ER+ breast cancer appears to be due to changes in the ERα+ cells
within the breast tissue [123]. Interestingly, ERα is only expressed in 15-30% of the
luminal cells of the breast, and 0% of non-luminal cells [124, 125]. Surprisingly, during
normal breast development and breast tissue maintenance in healthy females, these
ERα cells are not proliferative [125]. They are however activated by E2 and induce the
adjacent cells (including TEBs) to proliferative by secreting paracrine factors [125].
These include EGF-like factors, receptor activator of nuclear factor kappa-B (RANKL),
mouse mammary tumor virus (MMTV), wingless-type integration site family member 4
(WNT-4) and leukemia inhibitory factor (LIF) [124, 125]. Thus the model is not simply
that activation of the ER induces breast mammary cell proliferation and differentiation,
but rather the ERα+ cells respond to the changing E2 levels and then alter the
proliferative capacity of the adjacent cells via secretion of a number of factors [124,
125]. This model is represented in Figure 4. In ER+ breast cancer however, these
typically quiescent ER+ luminal cells now proliferate in response to E2, and thus cause
hormone-dependent tumors to form [123, 125].
Why these cells abnormally proliferate is still under debate and investigation.
Changes in cofactor expression levels have been reported in ER+ breast cancer,
namely overexpression of the coactivators SRC-3, activating signal cointegrator 2
(ASC2), thyroid hormone receptor-associated protein complex 220 kDa component
(TRAP220) have been reported in ER+ breast cancer tumors [126-128]. Additionally, a
decrease in the expression levels of corepressors have been reported [129]. Thus,
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these changes in cofactor levels within the ER+ cells may alter how they respond to the
E2 ligand, which may include an induction of proliferation. Additionally, increased
expression of ERα have also been reported in early benign and malignant ER+ breast
tumor tissue, with increased levels of ERα expression correlating with increased atypia
in these tissues [130, 131]. These findings suggest that dysregulated expression of ERα
itself maybe contribute to the pathogenesis of the disease. Studies have been
attempted to discern if this increase in E2 responsiveness causes changes in cell cycle,
specifically by using normal isolated ERα+ epithelial cells [132]. However, these cells
lose their responsiveness to E2 when they are isolated and cultured in vitro [132].
Because of this, most studies attempting to link E2 responsiveness to breast cancer
development have been done in animal models in which proteins including cyclins have
been deleted. For example, deletion of cyclin D1 causes disruption of mammary gland
development, leading to loss of post-pregnancy lactation, while also conferring
resistance to carcinogen-induced breast cancer [132, 133]. Alternatively, forced
overexpression of cyclin D1 increases mammary gland cell proliferation and is sufficient
to induce breast cancer formation in mice [134]. This correlation between higher ERα
and cyclin D1 expression is maintained in both normal and cancerous human breast
tissue, with a significantly fewer number of co-positive cells occurring in normal samples
compared to tumor specimens [135]. Other reports suggest that ER+ breast cancer is a
result of abnormal levels of secreted paracrine factors by the ERα+ cells [123]. One of
these factors is transforming growth factor beta (TGF-β). In human samples, TGF-β1 is
shown to co-localize with ERα+ cells, and heterozygous deletion of TGF-β1 in animals
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causes normal ERα+ mammary gland cells to proliferate [136]. This suggests under
normal conditions, ERα+ cells within the mammary gland block their own proliferation by
secreting TGF-β1, however this may become dysregulated in ER+ breast cancer,
allowing for the ERα+ cells to proliferate and form a cancerous mass [136].
ENDOCRINE THERAPIES IN TREATING ER+ BREAST CANCER
Due to the association between the ER and growth of ER+ breast tumors, and
the initial findings that loss of E2 production causes ER+ tumor regression, the primary
pharmacological goal of first-line therapies is blocking ER signaling via ETs [76, 77].
These therapies are among the least toxic and most effective therapies, at least initially,
of all cancer therapeutics [80]. Response to these ETs are predicted by and typically
correlate with tumor expression of the ER and PR [137]. Patients with the best
prognosis in terms of response to ET include those that are ER+, PR+, reporting a 69%
initial response rate [129]. Conversely, patients that are ER-, PR- report an 11%
response rate [129]. Three major groups of therapeutics exist, each with their own
distinct mechanism of action. These include Aromatase inhibitors (AIs), selective
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estrogen receptor modulators (SERMs) and selective estrogen receptor downregulators
(SERDs) [80].

FIGURE 4: PROPOSED MODELS OF ER+ BREAST CANCER PATHOGENESIS.
During normal breast tissue proliferation and differentiation, ERα+ cells are activated to
secrete paracrine factors by the ligand E2. These paracrine factors then stimulate the
surrounding ERα- cells to proliferate and populate the mammary gland. Under normal
conditions these ERα+ cells do not proliferate. In ER+ breast cancer, these normally
quiescent cells begin to proliferate in response to E2. This may be due to autocrine
response to secrete factors (A) or loss of normally inhibitory signals that prevent ERα+
cell growth (B).

AROMATASE INHIBITORS (AIs)
The aromatase enzyme normally synthesizes ligands of the ER by converting
circulating testosterone into E2 or androstenedione into esterone [138]. It is a member of
the cytochrome P450 family and is encoded by the gene CYP19A1, and is expressed in
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a wide variety of tissues including the ovaries, placenta, bone, adipose, testis, skin,
brain and even breast cancer tissue itself [139-142]. Thus inhibitors of this enzyme are
used to prevent patient production of estrogens that will stimulate growth of ER+
tumors. These inhibitors are typically given in the context of adjuvant therapy following
surgery (lumpectomy) to prevent cancer relapse [138]. They are primarily given to postmenopausal patients-only, as their use in pre-menopausal women has been shown to
cause a compensational increase in E2 production by the ovaries [143]. The first AI
tested was Formestane, which was given to women that were either postmenopausal or
had had an oophorectomy [144]. The original compound was suspended in a 0.5%
solution of carboxymethylcellulse in water and administered via intramuscular (IM)
injection [144, 145]. Further studies indicated that those patients whose E2 was
suppressed by therapy had a > 50% probability of being a responder, establishing the
link between suppression of ER activation and clinical response [146]. Due to this initial
success, new derivatives of AIs were developed to increase bioavailability and steroidal
or type I AIs, and non-steroidal or type II AIs [147]. Type I AIs have a structure similar to
that of the steroid androstenedione, and thus are referred to as steroidal AIs [147]. Due
to this structural similarity, these therapeutics bind the substrate-binding site of
aromatase and are converted to a reactive intermediate that covalently binds to the
enzyme causing its irreversible inactivation [148]. Thus these class of AIs are
sometimes referred to as “suicide inhibitors” [148]. AIs within this category include
formestane and exemestane, however only exemestane is used currently as it can be
convenience of AI therapy [147]. Presently, they are divided into two major groups,
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taken orally [147]. Type II AIs are reversible inhibitors of aromatase, because high
amounts of androgens can counteract or reverse their inhibitory effects on the enzyme
[149, 150]. Currently used type II AIs include anastrozole and letrozole [147]. All three
AIs (exemestane, anastrozole and letrozole) have similar clinical efficacy when
compared directly, are all well tolerated, and do not increase a patient’s risk of
endometrial cancer or thromboembolism like other ETs [151-153]. Major side effects of
AIs is an increased risk of osteopenia, osteoporosis and bone fracture when compared
to other ETs, however this seems to be only during active treatment [154]. This is due to
the loss of the protective or beneficial effects of ER signaling [154]. Using AIs has been
shown to be beneficial in both a local and metastatic breast cancer setting and as an
adjuvant or neoadjuvant treatment [154-156]. Additionally, as AIs have been shown to
reduce the risk of contralateral breast cancer, there is potential for their use as a
chemopreventative agent in ER+ Breast Cancer for high risk patients [154].
Although AIs have been shown to be effective in achieving stable disease in
patients, rates of resistance approach 50% long-term, and are considered inevitable in
metastatic disease [154, 157]. Several studies have indicated that in patient’s that have
lost ER expression in their tumors, AIs are no longer effective [158]. As this occurs in
roughly 1/4 of patients during ET, this is a population of clinical significance, but
unfortunately will no longer respond to any form of ET [158]. This is thought to be due to
changes in epigenetic modulators including histone deacetylases and
methyltransferases, causing loss of ER gene expression [159-161]. However other
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mechanisms of acquired AI resistance exists in ER+ breast tumors that still retain ER
expression [162].
Although AIs tend to decrease ER expression in ER+ tumors in vivo, the
phosphorylation of the ER, a read out for its activation status, remains high in resistant
tumors [163]. Further, molecular analysis indicated that this phosphorylation and thus
activation of the ER, was maintained by a compensatory increase in MAPK activation
[163-165]. However other mechanisms including an increase in ER cofactors like AP-1
and AIB1 (SRC-3) have also been reported [163-165]. This increase in MAPK activation
was found to be due to an increase in HER2 activation, and combination therapy of AI
and trastuzumab prevented the development of AI resistance [165]. Other studies
showed that this increase in HER2 signaling could be prevented by intermittent
treatment with AIs, or a “therapeutic holiday” [166]. Recent clinical trials have shown
that dual therapies of AI and trastuzumab have a clinical benefit approaching 50% in
patients with metastatic ER+/HER2- Breast Cancer [167]. Overall these findings
suggest AIs are an effective therapeutic option for the treatment of ER+ Breast Cancer,
however efforts to prevent overactivation of compensatory pathways that increase
ligand-independent ER activation may improve outcomes.
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
SERMs are an additional class within the umbrella term of ETs that are used in
the treatment and prevention of ER+ Breast Cancer [168]. They include arzoxifene,
bazedoxifene, lasofoxifene, ospemifene, raloxifene, and tamoxifen [169]. The use of this
class of drugs as a therapeutic in breast cancer was more or less by accident
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discovered through the initial failed drug, tamoxifen [169]. Tamoxifen was first
developed as a contraceptive to inhibit female fertility, however studies began to report
it had the opposite effect [170]. Further, other groups found it was effective in treating
metastatic breast cancer in postmenopausal women and was even shown to have
chemopreventative properties in breast cancer [171-173]. The hypothesis initially was
that tamoxifen was effective in treating ER+ Breast Cancer because it blocked ER
signaling, which would explain its initial effects on female fertility, however the
relationship between the ER and tamoxifen was found to be much more complicated
[170-173]. Specifically, tamoxifen was found to have pro-ER effects in some tissues
such as the bone (decreased osteoporosis and fractures), the cardiovascular system
(decreased cholesterol), and the uterine tissue (increased endometrial volume and rate
of endometrial cancer) [173-179]. This lead to the concept of tamoxifen and later others
being referred to as ER “modulators” as they seemed to antagonize estrogen action in
some tissues, but increase ER activity in others [169]. The mechanism for this was
made clearer via pharmacokinetic studies with additional SERMs including raloxifene
being discovered along the way [180].
Similar to E2, SERMs bind the ligand binding domain of the ER, resulting in a
conformational change of the receptor, namely in the AF2 region [181]. These changes
lead to the recruitment of cofactors, which alter gene expression of ER-responsive
genes [181]. For cells in the mammary gland, this change in the ER by SERM binding
leads to the recruitment of co-repressors, resulting in repression of ER-responsive
genes and thus preventing growth of ER+ tumor cells [181]. Structural analysis studies
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have revealed that this change in cofactor recruitment is due to a conformational
change within Helix 12 when comparing the E2-bound ER to SERM-bound ER near the
AF2 site [182, 183]. Thus, as the position of the Helix 12 changes, so does the ability for
the AF2 to recruit cofactors, ultimately altering the ER’s ability to regulate gene
expression. These findings may also help explain why SERMs have an agonist effect in
some tissues (bone, uterine, and cardiovascular) and an antagonist (breast) effect in
others [183]. Specifically, as breast and endometrial cells express different ratios and
amounts of ER cofactors, it can be postulated that they respond to SERMs differently
[183]. This may also explain a potential mechanism of resistance to SERMs as
tamoxifen-resistant breast cancers have been shown to alter their cofactor levels [184].
Tamoxifen is the first SERM to show clinical efficacy in treating ER+ breast
cancer in both pre- and post-menopausal women [185, 186]. It is orally administered
and metabolized to its active components by the liver to 4-hydroxytamxoifen and
endoxifen, both of which can compete with E2 for the ligand binding site of the ER [187].
It has a relatively long biological half-life and is well tolerated for long term use, for as
long as 10 years [169, 187]. It is the first drug to be approved by the US Food and Drug
Administration (FDA) for the prevention of breast cancer as research has shown a 50%
reduction in the risk of breast cancer development in high risk pre- and postmenopausal women [185, 186]. Of note, evidence in animals has shown that tamoxifen
is capable of forming DNA adducts, which are not rapidly repaired [188]. However no
evidence has been shown that this occurs in humans [189]. Although tamoxifen is used
to treat ER+ Breast Cancer in pre- and post-menopausal patients, it is first-line in pre-
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menopausal women due to the compensatory effects AIs have on ovarian E2 production
[143].
Raloxifene is a benzothiophene SERM that was originally considered a failure in
breast cancer treatment, however further work led to its use in the prevention and
treatment of breast cancer [180, 190]. Unlike tamoxifen, Raloxifene is short acting and
has a poor bio-avaliability, and it also is approved to maintain bone density/health [191194]. Specifically the multiple outcomes of raloxifene evaluation (MORE) study, the
therapeutic was shown to significantly reduce the risk of fractures while also reducing
the incidence of invasive ER+ breast cancer by 76% in female patients [194]. This was
without any increased risk of endometrial cancer [194]. Direct comparisons of raloxifene
vs. tamoxifen revealed that raloxifene was associated with a statistically significant
lower risk of developing endometrial cancer, while having a similar effect on preventing
the development of invasive ER+ Breast Cancer in high risk post-menopausal women
[195]. Additionally, as raloxifene does not react with DNA to form adducts, it may be a
safer option long-term for breast cancer prevention [194, 196].
Although SERMs are among the safest anti-cancer therapies, with very few side
effects, breast tumors of most patients that are initially responsive will develop
resistance to one or more therapies [196]. A compensatory increase in HER2
expression and activity is seen in breast tumors from patients given SERMs, with almost
1/3 of ER+ tumor having HER2 overexpression [184]. A similar finding has been
reported with the ER co-activator AIB1 (SRC-3) [126]. Further, overexpression of both
of these factors has been shown to increase the agonist activity of tamoxifen in ER+
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Breast Cancer cell lines [197]. High activity of the PI3K pathway is also associated with
SERM resistance [198]. One downstream target of PI3K is protein kinase B (PKB, aka
AKT), and high activity of AKT is associated with an increased risk of breast cancer
[199]. The mechanism for this is thought to be due to the AKT pathway being sufficient
to inhibit apoptosis and stimulate cell growth in breast cancer cells [199]. Thus, it is
hypothesized that a compensatory increase in AKT signaling protects ER+ Breast
Cancer from tamoxifen as it prevents tamoxifen-induced apoptosis while also facilitating
E2-independent growth [200]. As 2/3 of these SERM-resistance cancers are still
sensitive to AIs and SERDs such as fulvestrant, cycling different forms of ET may be
beneficial at preventing the growth of SERM-resistant tumors [201, 202].
SELECTIVE ESTROGEN RECEPTOR DOWNREGULATORS (SERDS)
Although AIs and SERMs have shown clinical efficacy and are among the safest
anti-cancer drugs to date, cancer recurrence rates following either of these treatments
remains relatively high [203]. Additionally, long term use of these therapeutics is
associated with significant side effects, including endometrial cancer and deep vein
thrombosis (DVT) for SERMs and bone loss with AIs [179, 204-205]. Thus, a pure
antagonist of the ER, fulvestrant, was developed in order to block the ER without
causing the side effects associated with other forms of ET [205-207]. In terms of its
pharmacological properties, fulvestrant is a pure ER antagonist [207]. It is a structural
analog of E2 and thus binds both ERα and ERβ at the ligand binding domain, but
promotes degradation of the receptor due to subsequent receptor misfolding [207, 208].
Hence its distinction as a SERD. Additionally, due to the conformational changes
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induced in the ER, if it is not degraded, it is still prevented from localizing to the nucleus,
thus ER-dependent gene expression is essentially “shut off” [209]. This is evident by
comparing gene expression of ER+ Breast Cancer Cell lines in response to SERMS vs.
fulvestrant as they were able to turn off ER-responsive gene expression by 47% vs.
95%, respectively [210]. In comparison with the AI anastrozole, it is just as effective in
treating tamoxifen resistant ER+ Breast Cancer, and is relatively well tolerated [211]. A
major downside however is that it must be administered via intramuscular injection vs.
AIs, which are taken orally [212]. Further in cell models, ER+ cells that have been longterm deprived of estrogen (LTED) and thus are resistant to AIs, still remain sensitive to
fulvestrant [213]. Additionally fulvestrant was shown to be effective in patients-refractory
to both tamoxifen and AIs [213]. An issue that still remains is the bioavailability of
fulvestrant is relatively low when compared to SERMs, and additionally it takes 3 to 6
months of dosing to reach clinically effective levels within patients [214]. Currently,
fulvestrant remains a second or third line therapy in ER+ Breast Cancer, specifically for
post-menopausal patients that are refractory to AIs and SERMs [215]. Currently, there
is an active effort by major pharmaceutical companies to develop oral SERDs.
As fulvestrant treatment results in degradation of the ER, changes in cofactor
levels and/or ligand independent phosphorylation of the ER are not typically a clinical
concern as it is with AIs and SERMs [126, 163-165, 197, 216]. In principle however,
mutations to the ER may alter the receptor’s structure and thus prevent fulvestrantinduced misfolding/degradation of the receptor [216]. The plausibility of this is supported
by studies indicating that mutations in ERα increase over the course of ET, specifically
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in patients with brain metastatic disease [217-219]. However analysis of samples from
two clinical trials (SoFEA and PALOMA-3 studies) indicated that mutations in ERα were
associated with a worse prognosis in patients treated with an AI, but not with fulvestrant
[220]. Thus, the only major mechanism of resistance to SERDs to date appears to be
loss of the ER within the tumor cells, which again occurs in roughly 1/4 of patients [65,
66].
LOSS OF ER AND ET RESISTANCE
Approximately 1/4 of ER+ breast tumors will lose expression of the ER over the
course of therapy, essentially converting to the TNBC subtype of breast cancer [65-66,
220]. As these tumors are no longer dependent on the ER for their growth, they are
intrinsically resistant to all ETs [157]. This phenomenon has been shown to occur in the
T47D ER+ Breast Cancer cell line, which decreases ER expression in response to E2
deprivation [60]. One proposed mechanism for this is the ability of ER+ breast tumors to
methylate the promoter of the ESR1 gene via the enzyme DNA methyltransferase 1
(DNMT1) [220-223]. As the primary function of DNMT1 is to directly methylate DNA at
cytosine-phosphate-guanine (CpG) islands, which if at the promoter region of the ESR1
gene, results in decreased expression within that cell [224]. As DNMT1 expression
positively correlates with a poor histological grade and the presence of metastatic
lesions in breast cancer, it represents a novel target in preventing therapeutic escape in
ER+ breast cancer [221, 225]. Why this occurs is not yet fully understood, but findings
suggest it may be a secondary response to ER inhibition by ET as decreased ER
expression correlates with increased DNMT1 levels within the tumor [221, 224-225].
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Agents that inhibit DNMT1 have been shown to be sufficient to induce ER expression in
TNBC cell lines, which is associated with an increase in response to ETs [226, 227].
This has led to clinical trials investigating the feasibility of DNMT1 inhibitors for the
treatment of breast cancer [Clinicaltrials.gov ID: NCT00978250].
TREATMENT OF ET RESISTANT ER+ BREAST CANCER
As mentioned above, a number of signaling pathways have been reported to be
upregulated in ER+ Breast Cancer that is resistant to ETs. These include the
overexpression of EGFR, HER2, PI3K, and the mTOR pathways [228]. Thus attempts
have been made to target these oncogenic pathways in ET resistant ER+ Breast
Cancer. For example, overactivation of PI3K signaling is associated with ligandindependent activation of the ER, and inhibition of PI3K is associated with a reduction in
ER activation [229]. Further, inhibition of the EGFR/HER2 pathway with lapatinib in ET
resistant breast cancer was associated with restored sensitivity to either tamoxifen or
AIs [230]. Unfortunately, these positive initial findings were not associated with
demonstrating significant clinical benefit in large-scale clinical trials [231]. Further,
attempts to inhibit the MAPK pathway, which is downstream of EGFR/HER2 were
unsuccessful in clinical trials as well [232].
Aberrant activation of the PI3K/mTOR pathway is another reported mechanism of
ET resistance [229]. Everolimus is an mTORC1 inhibitor that is typically used in organ
transplant patients to induce immune tolerance [233]. In the BOLERO-2 phase 3 trial,
use of everolimus and the AI exemestane was associated with a significantly longer
progression free survival than those treated with exemestane alone [234]. From this
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study everolimus was granted by the FDA to be used as a second-line therapy in
combination with exemestane in patients that have relapsed following treatment with
non-steroidal AIs [235]. Further in a clinical trial in which patients were treated with
tamoxifen or tamoxifen plus everolimus, the addition of the mTORC1 inhibitor was
associated with longer median time to cancer progression [236]. Interestingly in patients
refractory to AIs and SERMs, fulvestrant plus everolimus was associated with an
additional clinical benefit compared to fulvestrant alone [237]. Use of a pan-PI3K
inhibitor, Buparlisib has also shown positive effects in the treatment of ET resistant
breast cancer [238]. It is currently under investigation in patients with advanced ER+
Breast Cancer in combination with fulvestrant (NCT01610284, NCT01339442).
Finally the use of cyclin dependent kinase (CDK) inhibitors is currently under
investigation as another therapeutic option for treating ET resistant breast cancer. This
is based on initial reports that palbociclib, a CDK4 and 6 inhibitor, restored ET sensitivity
in tamoxifen resistant breast cancer cells and further in combination with non-steroidal
AIs increased progression free survival in ER+ Breast Cancer patients [239, 240]. This
finding was supported by an additional clinical trial (NCT01942135) indicating that
palbociclib plus fulvestrant significantly increased progression free survival time
compared to fulvestrant alone in patients refractory to other ETs [241]. Taken together,
results of these findings suggest that inhibitors of growth factor signaling pathways
(EGFR, HER, PI3K/mTOR, cell cycle) may offer an effective means to re-sensitize ER+
breast tumors to ETs.
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TUMOR INITIATING CELLS (TICS) AND THE CANCER STEM CELL (CSC)
HYPOTHESIS
Stem cells (SCs) are a well characterized cell type that are distinguished by their
ability to self-renew while also differentiate into specialized cells that populate healthy
tissues [242]. It is this unique ability of these progenitor cells to give rise to multiple cell
lineages that gives them their definitive “stem” nomenclature [243]. As these cells can
give rise to multiple lineages, these cells typically express high levels of genes
associated with cell multipotency, including OCT4, SOX2, KLF4, CMYC, and NANOG
[244-245]. Further, overexpression of these factors in differentiated cells causes
dedifferentiation to an induced multipotent or pluripotent SC [244]. Thus, expression of
these genes is not merely an identifying characteristic of SCs, but rather is sufficient to
induce stemness in any cell in which it occurs.
Healthy, normal SCs can be divided into two major categories which include
embryonic and adult SCs [242]. Embryonic SCs are formed during embryonic
development and are responsible for the formation and development of the three
primordial germ layers (ectoderm, endoderm and mesoderm), which will give rise to all
tissues in a newborn [244]. Adult SCs are cells that still retain stemness following birth,
but have a limited repertoire of differentiated cells they can give rise to [246]. Their
primary function is to maintain and repair various tissues that tend to have high turnover
rate and are maintained in specific niches based on the differentiated cells they give rise
to [246]. These include the bone marrow (hematopoietic stem cells), the epidermis
(epidermal stem cells), and the intestinal lining (gastric stem cells) [244]. It is these

38

adult SCs that are used in clinical therapies including bone marrow transplants and are
currently being used to potentially re-grow adult tissues [244]. Work in mice has also
demonstrated the presence of adult SCs in a mammary gland niche by Shackleton et.
al. [247]. Specifically they demonstrated that a single progenitor mammary SC isolated
from a mouse was capable of regenerating an entire adult mammary gland in vivo [247].
THE CANCER STEM CELL (CSC) HYPOTHESIS
CSCs were first identified in human acute myeloid leukemia (AML), in which it
was discovered that AML cells originated from a single multipotent cancer cell that had
progenitor-like properties [248]. This challenged the stochastic model of cancer
development which hypothesizes that cancer develops from normal, somatic cells that
have accumulated mutations over time. In breast cancer, this stochastic is supported by
the fact that mutations in DNA repair enzymes like BRCA1 and BRCA2 are associated
with an up to 80% probability of tumor development in the breast [24]. The CSC
hypothesis however considers a small subset of cancer cells that possess stem-like
properties [commonly referred to as tumor initiating cells (TICs)] that have the ability to
self-renew and give rise to more CSCs as well as differentiate into distinct, differentiated
tumor cells, resulting in a heterogeneous bulk tumor [249]. This is of clinical significance
because as the heterogeneity of a tumor increases, so too does the probability a
treatment resistant cell or cells will arise within the population [250]. As these CSCs are
thought to be multipotent, hypothetically just one CSC could give rise to a complete,
heterogeneous tumor, similar to a stem cell giving rise to an entire organ [249]. In breast

39

cancer, these multipotent, but cancerous cells have been shown to occur within the
tumor cell population [251].
The origin of these CSCs is still highly debated, but currently two distinct models
are hypothesized. These include the transformed adult SC model and the dedifferentiation model [252]. In the adult SC model, it is hypothesized that adult SCs
residing within their niche, acquire mutations that cause them to become tumorigenic,
the result is a cell that retains SC properties with the added distinction of being able to
form a tumor [252]. Conversely in the de-differentiation model, it is hypothesized that a
mutation occurs within a differentiated cell or cells, causing it to de-differentiate into a
multipotent stem-like cell [253]. This is supported by a common mutation in breast
cancer within the PI3-K pathway (PI3KCAH1047R) resulting in formation of a multipotent
cell capable of giving rise to a heterogeneous tumor [253]. Due to this controversy in the
field regarding the origin of these cells, these pathological cells will be referred to as
TICs, as regardless of their origin, these cells have been consistently demonstrated to
possess the ability to recapitulate the entire tumor and are associated with cancer
recurrence [254].
PROPERTIES AND MARKERS OF TICS IN BREAST CANCER
Molecular analysis has allowed for the phenotypic characterization of TICs in
terms of their role in tumor invasiveness, the development of therapeutic resistance,
and cancer recurrence. TICs are typically divided into two types, epithelial-like and
mesenchymal-like, based on the cell type they are thought to be derived from (epithelial
vs. mesenchymal) [255]. The two cell types differ largely in terms of their proliferation
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rate and invasiveness, with epithelial-like TICs having a relatively high proliferation and
low invasiveness rate, while mesenchymal-like TICs being more quiescent, but highly
invasive [255]. As ER+ breast tumors are derived from the luminal, epithelial cells,
epithelial-like TICs are thought to be the prominent cell type with this breast cancer
subtype [255]. These TICs have been found within the center of a developing tumor and
like normal luminal SCs are typically found below luminal cells of the mammary lobules
[255]. This epithelial vs. mesenchymal-like TIC distinction is not stationary however, as
epithelial-like TICs possess the ability to undergo epithelial to mesenchymal transition
(EMT), and thus can transition to a more invasive cell type [255]. Further as epitheliallike and mesenchymal-like TICs possess a similar gene expression profile, and thus
have a similar multipotency, distinguishing between epithelial vs. mesenchymal TIC
may not be clinically relevant [255]. From a prognosis standpoint however, patients that
express high levels of TIC-associated markers are associated with poorer survival
overall and higher likelihood of reccurence, suggesting TIC-markers may be useful
prognostic markers in the clinic [256, 261].
The presence of TICs within a breast tumor were first described by Al-Hajj et. al.
[252]. They reported that within the tumors of breast cancer patients they were able to
isolate TICs that exhibited a CD44+/CD24lo/Lin-/Epithelial specific antigen+ (ESA+ aka
EPCAM) phenotype by flow cytometry [252]. Cluster differentiation 44 (CD44) is a
hyaluronan receptor that is important for breast cancer cell adhesion, migration and
invasion that is associated with stem cell characteristics [252]. Alternatively CD24 is a
negative regulator of the chemokine receptor C-X-C motif chemokine receptor 4
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(CXCR4), which is a positive regulator of breast cancer cell metastasis [257]. The
presence of ESA indicated that these cells were of epithelial origin and derived from the
tumor and not the surrounding mesothelial cells [252]. The group demonstrated the
intrinsic ability of these cells to form new tumors, as only 100 of cells exhibiting this
expression phenotype were sufficient to initiate tumor formation in mice [252]. This is in
comparison of more differentiated cells that expressed CD24, and were unable to form
tumors at cell concentrations of up to 10,000 [251]. To date CD44/CD24 staining by flow
cytometry is a common method for quantifying TICs, however better phenotyping may
be needed as CD44/CD24 expression does not necessarily correlate with prognosis in
breast cancer patients [252]. Specifically, patients with high amounts of CD44+/CD24lo
cells is associated with a poor outcome, however patients with a high amount of cells
with a CD44-/CD24+ staining pattern are associated with an even worse prognosis [258259].
Due to the discrepancies in outcomes associated with CD44/CD24 staining,
other markers have been investigated for the identification of TICs in breast cancer.
Breast cancer TICs have been shown to overexpress aldehyde dehydrogenase 1
(ALDH1), an enzyme that catalyzes the oxidation of aldehyde into carboxylic acids
[261]. It however is a better predictor of the epithelial-like TIC subtype over the
mesenchymal-like subtype [255]. Prominin 1 (CD133) is another marker whose
expression is highest in CD44+/CD24lo cells, and thus is considered another TIC marker
in breast cancer [262]. Other markers for breast cancer TICs include CD49f, which was
identified in MCF-7 cells and CD61, which was recognized as a TIC marker in mouse
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models of breast cancer [263, 264]. The discovery and characterization of new TIC
markers however is continuously ongoing and variable, suggesting that these TICs are
heterogeneous, which would explain the high degree of heterogeneity that exists in
breast cancer [265].
TICS AND EPITHELIAL MESENCHYMAL TRANSITION/MESENCHYMAL
EPITHELIAL TRANSITION (EMT/MET)
EMT is a cellular process in cancer in which tumor cells dedifferentiate and lose
their epithelial cell traits including cell-cell adhesion and acquire mesenchymal cell traits
[266]. This is associated with tumor cell loss of E-cadherin expression (an epithelial cell
marker) and upregulation of mesenchymal markers including N-cadherin, vimentin and
fibronectin, as well as an increase in the transcription factors SNAIL, SLUG, ZEB1/2,
and TWIST1/2 [266-268]. It is the upregulation of these transcription factors that
appears to be critical for EMT, as over expression of TWIST or SNAIL leads to inhibition
of epithelial marker expression including E-cadherin [267]. This transition has been
demonstrated in breast cancer patients following conventional chemotherapy as well as
in ER+ breast cancer patients following ET [269-272]. This suggests that breast cancer
cells have plasticity in terms of their epithelial-mesenchymal state, allowing the tumor to
adapt to changing conditions induced by therapeutics, and ultimately may contribute to
drug resistance [271, 272]. Multiple groups have demonstrated this trend, indicating that
breast tumor cells that survive chemotherapy have altered gene expression and exhibit
changes in cytokeratin expression [269-272]. Again, comparison of epithelial and
mesenchymal TICs within the breast indicates a similar gene expression profile,
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regardless of cell state [256]. This demonstrates the overall plasticity of these cells and
their ability to transition between epithelial and mesenchymal cell states [256]. How
TICs upregulate mesenchymal transcription factors to induce EMT is still not clear.
Asiedu et. al. have shown that AXL is constitutively active in TICs, and this tyrosine
kinase has the ability to inhibit E-cadherin expression while increasing SNAIL, SLUG
and N-cadherin expression [273]. AXL is thought to do this by regulating a number of
pathways including Signal transducer and activator of transcription (STAT), AKT, NFκB, and MAPK, allowing for reprogramming of the epithelial to adopt a more
mesenchymal state [273]. Overall these results suggest that breast tumor cells have the
ability to transition to TICs in response to ET and/or chemotherapy, and it is this highly
plastic cell-type that contributes to therapeutic resistance, metastasis and thus a poor
clinical prognosis.
TICS AND THE BREAST TUMOR MICROENVIRONMENT
It is known that normal adult SCs rely on interactions with their microenvironment
and that these interactions regulate their viability and ability to self-renew or
differentiate, specifically in the breast tissue [253, 274]. Recently it has been shown that
the tumor microenvironment has a similar effect of promoting TIC survival and their selfrenewal capacity [275, 276]. These microenvironment characteristics include induction
of hypoxia, cytokine/growth factor production, and changes in immune cell trafficking
that occur within the tumor microenvironment (TME).
Conditions of low oxygen (hypoxia) have been demonstrated to be sufficient to
induce TIC formation and to enrich for the population in general [277]. This has been
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illustrated in primary epithelial cells, breast cancer cell lines, and patient-derived tumor
cells [277, 278]. This appears to be due to the hypoxic induction of hypoxic-inducible
factor 1 alpha (HIF1α), which is required for hypoxic-enrichment of TICs due to its
induction of ALDH1 expression [278]. Further, Mathieu et al. demonstrated that
induction of HIF1α causes an upregulation of SC genes associated with multipotency
including OCT4, SOX2, KLF4, NANOG, and CMYC [279].
Cells within the TME can also increase expression and secretion of cytokines
and growth factors via a positive feedback loop. First stromal and immune cells within
the TME secrete factors that enhance TIC survival and self-renewal, causing TICs
themselves to secrete factors including chemotactic cytokines [280]. These cytokines
then recruit more TIC-promoting cells into the TME, perpetuating the loop [280]. Using
the ER+ MCF-7 breast cancer cell line and human derived mesenchymal stromal cells
(MSCs), Ma et al. demonstrated that MSC co-culture with the MCF-7s lead to an
increase of interleukin-6 (IL-6) and IL-8 production and signaling, resulting in an
enrichment of TICs within the tumor cell population [280]. In TNBC cells, secretion of IL6 was required to activate OCT4 gene expression via the Janus Kinase/Signal
Transducer and activator of transcription (JAK-STAT) pathway [281]. Further, OCT4
forced expression was shown to be sufficient to induce TIC formation within these cells
[281]. Cross-talk between tumor cells and the surrounding endothelial cells has also
been shown to enrich for TICs in the breast cancer TME [282]. Specifically, TICs were
shown to secrete growth factors including fibroblast growth factor 12, vascular
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endothelial growth factor, neurofibromin 1, and pleiotrophin, inducing the endothelial
cells to secrete plate derived growth factor subunit B to promote TIC survival [282].
Immune cell trafficking within the TME also facilitates TIC survival and activity.
One specific pathological cell type of interest are tumor associated Macrophages
(TAMs), which are thought to promote leukocyte accumulation within the TME to
enhance TIC survival [283]. For example, TAMs have been shown to increase SOX2
expression through paracrine activation of the EGFR/STAT3 pathway [284]. As TAM
infiltration within the breast TME is associated with a worse overall prognosis and high
rate of recurrence, targeting these cells may be an avenue for preventing TIC survival
[285]. T-cells, specifically CD4+ helper T-cells have also been indicated as a cell type
that promotes TIC-survival [286]. This is through the ability of CD4+ T-cells to secrete
tumor necrosis factor alpha (TNFα), promoting upregulation of NF-κB, which in turn
stimulates SNAIL, SLUG, and TWIST expression within TICs to promote their survival
and self-renewal [286]. Thus, cell trafficking within the TME, specifically the TAMs and
T-cells, can enhance TIC survival and activity in breast cancer.
TICS IN ER+ BREAST CANCER
Although the frequency of TICs is thought to vary across breast cancer subtypes,
significant evidence exists that they occur in ER+ breast cancer and contribute to
cancer recurrence and the development of therapeutic resistance [287]. In MCF-7 cells,
tamoxifen has been shown to induce SOX2 expression, which was associated with the
development of treatment resistance [288]. Similarly, treatment with AIs is associated
with an increase in TIC frequency in residual patient tumor cells [269]. These findings
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are supported by groups demonstrating that the ER promotes E-cadherin expression
and inhibits SNAI1 (SNAIL), SNAI2 (SLUG), SOX2, OCT4, and NANOG [289-292]. The
mechanism by which the ER is thought regulate expression of these TIC-associated
markers has been suggested to be through epigenetic regulation [293]. One group
showed that cell-fate in breast cells was predominantly determined by the genome-wide
methylation pattern within breast cells [294]. Specifically, they showed that TICs had a
similar methylation pattern to that of normal adult mammary SCs, which included areas
of hypomethylation near genes associated with stemness [294]. This is in agreement
with findings indicating that stemness genes such as SOX2, OCT4, and NANOG are
negatively regulated by DNMT1 activity, and inhibition of DNMT1 activity improves
formation of induced pluripotent stem cells [295]. This suggests that ET may increase
TICs via its direct effects on the ER, the question remains however is why are these
TICs resistant to ET? Considerable evidence suggests that TICs in ER+ breast tumors
express very low levels of the ER, and thus represent a population that is intrinsically
resistant to ET [288, 296-297]. With this in mind, the current hypothesis is that the
cellular hierarchy within a primary tumor or a metastatic lesion derived from an ER+
tumor matches a similar hierarchy that is observed in a normal, healthy breast [298].
Namely, the tumor contains a large number of bulk tumor cells and a small number of
ERlow TICs from which the bulk cells were derived from [298, 299]. This hypothesis is
supported by findings of Horwitz et al. who demonstrated that within the cell population
of T47D cultured cells, there exists a TIC-like cell that is ER- [299]. Thus, because these
TICs are ERlow, ET effectively targets the ER+ bulk cells, the TICs persist and are able
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to give rise to a new, heterogeneous tumor that may be resistant to ETs. This model is
supported by circumstantial evidence that in patients with an ER+ primary tumor, 1/5
had metastatic lesions that were ER- and varied considerably in terms of gene
expression profile from the original tumor [300].
ASSAYS FOR MEASURING TIC SURVIVAL, FREQUENCY AND ACTIVITY
Multiple methods have been reported and are currently used in quantifying TIC
levels and activity in breast cancer. The mammosphere assay is an in vitro propagation
method in which breast tumor cells are cultured in a 3D system to quantify TIC survival
[301]. Each mammosphere that forms in this methylcellulose-based system is believe to
arise from an individual TIC and the quantification of the amount of mammospheres that
form gives a quantitative method for measuring the TIC frequency in vitro in a given cell
population [301]. It is calculated as % mammosphere forming efficiency (%MFE) using
the equation: % MFE = (Number of mammospheres formed/Number of cells seeded)
*100 [301]. It can also be used to quantify the self-renewal capacity within a cell
population by disaggregating and re-plating the resulting spheroids a second time in the
3D culture system [301]. These cells have been demonstrated to be sufficient to give
rise to both epithelial and myoepithelial cells, and thus are thought to be a sufficient in
vitro measurement of the number of TICs within the cell population [12].
Quantification of the TIC frequency in vivo within a given cell population is
performed via a limiting dilution assay [302]. In this assay, cells are injected into
immune compromised mice (athymic or SCID/NOD) at various log-fold dilutions (for
example: 10, 100, 1000 cells), allowed to propagate, and at a specified time-point tumor
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frequency is assessed [302]. Based on the tumor frequency in each cell dilution, TIC
frequency can be calculated using a statistical modeling software.
THE NOTCH SIGNALING PATHWAY
The NOTCH signaling pathway was initially discovered through a genetic screen
of fruit flies (Drosophila melanogaster) in the early 20th century [303]. It received its
name due to the “notched” appearance that resulted in the wings of flies that had
mutant alleles within the pathway, and were shown to be an inheritable characteristics
[304]. The signals relayed through this pathway are critical for cell development namely
in cell fate determination, but are also important in other SC-associated processes like
adult progenitor cell self-renewal and regulation of cell proliferation and death [305].
Due to this, mutations resulting in aberrant gain or loss of NOTCH signaling have been
implicated in a multitude of developmental and adult diseases [305].
COMPONENTS AND OUTLINE OF THE NOTCH SIGNALING PATHWAY
NOTCH signaling is dependent on cell-cell contact and thus is a pathway
mediated by cell-cell communication [305]. Typically a signal sending cell will present
the ligand and the adjacent receiving cell will recognize this ligand via its NOTCH
receptor [305]. There are currently five known NOTCH ligands which include: Jagged1,
Jagged2, Delta-like ligand-1 (DLL1), DLL3, and DLL4 [305]. These ligands are singlepass type I transmembrane proteins that are characterized by their expression of three
structural motifs: an N-terminal delta/serrate/LAG-2 (DSL) motif, tandem EGF repeats
called the delta and OSM-11-like proteins (DOS domains) and EGF-like repeats that
have calcium and non-calcium binding [306]. It is the DSL and DOS domains that
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participate in NOTCH receptor binding. The N-terminal domain is highly conserved
amongst all NOTCH ligands, and it can be subdivided into N1 cysteine-rich region and a
N2 cysteine-free region [307]. The Jagged ligands are longer than the DLLs, as they
have more EGF repeats in the extracellular domain, but all EGF repeats contain 6
cysteine residues which are designed to form disulfide bridges to stabilize the ligand
itself [306]. Only the Jagged and DLL1 ligands contain a DOS domain while DLL3 and
DLL4 do not [306]. All of these ligands contain a multitude of lysine residues, which are
sites of E3 ubiquitin ligase modification, except for DLL3 [306].
The ligands can be recognized by one of four NOTCH receptors that include
NOTCH1, NOTCH2, NOTCH3, and NOTCH4 [305]. The extracellular domain of the
receptors are comprised of 29-36 EGF tandem repeats, which can mediate ligand
interaction in two different ways [305]. One is the activating interaction in which a
neighboring cell provides the ligand (trans-activation), mediated by EGF repeats 11-12
[305]. Conversely, the inhibitor interaction in which the ligand and receptor on the same
cell interact (cis-inhibition), which is mediated by EGF repeats 24-29 [305]. It is these
two interactions that regulate binary cell fate by either activating NOTCH signaling
through trans interaction of neighboring cells or preventing self-activation of NOTCH by
causing inhibition if cis interaction occurs [305]. This cis/trans interaction is known as
lateral inhibition and it is this process that is crucial during development when the fetus
must distinguish between differentiated cells that exist within a sheet of undifferentiated
cells [308]. In the absence of ligand binding, the NOTCH receptors have a negative
regulatory region (NRR) that consists of three cysteine-rich repeats and a
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heterodimerization domain [308]. The receptors themselves are initially synthesized as
a 300 kDa precursor in the endoplasmic reticulum that is cleaved in the trans-Golgi by
furin-like convertase(s) through S1 cleavage [305]. This results in a heterodimer that
consists of the N-terminal NOTCH fragment and a transmembrane plus intracellular
domain C-terminal fragment [305]. These are linked together by non-covalent bonds
that requires the cation, Ca2+ [305]. During this assembly in the trans-Golgi, the
extracellular domain of the receptor is extensively N- and O-linked glycosylated by
Fringe glycosyltransferase [305]. It is this process that greatly increases the affinity of
the NOTCH receptors for the DLLs, but decreases the affinity for Jagged ligands [306].
In mammals, three enzymes accomplish this and include Lunatic fringe, Manic fringe
and Radical fringe [309].
Trans-association of the NOTCH receptor and one of its ligands causes E3
ubiquitin-mediated endocytosis of the ligand via mono-ubiquitinylation by either
Neuralized 1/2 or Mindbomb 1/2 [309]. This endocytosis provides the pulling force
necessary to expose the ADAM10/TACE/kuz/SUP-17 cleavage site within the Cterminus of the NOTCH receptor [309]. S2 cleavage then occurs via a disintigrin and
matrix metalloproteinase 10 or 17 (ADAM10/17) allowing ectodomain shedding of the
extracellular domain of the receptor forming the NOTCH extracellular truncation (NEXT)
fragment [310]. In parallel, the extracellular domain of the NOTCH receptor and the
original activating ligand are endocytosed by the signal sending cell [310]. NEXT then
undergoes S3 and S4 cleavages by a membrane-bound γ-secretase complex,
ultimately releasing the NOTCH intracellular domain NICD from the complex [311]. This
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γ-secretase consists of a catalytic subunit of either presenilin 1 or 2, a seven-pass
transmembrane domain, and accessory subunits including nicastrin, anterior pharynxdefective 1 (APH1), and presenilin enhancer 2 (PEN-2) [310]. PEN-2 is stabilized by
nicastrin and APH1 and mediates endoproteolysis of presenilin [310]. Although this
cleavage by γ-secretase typically occurs on the cell surface, it can also occur during
endosomal trafficking [312].
Under conditions when NOTCH activity is low, NOTCH target genes are
repressed by the CSL complex [CBF1 (C promoter binding factor-1), suppressor of
hairless,C-C motif chemokine ligand 4 like 1( Lag-1)] [312]. When NOTCH is activated
and NICD translocates into the nucleus of the target cell, the Ankyrin-repeat motif docks
with the Rel homology region of the DNA-binding domain of CSL to form a complex that
activates transcription [312]. This causes the removal of co-repressors including histone
deacetylases, CBF-1 interacting repressor (CIR) and recruitment of transcriptional coactivators including mastermind-like 1-3 (MAML) protein [306]. MAML then further
recruits histone acetyltransferases, cyclic AMP response element binding protein
CBP/p300 (CREB) or general control non-depressible 5 (GCN5) [312]. This leads to
histone acetylation, opening of the DNA wrapped around histones and ultimately
transcription of NOTCH target genes which include helix loop helix family of
transcriptional repressors including Hairy/Enhancer of a Split 1-7 (HES1-7),
Hair/Enhancer of a split with a unique YRPW motif 1-2 and L (HEY1 and 2, and HEYL),
DLTX1-4, CMYC, p21WAF1, and BCL2 [314].
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Sustained or aberrant activation of NOTCH signaling can be deleterious, thus the
process of NOTCH activation and release of NICD into the target cell is tightly regulated
[314]. For example, when NICD is released, over time it can be phosphorylated at its
PEST domain by CDK 8 and glycogen synthase kinase 3β (GSK-3β) [314]. This
phosphorylation is then recognized by the E3 ubiquitin ligase Sel10/Fbw7 for
proteasome-mediated degradation [314]. When NICD is depleted, the CSL/NICD/MAML
complex can no longer form, resulting in the turning off of NOTCH target genes until
further NOTCH activation occurs [314].
NOTCH SIGNALING AND DEVELOPMENT OF THE MAMMARY GLAND
SCs are required for the development (embryonic SCs) and
maintenance/homeostasis (adult SCs) of the breast tissue [315]. This has been
demonstrated in mice, in which a single mammary stem cell was sufficient to
reconstitute the entire mammary gland [248]. Further investigation of this process of
proliferation and differentiation to form the mammary gland has shown that these
mammary SCs give rise to the complete adult tissue through a series of lineage
restricted intermediates [10, 316-318]. This process is thought to be controlled by
extracellular cues including growth factors, cytokines, and cell-cell contact signaling
[319].
One cell signaling pathway that has been indicated as essential for mammary
cell-fate determination and SC maintenance is NOTCH [320-321]. This is supported by
findings of high expression levels of NOTCH receptors (NOTCH3), their ligands
(Jagged1, DLL3), and NOTCH targets (HEY2) in mammary SCs [322]. Further during
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pregnancy, when terminal mammary gland development occurs, NOTCH has been
shown to regulate cell maintenance and proliferation for proper tissue development
[323]. The NOTCH1 receptor appears to be a critical mediator of the luminal cell
commitment as forced overexpression converts basal cells within the mammary gland to
luminal cells [324]. Postnatally (after birth) these NOTCH1 expressing cells have a high
self-renewal capacity, and have the ability to form the complete mammary gland [325].
NOTCH4 expression tends to be highest in the undifferentiated mammary progenitors,
and this expression is decreased once the cells commit to the luminal lineage within the
epithelial tissue [326]. Forced overexpression of NOTCH4 in vitro inhibits breast
epithelial cell differentiation, and in vivo inhibits the ability of SCs to populate the
mammary gland with differentiated cells, while also being associated with mammary
tumor formation [326-328]. Together these findings demonstrate the importance of the
NOTCH signaling pathway in mammary SC maintenance and activity, while also
suggesting aberrant activation can lead to breast tumor formation.
NOTCH SIGNALING IN BREAST CANCER
The receptors, ligands (DLL 1, 3, 4) and gene targets (HES and HEY) have all
been reported to be elevated in invasive breast cancer, and high co-expression of
Jagged1 and NOTCH1 is linked to a poor prognosis in the disease [329, 330]. Further
Numb, a negative regulator of NOTCH, has been found to be lost in nearly 1/2 of breast
cancers [331]. In vivo, forced overexpression of NICD1 and NICD3 in the MMTV
transgenic mouse model inhibited mammary gland differentiation and development
while also inducing mammary tumor formation [332, 333]. Similar results were reported
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when MMTV was found to be inserted into the Int3 (NOTCH4) gene, leading to aberrant
overexpression and mouse mammary epithelial cell transformation in vitro, while forced
overexpression of NICD4 was sufficient to cause mammary tumor formation in vivo
[334, 335]. Conversely the NOTCH2 receptor may be protective in breast cancer as
high NOTCH2 expression was associated with a more differentiated tumor and a higher
survival probability in breast cancer patients [336]. This was further demonstrated in
TNBC cells in which overexpression of NICD2 increased apoptosis and inhibited tumor
growth in vivo [337].
Why NOTCH is associated with a poorer prognosis in breast cancer appears to
be due to its ability to promote TIC survival and activity. NOTCH4 has been shown to be
critical for proper mammopoiesis by SCs, suggesting it may also be important in TIC
survival [321]. This was demonstrated in vitro by Dontu et al., in which they showed that
activation of NOTCH resulted in an increase in TIC survival, self-renewal, and activity,
and these effects were lost if NOTCH4 was inhibited via a blocking antibody [321]. This
was supported by a separate group indicating that inhibition of NOTCH4 reduced the
amount and tumor initiating potential of TICs in vitro and in vivo, more so than inhibition
of NOTCH1 [338]. This together not only indicates the importance of NOTCH signaling
for promoting TIC activity, but also offers a potential drug target to better treat breast
cancer.
NOTCH IN ER+ BREAST CANCER
A crosstalk between NOTCH signaling and the ER is well documented. Rizzo et
al. demonstrated in MCF-7 cells that activation of the ER inhibited NICD1 and reduced
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expression of NOTCH target genes [339]. Further, inhibition of the ER by the SERMs
tamoxifen or raloxifene caused NOTCH expression and activity to increase [339]. In
patient samples however, high levels of Ki67 staining only correlated with high NOTCH4
expression [339]. Further, short-term ET of breast cancer cells derived from patientderived xenografts (PDXs), results in an increase in ALDH activity which correlated with
an increase in TIC survival and self-renewal [340]. This was also associated with an
increase in NOTCH signaling, specifically NOTCH4 activation [340]. The mechanism of
this cross-talk between the ER and NOTCH appears to be due NOTCH activation of
inhibitor of nuclear factor kappaB kinase subunit alpha (IKKα) [341, 342]. Hao et al.
found that ET increases NOTCH signaling in ER+ breast cancer cells, leading to an
increase in activation of IKKα, and it is this activation of IKKα that leads to the induction
of estrogen-responsive genes, independent of E2 [341]. Overall, these findings provide
a few key conclusions. First, NOTCH signaling, specifically NOTCH4, promotes the
survival of TICs in ER+ breast cancer. Second, activation of the ER by E2 restricts
NOTCH activation and inhibits TIC survival. Together these conclusions suggest that
ETs, which inhibit ER activation, select for TICs by increasing NOTCH and thus may
actually contribute to a poor prognosis in a subset of ER+ breast cancer patients. This is
reflected in clinical findings that report 50-60% of early breast cancers and nearly all
patients with advanced disease will develop resistance to one or more forms of ET
during the course of therapy [54, 340, 343]. Further, ER+ breast cancer patients treated
with ET have a 20% drop in survival probability between 10-20 years following therapy,
the biggest drop for any subtype of breast cancer [33].
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USE OF NOTCH INHIBITORS IN ER+ BREAST CANCER
Due to this pathological relationship between NOTCH signaling and ER+ breast
cancer prognosis, recent work has focused on discerning if inhibition of NOTCH
signaling in combination with ETs improves outcomes. Currently there exist two ways to
inhibit NOTCH signaling clinically. These include inhibiting ligand-receptor interaction by
the use of blocking antibodies, or by inhibiting the cleavage activity of the membranebound γ-secretase via a γ-secretase inhibitor (GSI) [344]. The efficacy of this treatment
strategy has been demonstrated by multiple groups who demonstrated that inhibition of
NOTCH signaling in combination with ET in vitro is effective at limiting TIC survival [297,
345]. This was corroborated in vivo in which inhibition of NOTCH signaling by GSI + ET
combination therapy was superior to ET alone in the T47D cell line and PDX implanted
samples [339-340, 346]. Although preclinical testing of GSI + ET yielded promising
results, the use of this treatment strategy in the clinic to improve outcomes in ER+
breast cancer has been met with issues. This is mainly due to the intolerable side
effects that result from GSI therapy including gastrointestinal distress and neurological
side effects [347].
DEATH DOMAIN-ASSOCIATED PROTEIN 6 (DAXX)
Death domain-associated protein 6 (DAXX) is a protein that has been implicated
in a number of cell processes including apoptosis, epigenetic regulation, and
heterochromatin maintenance [348]. Its gene is located on chromosome 6 at the p21.32
region, and it is known to be expressed in a variety of tissues including immunity-related
tissues, the prostate, kidneys, breast, and skin, with highest expression occurring in the
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prostate [349]. Although studies investigating its role in breast cancer are sparse, it has
been shown to have a pro-apoptotic and transcriptional repressor roles in the disease
[350, 351].
STRUCTURE AND CELLULAR LOCALIZATION OF DAXX
The full structure of DAXX is depicted in Figure 5A. DAXX is composed of 740
amino acids and contains two amphipathic helices (PAH1 and PAH2), a
serine/proline/threonine (S/P/T) domain, a single coiled-coil domain, and a highly acidic
domain (D/E) [348]. Multiple splice variants have been reported for DAXX including
DAXX-β (688 amino acids) and DAXX-γ (682 amino acids) which have a truncated Cterminus due to alternative splicing of base pairs in exon 6, resulting in a shorter DAXX
in length (depicted in Figure 5B) [352]. DAXX-β has base pairs 19-170 on exon 6
removed, while DAXX-γ has base pairs 1-170 removed [352]. Within the polypeptide
chain, DAXX has three nuclear localization regions [353-356]. These include a leucine
rich nuclear export signal (NES) from amino acids 188-197, and two lysine rich import
sites at amino acids 391-395 (NLS1) and 628-634 (NLS2) [353]. Due to these NLS
sites, DAXX is predominantly found in the nucleus of cells that express it [353].
The cellular localization of DAXX appears to be controlled in part by its NLS sites.
Within the NLS2 there exists a small ubiquitin-like modifier (SUMO) site at amino acids
732-740, which has been shown to be required for DAXX to interact with SUMOconjugating enzymes [354]. This includes the SUMO-conjugating enzyme ubiquitinconjugation enzyme E2 I (Ubc9), which is able to add a small ubiquitin-like modifier
(SUMO) to lysine residues (K630-K631) near NLS2 site [355]. Both the SIM and lysine
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residues as well as Ubc9 are required for this sumoylation reaction to occur, with loss of
any of these components resulting in DAXX being trapped in the cytoplasm [354-356].
This has been demonstrated in multiple studies. Loss of the NLS2 site, the K630/K631
sites, or loss of Ubc9 are all associated with cytoplasmic localization of DAXX [355,
356]. Additionally, loss of the DAXX SUMO-interacting motif (SIM) motif prevents Ubc9
interaction with DAXX, which again is associated with cytoplasmic localization of the
protein [357]. As Ubc9 expression in MCF-7 cells is dependent of ER activation by E2,
this would suggest that in ER+ Breast Cancer, nuclear expression of DAXX requires ER
activation [356, 358]. Further, polymorphisms in Ubc9 are associated with an
increased/decreased risk of breast cancer development [359].

FIGURE 5: STRUCTURE(S) OF DAXX. A. Pictorial depiction of the full-length DAXX. It
contains two amphipathic helices (PAH1 and PAH2). Within PAH is the nuclear export
sequence (AA 188-197). Within the Coiled-coil loop (CC) contains the first nuclear
import sequence (NLS1), which is a lysine rich region of amino acids (391-395). There
is then an acid-rich region (D/E) and a serine/proline/threonine rich region (S/P/T). The
S/P/T region is a site of heavy modification including phosphorylation. The second
nuclear import sequence (NLS2) occurs in this region (amino acids 628-634). B.
Pictorial depiction of wild-type full length DAXX and its small splice variants (β and γ).
Both variants have deletions in exon 6, causing a loss of the C-terminus of the S/P/T
domain.
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STABILITY OF DAXX
The mechanisms that stabilize DAXX protein levels within cells appears to be a highly
complex interaction of multiple proteins within the proteasome degradation pathway
[360-363]. DAXX has been shown to interact with both an E3 ubiquitin ligase mouse
double minute 2 (Mdm2) and the deubiquitinase Ubiquitin specific peptidase 7 (USP7
aka HAUSP) [360]. In both in vitro and in vivo systems, Tang et al. indicated Mdm2
activity causes a reduction of DAXX protein levels by directly ligating ubiquitin, even
upon overexpression of DAXX [361]. Further they showed that USP7 is necessary and
sufficient to reduce Mdm-2-mediated ubiquitinylation, which increased the protein
stability of DAXX [361]. This suggests that the interplay of Mdm2 and USP7 is a key
regulator of DAXX protein stability within cells. This is in contrast with a study by Zhang
et al., that indicated that therapeutics that degrade Mdm2 decrease DAXX levels in
acute lymphoblastic leukemia (ALL) cells [363]. Another group indicated a similar finding
in which inhibition of Mdm2 via Ras association domain family member 1 (RASSF1A)
causes a decrease in DAXX protein levels, and this decrease in DAXX is abrogated
when RASSF1A expression is inhibited by small interfering RNA (siRNA)-mediated
knockdown [362]. These findings suggest the opposite, specifically that Mdm2 might
increase DAXX protein stability. Interestingly in ER+ breast cancer, activation of the ER
by E2 increases Mdm2 transcript expression and protein levels [364]. Conversely, high
expression of USP7 is associated with poor outcome for women with breast cancer
[365]. Together these findings demonstrate DAXX protein stability is regulated through
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multiple modes of regulation within cells, and suggest that the stability of the DAXX
protein may be regulated by ER activation in ER+ breast cancer.
REPORTED FUNCTIONS OF DAXX
Although DAXX was initially discovered due to its association with the tumor
necrosis factor receptor superfamily member 6 (FAS, CD95), many subsequent reports
show that DAXX has multiple functions [366]. These include regulation of FAS-mediated
apoptosis, regulation of promyelocytic leukemia protein (PML) function, a facilitator of
heterochromatin maintenance by its histone3.3 chaperone function, and a
transcriptional repressor [348]. As all of these functions are associated with the
development, progression, and treatment of cancer, thus any or all could be relevant in
the context of breast cancer.
DAXX was initially discovered and characterized as a novel FAS-binding protein
by Yang et al. [366]. It was demonstrated to associate with the intracellular domain
(death-domain, DD) of the FAS receptor via its C-terminus region, specifically in the
S/P/T domain of amino acids 628-739 [366]. This was shown in DAXX mutants lacking
the 628-739 being unable to associate with the FAS DD. Further they indicated that
when DAXX associates with the DD of the FAS receptor, it is able to initiate caspaseindependent apoptosis via activation of the Jun N-terminal Kinase (JNK) pathway [366].
Others has shown JNK induces apoptosis by phosphorylating c-Jun, resulting in
activation of pro-apoptotic genes including JNK1 and JNK2 [367-370]. It was later
shown that DAXX activates JNK signaling by activating mitogen-activated protein kinase
kinase kinase (ASK1), and loss of ASK1 prevented DAXX activation of caspase-
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independent apoptosis [370]. This process is thought to be independent of the classical
FAS pathway of apoptosis that is characterized by FAS associated via death domain
(FADD) binding to the FAS DD, activating Caspase 8, and ultimately leading to
induction of apoptosis [371]. Thus, this canonical signaling of FAS is considered a
caspase-dependent mechanism of apoptosis [371]. As JNK has been shown to be
required for the induction of apoptosis in MCF-7 cells, DAXX activation of caspase
independent apoptosis represents a novel pathway of interest in ER+ breast cancer
[372]. These two separate apoptotic pathways are depicted in Figure 6. However, other
findings suggest this relationship between DAXX and JNK-mediated apoptosis is not so
clear cut. Chang et al. found that a mutant FAS receptor that can only bind DAXX and
not FADD was able to activate JNK, but this was insufficient to activate apoptosis,
suggesting DAXX-mediated apoptosis requires FADD [373]. In vivo studies support this
and have found that animals lacking caspase 8 or FADD are completely resistant to
FAS-mediated apoptosis [374, 375]. These findings indicate more work needs to be
done to further elucidate how DAXX induces apoptosis, and whether these
requirements are tissue/cell type specific [348]. Nuclear DAXX has also been reported
to co-localize with PML in normal and tumor cells, and that this association requires
sumoylated DAXX [376, 377]. This is further supported by the report that DAXX is not
localized in the nucleus in cells that lack wild-type PML structure in ALL [376]. This
association between DAXX and PML bodies has been shown in ALL to induce
apoptosis, as increased PML-DAXX association by retinoic acid treatment induces cell
death in ALL cells, and lack of PML-DAXX association resulted in an increase in cell
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proliferation [376]. This is supported by separate findings indicating depletion of DAXX
expression by siRNA in HEK293 cells results in loss of PML-induced apoptosis in
response to interferon gamma (IFNγ) and/or arsenic trioxide [378]. These findings
remain controversial as other studies have shown that the majority of DAXX does not
associate with PML bodies, and that this free DAXX may inhibit PML-mediated
apoptosis [376, 378]. Overall, these findings suggest another mechanism in which
DAXX can mediate apoptosis, but again this pathway may be tissue/cell type specific.
DAXX has also been demonstrated to co-localize with a component of
centromeric heterochromatin, specifically the SWI/SNF protein α-thalassemia/mental
retardation syndrome (ATRX) [379]. This co-localization is shown to occur during Sphase of the cell cycle in mouse fibroblasts, and their disassociation occurs during the
G2 phase [379]. When DAXX is depleted in these cells, S-phase is disrupted, resulting
in acceleration of the process [379]. Others have shown DAXX directly interacts with
ATRX and that this complex is required for chromatin changes that occur during Sphase [380, 381]. Alternatively, DAXX has also been shown to interact with centromere
protein-C (CENP-C), another protein that is known to promote heterochromatin [382].
Although these findings together suggest DAXX may have a role in chromatin structure
and thus DNA accessibility for transcription, the direct relationship between DAXX and
changes in global gene expression has not been investigated.
Finally, DAXX has also been reported to regulate the transcription of a number of
specific genes. This idea of DAXX as a transcriptional regulator was initially a surprise,
because DAXX itself does not contain any known DNA binding domains, however it
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does bear a high degree of homology to other known co-repressors [383]. This includes
Sin3A based on its two amphipathic helices that occur in DAXX (PAH1 and PAH2)
[383]. Further, DAXX has been reported to repress expression of a number of
transcription factors including Pax3, ETS1, E2F1, NFκB, p53, and p73 [383-386]. It is
thought to repress the expression of these genes by binding other associated
transcription factors including AP-1 and RELB, allowing it to localize at the promoter
regions of its target genes [387, 388]. Following DAXX recruitment to these sites, DAXX
is thought to repress gene expression by recruiting epigenetic modifying enzymes
including DNMT1, histone deacetylase II, and DEK [388-390].

FIGURE 6 SCHEMATIC OF FAS-MEDIATED APOPTOSIS. Both FADD and DAXX
associate with the death-domain (DD) of the FAS receptor at the C-terminus region.
FADD has been shown to activate apoptosis by directly activating caspase 8, leading to
a cascade that ultimately results in cell death. This is considered the canonical or
classical FAS-mediated apoptotic pathway. DAXX has been shown to also mediate
apoptosis through FAS. It does this by associating with the DD at it C-terminus domain,
allowing it to interact with ASK1. ASK1 then phosphorylates JNK, leading to its
activation.
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DAXX IN CANCER
In the context of cancer, whether DAXX is a positive or negative prognostic
marker appears to be tissue-specific. RNA expression data from the TCGA database
indicates that high levels of DAXX RNA are associated with a poorer overall survival in
renal cancer, while high DAXX RNA expression is associated with improved overall
survival probability in breast cancer [349]. Further, recent whole-genome and exome
sequencing studies have indicated DAXX and its heterochromatin partner ATRX are
frequently mutated in a number of cancers including gliomas, adrenocortico carcinomas,
osteosarcomas, and neuroblastomas [391]. Together, these suggest that DAXX may
play a role in a number of malignancies. In lung cancer, high DAXX RNA expression is
associated with better overall survival probability [392]. This is thought to be due to the
ability of DAXX to bind the transcription factor Slug, blocking its activity and thus
preventing EMT in lung cancer [392]. In hormone-dependent prostate cancer, Puto et
al. demonstrated that DAXX has a tumor promoting effect [390]. Specifically they found
that DAXX repressed autophagy genes within tumor cells by recruiting DNMT1 and
facilitating methylation of their promoter regions [390]. In breast cancer, DAXX may
have a protective or tumor suppressor effect. In patient samples, DAXX protein levels
inversely correlated with expression of the oncogene hepatocyte growth factor receptor
(c-MET) [393]. This is proposed to be due to DAXX’s ability to facilitate methylation of
the c-MET promoter, resulting in a decrease in its gene expression and subsequent
protein levels [393]. In a MCF-7 clone that is resistant to AIs (MCF-7/5C), RNA
sequencing indicated higher expression of miRNAs known to target DAXX compared to
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the AI sensitive MCF-7 parental line, suggesting an inverse relationship between DAXX
levels and AI sensitivity [394]. Overall these findings suggest that DAXX may be a
positive biomarker in breast cancer that warrants further investigation.
PHYTOESTROGENS (PE)
Phytoestrogens (PEs) are naturally occurring compounds found in plants that are
structurally similar to E2 [395, 396]. Thus they are able to interact with ERα and/or ERβ
and partially activate these receptors [395, 396]. PEs are typically separated into five
groups based on their structure which include isoflavones, flavones, flavonols,
flavanones, and stillbenoids [396]. Isoflavones include genistein, daidzein,
formoononetin and biochanin A, and are classified by a 3 ring structure with the third
benzyl group attached to the carbon that is ortho to the ketone group [396]. Flavones
include apigenin, chyrsin and flavone and are differentiated from isoflavones as their
phenyl group attaches to the carbon that is meta to the ketone [396]. Flavonols are
tricyclic aromatic compounds that include quercetin and kaempferol and are
characterized by the presence of hydroxyl group adjacent to the ketone within the
aromatic ring [396]. Flavanones include naringenin and are classified by the absence
of a double bond on their second or middle carbon ring [396]. Stillbenoids are dicyclic
compounds that are classified by the presence of an ethylene group that separates
them, resveratrol is an example of this category [396]. Of these compounds, the most
commonly used in scientific research include genistein (found in soy), quercetin (found
in cranberries), resveratrol (found in grapes and wine), and naringenin (found in
grapefruit and tomatoes) [397-399]. A number of beneficial health properties have been
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reported with dietary or supplementary intake of these compounds including anticancer, improved cardiovascular health, increased bone density, a decrease in
menopause-related symptoms, and decreased fasting blood glucose [399].
Interestingly, many of these properties have also been reported for E2, which are
typically lost when a woman enters menopause or undergoes ET [400].
PES AS MODULATORS OF ER ACTIVITY
As PEs contain aromatic structures that are similar to ER ligands and SERMs, it
was hypothesized (correctly) that these compounds modulate ER activity [395]. The
first studies to test this hypothesis investigated the effects genistein, a component of
soy, which concluded in 1955 that the PE did have estrogenic effects [401]. It was not
until the late 20th century (1998) through the development of assays that quantified
ligand binding affinity and transcription activity of the ERs that this hypothesis was
proven correct [396]. Kuiper et al. via the relative binding assay (RBA) found that the
both ERα and ERβ were able to bind PEs, using HEK293 transfected with each
receptor individually [396]. Setting the binding affinity of E2 to 100, they found the PEs
genistein, apigenin, quercetin, and naringenin were able to bind both receptors with
variability, albeit less, affinity [396]. A portion of these results are summarized in Table
2. Overall all of the PEs had a higher affinity for ERβ vs. ERα with the following
hierarchy: E2>Genistein>>>Apigenin>>Naringenin>Quercetin [396]. Additionally, they
investigated if this correlated with transcriptional activity, using a luciferase reporterdriven by an ERE-containing promoter [396]. They demonstrated that the transcriptional
activity correlated, somewhat, with binding affinity, however the hierarchy changed to
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the following: Genistein>E2>Apigenin>Naringenin>>Quercetin [396]. This is in
agreement with Barkhem et al. who also showed that genistein has a higher binding
affinity for ERα when comparing HEK293 cells transfected with ERα or ERβ [402]. The
effects of genistein on ER transcription were somewhat unexpected as not only did it
more efficiently activate luciferase activity compared to E2, it also was superior in
activating ERα compared to ERβ, even though its RBA was the opposite [396]. This
discrepancy may be due to differences in cofactor recruitment, which is also required for
activation of ER signaling [80, 403]. This was supported by Smith et al. who found that
activation of ERα by individual PEs led to the recruitment of different ER-associated
cofactors [404]. For example like E2, genistein binding of ERα led to recruitment of
SRC-1 and SRC-3, whereas bisphenol-A (BPA), led to recruitment of SRC-1 only [404].
Interestingly, although PEs have been shown to activate ER signaling, a subset do not
induce cell proliferation [405]. Specifically, one group found that neither naringenin nor
quercetin were sufficient to induce ER+ HeLa cell (cervical cancer cell line) proliferation,
but still activated genes containing an ERE promoter [405]. They concluded that this
was because naringenin and quercetin did not activate MAPK cascade, whereas E2 did
[405]. These findings are supported by a separate group that demonstrated that
naringenin was insufficient to induce TEB proliferation and development in the rat
mammary gland compared to E2 [406]. Narigenin was however sufficient to induce ER
target gene expression in MCF-7 cells, including amphiregulin (AREG) [406]. Together
these findings suggest that PEs can preferentially bind one or both of the ER isoforms
and turn on some of their target genes, but they may not induce proliferation in ER+
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breast cancer. Thus, like currently used SERMs, PEs can be considered modulators of
the ER.

TABLE 2. PE AFFINITY AND SUBSEQUENT ACTIVATION OF ER SIGNALING.
Adapted from Kuipper et al. [396].Relative binding affinity was determined by calculating
the ratio of E2 and competitor required to reduce specific radioligand binding by 50%
(ratio of IC50 values for each PE). These were determined by solid-phase competition
experiments. Relative transcriptional activity was determined by dual-transfecting
HEK293 cells with an ER (alpha or beta) plasmid and a luciferase reporter plasmid
controlled by a promoter ERE sequence. 1000 nM of each compound were used to
determine the transcriptional activity and E2 induction was arbitrarily set to 100.

PES AND BREAST CANCER
Rationale for investigating whether PEs have therapeutic properties in cancer
originates from population health studies indicating that countries that have a higher
intake of PEs, have a lower incidence of cancer [407]. This includes colon, prostate and
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breast cancer [407]. In breast cancer, PEs have been reported to act similar to SERMs
in that they can have agonist effects in some contexts and antagonist effects in others,
depending on the cell-type, presence or absence of E2, and the concentration of the PE
[407-411]. The most common PEs found in human diets include resveratrol, genistein,
quercetin, and narigenin, all of which show some degree of benefit in ER+ breast
cancer. Resveratrol alone appears to be weakly estrogenic in MCF-7 cells as it mildly
increases PR expression, however in the presence of E2, resveratrol has a clear, dosedependent antagonistic effect on PR expression [408]. Conversely, resveratrol was
completely antagonistic in the T47D cell line [408]. Further In vitro studies indicated that
resveratrol was sufficient to induce PR expression in mammary organ cultures from
rats, but again in the presence of E2, it became antagonistic [408]. Population health
studies indicate a weak relationship between genistein intake and breast cancer
prevention, however this appears to be time dependent, as this relationship only holds
true if high intake occurs during adolescence [409]. Further genistein is a strong
activator of the ER, resulting in an increase in proliferation of MCF-7 cells in vitro,
suggesting it may promote ER+ breast cancer cell growth [410]. This may depend on
the ERα/ERβ ratio within the cells, as cells with a high ratio (MCF-7) proliferated in
response to genistein, while cells with a low ratio (T47D) did not [412]. This was further
supported by experiments demonstrating that if MCF-7 cells were forced to overexpress
ERβ, thus decreasing the ERα/ERβ ratio, genistein no longer induced proliferation
[412]. Quercetin also appears to have a complex relationship with breast cells as it
inhibits MCF-7 cell proliferation, but induces proliferation of the “normal” MCF-10A
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epithelial breast cell line [412]. Further, in MCF-7 cells that are resistant to tamoxifen,
quercetin also inhibits cell growth, and was sufficient to induce apoptosis, albeit at high
levels (50 uM) [413]. Naringenin has been shown to have similar effects on ER+ breast
cancer cells as quercetin as it induces ER activity, but does not induce proliferation in
MCF-7 cells [414, 415]. This again is thought to be due to the observation that
naringenin does not induce MAPK activation like E2, as naringenin or E2 + U0126 (a
MAPK inhibitor) resulted in a similar inhibition of MCF-7 cell proliferation [415]. These
findings demonstrate two important points. First, PEs have ER agonist activity in ER+
breast cancer cell lines. Second, some PEs are able to do this without inducing tumor
cell growth. To date however the consequences or potential benefits of these two points
has not been fully utilized in the treatment of ER+ breast cancer. The majority of
studies have investigated the cytotoxic effects of these PEs, with doses ranging from
10-250 µM [416]. These are levels that are unlikely to be reached in human patients and
have a greater likelihood of causing off-target effects. This is supported by groups also
reporting that PEs have cytotoxic effects in TNBC cell lines at these levels, which lack
expression of the ER [417, 418]. Together these findings suggest that PEs have
potential therapeutic clinical significance in ER+ breast cancer, however the effects of
lower, more ER-specific doses, should be investigated in the context of the disease.
CONCLUSIONS
Although diagnosis of ER+ breast cancer is more favorable compared to other
breast cancer subtypes, significant clinical problems still exist in the disease. One major
problem is the high rates of treatment resistance and tumor recurrence that occur after
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five years of ET. As these high rates of resistance and recurrence are thought to be due
to, in part, the persistence of TICs in ER+ breast cancer, recent efforts have been made
to decrease the survival of these cells to improve clinical outcomes. The NOTCH
signaling pathway is demonstrated to be required for the survival and activity of TICs in
ER+ breast cancer, thus a logical idea was to inhibit NOTCH signaling with therapeutics
such as GSIs. This was effective in preclinical studies, however its feasibility in the clinic
is questionable presently as current GSI therapies are associated with adverse and
many times intolerable side effects. This suggests the discovery of new therapeutic
markers and treatment modalities to target these TICs may greatly improve the longterm prognosis in ER+ breast cancer.
Activation of the ER by E2 is known to drive breast cell proliferation and
differentiation, allowing healthy females to form a fully functional mammary gland. In
ER+ breast cancer, this becomes problematic as tumor cells undergo unchecked
proliferation in response to ER activation. ETs prevent ER+ breast tumor cell growth,
but are also associated with survival of less differentiated TICs. Alternatively, under the
absence therapy, breast tumor cells proliferate but maintain their more differentiated
state. This would suggest that proliferation and differentiation in the context of ER
activation are linked. Thus, a therapeutic regiment that could maintain breast tumor cell
differentiation without inducing proliferation would be ideal. Further, a biomarker that
identified breast tumor cell differentiation would be useful for tracking this phenomenon
and aid in designing suitable therapies. PEs are known to partially activate ERs, leading
to expression of ER gene targets. Some of these PEs are able to do so without inducing
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cell proliferation. However, the use of these agents in preventing the survival of
undifferentiated cells, like TICs, has not been investigated to date. In this current study
we intended to identify a novel positive prognostic marker in ER+ breast cancer that is
associated with a decrease in TIC survival. Further we sought to determine if this
marker could be used in a therapeutic context to restrict TIC survival in ER+ breast
cancer.

CHAPTER 2
MATERIALS AND METHODS
CELL CULTURE.
MCF-7, T47D, MDA-MB-231 and MDA-MB-468 cells were purchased and obtained from
American Type Culture Collection (ATCC, Manassas, VA). MCF-7 variants including a
long-term E2 deprived (LTED) MCF-7/5C clone, a MCF-7 fulvestrant resistant clone
(MCF-7/FULR) and a MCF-7 tamoxifen resistant clone (MCF-7/TAMR) were gifted from
Drs. Craig Jordan, Eric Ariazi and Debra Tonetti, respectively. MCF-7, MCF-7/FULR
and T47D cell lines were grown in Roswell Park Memorial Institute Medium (RPMI1640, Thermo Fisher Scientific, Waltham, MA). RPMI-1640 was supplemented with
10% Fetal Bovine Serum (FBS, Gemini Bio Products, Sacramento, CA), 1% (2mM) Lglutamine (Thermo Fisher Scientific, Waltham, MA) and 1% (100µM) non-essential
amino acids (Invitrogen, Carlsbad, CA). The MCF-7/FULR had their medium
supplemented with 100nM fulvestrant. The MCF-7/5C and MCF-7/TAMR cell lines were
grown in phenol red-Free RPMI-1640 (Thermo Fisher Scientific Waltham, MA)
supplemented with 10% FBS that was dextran charcoal-stripped to remove E2 from the
solution as well as 2mM L-glutamine (Thermo Fisher Scientific, Waltham, MA) and 1%
non-essential amino acids (Invitrogen, Carlsbad, CA). The MCF-7/TAMR cell line has
their medium maintained with 4-hydroxytamoxifen at a concentration of 100nM. For
experimental conditions the phenol red-free RPMI was used and supplemented with the
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appropriate compounds, for example E2 was added directly to create a final
concentration of 5nM E2. MDA-MB-231 and MDA-MB-468 cells were maintained in
Dulbecco's Modified Eagle Medium (DMEM, Thermo Fischer Scientific, Waltham, MA)
which was supplemented with 10% (MDA-MB-468 cells) or 5% (MDA-MB-231 cells)
FBS (Gemini Bio Products, Sacramento, CA) 1% (2mM) L-glutamine (Thermo Fisher
Scientific, Waltham, MA) and 1% (100µM) non-essential amino acids (Invitrogen,
Carlsbad, CA). For experimental conditions, phenol red-free DMEM (Thermo Fisher
Scientific Waltham, MA) was used and supplemented with FBS that was dextran
charcoal-stripped to remove E2 from the solution as well as 2mM L-glutamine (Thermo
Fisher Scientific, Waltham, MA) and 1% non-essential amino acids (Invitrogen,
Carlsbad, CA). All cell lines were authenticated December 2018 by short tandem
repeat allelic profiling (ATCC, Manassas, VA) and maintained at a low passage number
(below 20 passages/cell line). All cell lines were maintained in a 37oC incubation
chamber at 95% humidity and 5% CO2. Cell maintenance and experimental medium
was changed daily.
DRUGS, CHEMICALS, REAGENTS.
17β-Estradiol (E2) was purchased from Sigma Aldrich (Catalogue # E8875) and
suspended in 100% ethanol to form a 5µM stock solution which was protected from light
and maintained in -20oC. This solution was diluted in growth medium to form a working
concentration of 5nM. Fulvestrant, a SERD of the ER, and 4-hydroxytamoxifen, a
SERM, were purchased from Selleck chemicals (Houston, TX) and suspended in 100%
ethanol to a stock concentration of 100µM, which was protected from light and
maintained at -20oC. This solution was diluted in growth medium to obtain a working
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concentration of 100nM. Cycloheximide (CHX), an active inhibitor of protein translation,
was generously provided by Dr. Charles Hemenway. A stock solution of 10mM
maintained at -20oC was diluted in growth medium to form a working concentration of
10µM. MG132, an inhibitor of the proteasome, was purchased from Sigma Aldrich
(Catalogue # M8699), a stock solution of 10mM was maintained at -20oC and diluted in
growth medium to obtain a working concentration of 10µM for subsequent experiments.
5-azacytidine (5-AZA) was purchased from Sigma Aldrich and suspended in DMSO to
form a 10mM stock which was protected from light and maintained in -20oC. This
solution was then diluted in growth medium to form an experimental working
concentration of 10µM for subsequent experiments. PEs, including Naringenin (NG),
Genistein (GS), Apigenin (AG), Resveratrol (RES), and Quercetin (Q) were purchased
from Selleck chemicals (Houston, TX) and suspended in 100% ethanol. Drugs that are
selective towards ERα or ERβ were generously provided by Dr. Stephanie Watkins.
They include the ERα-specific agonist 4, 4', 4''-(4-Propyl-[1H]-pyrazole-1, 3, 5triyl)trisphenol (PPT) and antagonist 1, 3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP) [419, 420]. The ERβspecific agonist and antagonist used are 2, 3-bis(4-Hydroxyphenyl)-propionitrile (DPN)
and 4-[2-Phenyl-5, 7-bis(trifluoromethyl)pyrazolo[1, 5-a]pyrimidin-3-yl]phenol (PHTPP)
respectively [421, 422]. For in vivo experiments a basement membrane solution called
Matrigel® was used. Corning® Matrigel® Basement Membrane Matrix (Tewksbury, MA,
Cat. 354234) is a solubilized basement membrane preparation extracted from the
Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix
proteins. Its major component is laminin, followed by collagen IV, heparan sulfate
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proteoglycans, entactin/nidogen. It also contains Corning Matrigel Basement Membrane
Matrix also contains TGF-β, EGF, insulin-like growth factor, fibroblast growth factor,
tissue plasminogen activator, and other growth factors which occur naturally in the EHS
tumor.
EXPRESSION VECTORS AND TRANSFECTION.
A mammalian expression vector, pCMV6-entry, containing nothing (Empty
vector, EV) or a human DAXX cDNA (DAXX) were purchased from Origene (Rockville,
MD) and used to transiently overexpress DAXX in cell lines. All cell lines were plated at
a concentration of 1 X 106 cells into 10 cm2 dishes. The following day cells were washed
2X with PBS and transfection medium consisting of 8 mL of growth medium and 2 mL of
Opti-MEM (Life Technologies, Carlsbad, CA) supplemented with 8µg of control Empty
vector or DAXX cDNA-containing vector and Polyethylenimine (PEI) was added to each
plate. PEI was added at a 1:3 ratio with Empty vector or DAXX (8µg) from a 1µg/µL
stock solution. Cells were allowed to propagate for 2 days, following which cells were
trypsinized and added to culture dishes containing their respective growth conditions.
RNA INTERFERENCE AND TRANSFECTION REAGENTS.
A pool of four DAXX siRNAs were used to effectively knockdown DAXX
expression in vitro. These sequences include DAXXi-A (CAGCCAAGCTCTATGTCTA),
DAXXi-B (GGAGTTGGATCTCTCAGAA), DAXXi-C (GAGGTTAACAGGCGCATTG),
DAXXi-D (GCAAAACAAAGGACGCATA), which were purchased from Dharmacon GE
Life Sciences (Lafayette, CO). Non-targeting scrambled control siRNA (SCBi) was
purchased from Qiagen (Germantown, MD). DNMT1 was also targeted using sequence-
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specific siRNA purchased from Origene (Catalogue # SR301244). The transfection
reagent Lipofectamine RNAiMAX (Catalogue # 13778150) was purchased from Thermo
Fisher Scientific (Waltham, MA) and used at a ratio of 1:1 ratio with 10nM of appropriate
siRNA according to the manufacturer’s protocol. All were seeded at a density of 3 X 105
cells into 6 cm dishes. Cells were allowed to adhere for 1 day. The iMAX solution was
made by adding 137.5 uL of RNAiMAX to 2.3 mL of Opti-MEM in a 15 mL tube. In
parallel 23µL of siRNA was added to 381µL of Opti-MEM. Solutions were incubated for
5 minutes. 382µL of iMAX solution was then added to the siRNA solution and allowed to
incubate for 20 minutes at room temperature. The adherent cells were then washed with
PBS 2X and 3.4mL of RPMI was added to each plate followed by 786µL of the siRNA +
iMAX solution.
ANTIBODIES.
Antibodies and their respective concentrations of use include DAXX (1:1000,
25C12, Cell Signaling Technology), β-ACTIN (1:2000, A5441, Sigma Aldrich), NOTCH4
(1:1000, A-12, Santa Cruz Biotechnologies), DNMT1 (1:1000, H-12, Santa Cruz
Biotechnologies), PARP-1 (1:1000, B-10, Santa Cruz Biotechnologies), ER-α (1:1000,
D8H8, Cell Signaling Technologies). β-ACTIN was used as a loading/endogenous
control for total protein western blots and the cytoplasmic extract for the cell
fractionation western blots. PARP-1 was used as a loading control for the nuclear
extract during cell fractionation analysis. Secondary antibodies used for band
visualization include anti-Rabbit and anti-Mouse Horseradish peroxidase (HRP)conjugated secondary antibodies purchased from Cell signaling (Cell Signaling
Technologies).
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WESTERN BLOT ANALYSIS.
1 X 106 cells were seeded into 10 cm2 tissue culture dishes. The following day
cells entered their respective experiments. For siRNA transfection, cells were
transfected with SCBi/DAXXi or SCBi/DNMT1i, for vector transfection EV/DAXX, or
treatments (ethanol, E2, PE, or ER agonists/antagonists) were started immediately as
noted in each subsequent figure. For transfection experiments, cells were incubated for
two days. Following this, cells were washed with PBS 2X. Phenol-red free RPMI with
the addition of vehicle (EtOH), E2 (5nM), 5-AZA (10µM), individual PEs (varying
concentrations), or specific ER agonists/antagonists (varying concentrations) for three
days. 300µL of lysis buffer (1% TritonX-100, 50mM HEPES, 150mM sodium chloride,
5mM ethylene-diaminetetraacetic acid (EDTA), 1mM phenylmethylsulfonyl fluoride
(PMSF), 1mM sodium orthovanadate, 10mM sodium fluoride and 1 protease inhibitor
cocktail tablet (Thermo Fisher Scientific) was used to lyse cells. Cells were scraped
from each plate and the fluid lysate was collected. The lysate was incubated on ice for
10 minutes, following which cells were sonicated 2 times for 10 seconds/each using the
Sonic Dismembrator (Model 100, Thermo-Fisher Scientific, Waltham MA) at 20%
magnitude. 10μL of each sample were plated into a 96-well plate, along with 0, 0.5, 1, 2,
4, 6, 8, and 10mM bovine serum albumin (BSA) protein standards, to determine protein
concentration by BCA protein assay [50:1 Reagent A:Reagent B (Thermo Fisher
Scientific)]. The plate was incubated at 37oC for 30 minutes then read on a 96-well plate
fluorescent plate reader. Protein concentrations were calculated [regression line from
protein standard curve (y=mx+b) used to calculate Average protein concentration – b /
m)]. 20 ug of total protein-containing samples were prepared using 2X Laemmli buffer
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(BioRad, Hercules, CA Catalogue # 1610737) and β-mercaptoethanol (Thermo Fisher
Scientific, Waltham, MA, Catalogue # BP-176-100). Samples were boiled at 95oC for 10
minutes to denature proteins. Proteins were separated by molecular weight using SDSPAGE buffered with 8% tris-glycine along with HiMark Prestained protein standard
(Thermo Fisher Scientific, Waltham, MA, Catalogue # LC5699). Proteins were
separated at 150V for 60 minutes in Tris-glycine SDS Running Buffer. Separated
proteins were transferred to a nitrocellulose membrane using 100V for 60 minutes.
Following transfer, the membrane was blocked using 5% non-fat dry milk or 20% Roche
buffer for 60 minutes at room temperature. TBST (Tris buffered saline plus Tween-20,
5mM Tris-HCL, 5mM Tris-base, 150mM sodium chloride, 0.05% Tween-20 and 0.2%
NP-40 at pH 8.0) was used for dilution of the Roche (NOTCH4 only) or 5% milk (all
other markers) buffer. Primary antibody for the marker of interest was added to the
membrane and incubated overnight at 4oC overnight with constant agitation. The next
day (two day incubation for DAXX) the membrane was washed 3X with TBST (TBS
(Tris buffered saline) for NOTCH4) for 10 minutes each under constant agitation at
room temperature. The appropriate secondary conjugated to HRP was added to the
membrane and allowed to incubate for 60 minutes under gentle agitation. Membranes
were then washed 3X with TBST (TBS for NOTCH4) for 10 minutes. Relative protein
amounts were then detected using enhanced chemiluminescence (ECL) Western
Blotting Substrate (Pierce, Rockford, IL) or SuperSignal West Extended Duration
Substrate (Thermo Fisher Scientific) if needed in a 1:1 volume. Protein bands were
visualized by exposing the membrane to X-ray film in a dark room for 1 to 5 minutes as
needed to for band visualization (MedSci). Re-probing was performed by washing the
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membrane in TBST and then membrane stripping buffer for two 5 minutes incubations.
The membrane was then blocked again in 5% milk or 20% Roche buffer for one hour
and re-probed with the appropriate primary antibody overnight. Densitometry analysis of
the Western blot was done using ImageJ software. All samples were normalized to their
endogenous loading control.
TOTAL CELL GROWTH ASSAY.
1 X 105 cells were seeded in separate wells of a 6-well tissue culture plate and
allowed to adhere overnight. Cells were then washed 2X with PBS and phenol-red free
RPMI was added to each well supplemented with ethanol as a vehicle (EtOH), E2
(varying concentration), individual PEs (varying concentration), or specific ER
agonists/antagonists (100nM). The media was changed every day for a total of seven
days. Cells were removed from the plate by 500µL of trypsin and the trypsin was then
quenched by adding 3mL of phenol-red free RPMI. Cells were spun down at 1200
rotations per a minute (RPM) for 3 minutes. Cell pellets were dissolved in 3mL of
pheno-red free RPMI and a 10µL sample of each condition was isolated. Trypan blue
was then added in a 1:1 mixture and the number of live cells was determined using the
automated Countess® Cell Counter (Invitrogen, Carlsbad, CA). Fold increase in total live
cells was finally calculated by Fold increase= Total viable cells/1 X 105.
CELL CYCLE ANALYSIS.
MCF-7 or T47D cells at a density of 1 X 105 cells were plated in separate wells of
a 6-well plate and allowed to adhere for 24 hours. Cells were washed with PBS 2X and
phenol-red free RPMI medium supplemented with EtOH or 5nM E2 was added to each
well. Growth medium was changed daily for a total of 7 days. Cells and media were
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isolated, put into flow-activated cell sorting (FACS) tubes and centrifuged at 1200 RPM
for 3 minutes. The cell pellet was resuspended and fixed in 2mL of ice-cold 100% EtOH.
The next day cells were again spun at 1200 RPM for 3 minutes and the cell pellet was
resuspended in PBS + 5% FBS. The solution was removed resuspended in 500µL of
5% FBS + 10µg/mL of RNAse A. Cells were incubated at 37oC for 15 minutes and then
allowed to cool at room temperature for 5 minutes. 500µL of 100µg/mL Propidium
Iodide (Sigma Aldrich) was added to each tube. Tubes were then gently vortexed and
incubated in the dark for 1 hour at room temperature. Cell cycle analysis was conducted
using FACS according to the manufacturer’s instructions (Cell Signaling Technology).
REVERSE TRANSCRIPTION AND REAL-TIME POLYMERASE CHAIN REACTION.
3 X 105 cells were plated in separate 6 cm2 dishes and allowed to adhere
overnight. The next day cells were transfected with the appropriate transfection
reagents and siRNA and incubated at 37oC and 5% CO2 for 2 days. Following this, cells
were washed 2X with PBS and phenol-free RPMI supplemented with the appropriate
drugs and concentrations (EtOH, E2, PEs, 5-AZA) were added to the appropriate plate.
After 1 day, cells were harvested on ice by trypsin, trypsin was quenched with phenolfree RPMI and the cells were spun down at 1200 RPM for 3 minutes. The cell pellet was
then resuspended in 500 uL of TRIzol® (Thermo Fisher Scientific, Waltham, MA), vortex
for 10 seconds, and allowed to incubate at room temperature for 5 minutes. 50µL of 1bromo-3-chloropropane (BCP) was then added to each sample (Sigma Aldrich, St.
Louis, MO). The sample was vortexed vigorously 2X for 10 seconds and the sample
was allowed to incubate at room temperature for 5 minutes. Samples were then
centrifuged at 15,000 RPM for 10 minutes at 4⁰C. The clear, aqueous phase was then
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transferred to a new tube and 200µL of 100% EtOH was added, the solution was mixed
immediately to avoid precipitate formation. The total RNA from the sample was then
isolated using the RiboPureTM Kit (Thermo Fisher Scientific). The sample was passed
through a filter cartridge by centrifugation at 12,000 RPM for 1 minute at room
temperature. Each sample was washed twice with 250μL of wash buffer and spun at
12,000 RPM for 1 minute at room temperature. After the second wash, the tubes were
spun one more time at 12,000 RPM for 1 minute to discard any access EtOH buffer.
Each filter cartridge was added to a new tube and 50μL of elution buffer was added to
each cartridge. Samples were allowed to incubate at room temperature for 10 minutes.
Tubes were spun a final time at 12,000 RPM for 1 minute. Total RNA quality and
quantity was determined by measuring the UV absorbance at 260nm using the
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific).
The isolated RNA was then converted to cDNA using a reverse transcriptase
reaction. This was done using the TaqMan Reverse Transcriptase Kit (Applied
Biosystems, Ford City, CA). 1µg of RNA was converted to cDNA in a 100µL volume
consisting of 1X RT buffer, 505mM MgCl2, 500µM dNTPs, 2.5µM random hexamers, 0.4
U/µL RNase inhibitor, and 1.25 U/µL RT enzyme (Multiscribe™ Reverse Transcriptase
Enzyme, Applied Biosystems). The reverse transcriptase reaction was conducted in a
thermal cycler under the following parameters: 10 minutes at 250C, 30 minutes at 480C,
5 minutes at 950C, 60 minutes at 250C, and held at 40C until use. RT-PCR was
performed using the iTaq™ SYBR® Green Enzyme Supermix with ROX (BioRad,
Hercules, CA) in a 96-well optical PCR plate. A mastermix solution of 11.25µL per a
sample was composed of: 50μM forward and reverse primers, and 2x SYBER® Green
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Universal Master Mix. 1.25μL of cDNA was added to 11.25μL of mastermix in duplicate
wells and run using a StepOnePlus thermocycler (Applied Biosystems, Foster City, CA).
The reaction conditions were as follows: initial denature at 950C for 10 minutes, PCR
cycling for 10 seconds at 950C for 40 cycles, and annealing for 45 seconds at 600C.
Melt curves were analyzed to ensure single, consistent amplicon formation. The
average cycle threshold (CT) was used to determine the relative gene expression for
each experimental condition. The CT value is the number of cycles necessary for the
fluorescent signal to overcome the background level, or threshold, of fluorescent signal.
CT values were normalized to the housekeeping gene hypoxanthine-guanine
phosphoribosyltransferase (HPRT), an endogenous control, to discern ΔCT. In short
ΔCT for gene of interest= CT (experimental gene)-CT (HPRT). . ΔΔCT was calculated by
normalizing the ΔCT values to a control sample, for example SCBi transfected cells
grown in 0 nM E2. As described by Rao et. al., relative quantification (RQ) was
calculated using the 2- ΔΔCT method to determine relative fold increases or decreases in
transcript compared to the designated control sample [423]. The PCR primers used for
the detection of specific transcripts are shown in Table 3.
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CYCLOHEXAMIDE CHASE REACTION.
1 X 106 MCF-7 cells were grown in 0, 5nM E2 or 5nM E2 + 100nM fulvestrant for
24 hours, following which, cyclohexamide (CHX) was added to the growth medium to
form a final concentration of 10µM in the presence or absence of the proteasome
inhibitor MG132 (10µM concentration). CHX and MG132 were used in combination
under double positive conditions. Cells were incubated for their specified times (0-20
hours) and total protein was isolated and processed to create 20µg lysates as described
in the Western Blot Analysis methods. The relative amounts of DAXX for each
experimental condition were determined by running the lysates on an 8% Tris-glycine
gel as described in the Western Blot Analysis methods. These experiments were
conducted in triplicate. Densitometry analysis of the Western blot was done using
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ImageJ software and the density of DAXX was plotted relative to the endogenous
control of β-ACTIN. The half-life of DAXX for each CHX experiment and condition was
then determined by linear regression based on the image density of each time point.
The determined half-life for each independent experiment was then pooled and
averaged together in order to analyze statistically significant differences in the half-life of
DAXX based on each experimental condition.
CELL FRACTIONATION.
1 X 106 MCF-7 or T47D cells were isolated and seeded on a 10 cm2 cell culture
dish. Cells were allowed to adhere overnight. Cells were grown in their specified
experimental conditions for 3 days (0 vs. 5nM E2), following which they were trypsinized
and the protein within each cell compartment (cytoplasmic or nuclear) was isolated
using the SubCellular Protein Fractionation Kit (Thermo Fisher Scientific, Waltham, MA)
using the specified manufacturer’s protocol. Cells were washed in PBS and pelleted at
1200 rpm for 3 minutes. The supernatant was removed and CERI buffer supplemented
with a protease inhibitor solution was added to the cell pellet. Cells were vortexed
vigorously for 10 seconds 2X and incubated on ice for 10 minutes. 25µL of CER II buffer
was then added and the solution was again vortexed vigorously for 10 seconds. The
solution was incubated on ice for 1 minute, vortexed and spun at 14,000 RPM for 5
minutes at 4oC. The supernatant was removed and added to a chilled 1.5mL tube. This
was considered the cytoplasmic fraction. The NER buffer was added to the remaining
cell pellet (200µL) and the solution was vortexed for 10 second vigorously 2X every 10
minutes for 40 minutes. In between the tubes were incubated on ice. The tubes were
then spun at 14,000 RPM for 10 minutes. The supernatant was removed and this was
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considered the nuclear fraction. Protein concentrations were determined as described in
the Western Blot analysis methods using the BCA assay. Protein levels were then
visualized by Western Blotting running on an 8% tris-glycine gel as described in the
Western Blot analysis methods. β-ACTIN was used as a loading control for total protein
and the cytoplasmic fraction, while PARP-1 was used as a loading control for the
nuclear fraction.
CHROMATIN IMMUNOPRECIPITATION.
Chromatin Immunoprecipitation (ChIP) assays were performed using the
SimpleChIP© Plus kit (Cell Signaling Technology, Danvers, MA). Specifications for
some of the components used in this kit would not be disclosed by Cell Signaling
Technology. 6 X 106 MCF-7 and T47D cells were seeded in 15 by 3 cm2 tissue culture
dishes. The following day cells were washed 2X with PBS and phenol red-free RPMI
supplemented with EtOH or 5nM E2 was added to the appropriate dish. Cells were
allowed to propagate for 1 day. The next day cells were washed in cold PBS and crosslinked in formaldehyde (Sigma Aldrich, St. Louis, MO) at a final concentration of 1% for
30 minutes at room temperature under constant, gentle, agitation. The reaction was
then quenched in 1.25M glycine and incubated for 5 minutes at room temperature. Cells
were scrapped off the plate and spun at 1200 RPM for 5 minutes at 4oC. Cells were
then washed with PBS and spun at 1200 RPM for 5 minutes at 4oC 2X. Following the
second spin, the pellet was resuspended in 1 mL of ice cold Buffer A (750μL deionized
water, 250μL 4x Buffer A, 0.5μL (1M) Dithiothreitol (DTT), 5μL (200x) PIC) for each
immunoprecipitation and incubated on ice for 10 minutes. During this incubation cells
were inverted every 3 minutes. Nuclei were then pelleted at 3000 RPM for 5 minutes at
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4oC. The supernatant was removed and the nuclei were resuspended in 1 mL of ice
cold Buffer B (825μL deionized water, 275μL 4x buffer B, 0.55μL (1M) DTT). The
solution was spun at 3000 RPM for 5 minutes at room 4oC, and the pellet was
resuspended in 100µL of Buffer B along with 3µL of micrococcal nuclease (4000 gel
units/µL). The solution was incubated at 37oC for 1 hour with intermittent mixing by tube
inversion every 5 minutes. The digestion was then stopped by adding 10µL of 0.5M
EDTA. Nuclei were pelleted again by spinning at 13,000 RPM for 1 minute at 4oC. The
supernatant was removed and 100 uL of 1X ChIP buffer (90μL deionized water, 10μL
10x ChIP buffer, 0.5μL 200x PIC) was added. The tube was incubated on ice for 10
minutes, following which it was sonicated for 20 seconds at 30% power, allowed to sit
on ice for 1 min and then re-sonicated for a total of 6 sonications. The chromatin was
the spun for 10 minutes at 10,000 RPM at 4oC and the supernatant was transferred to a
new tube. 10µL of digested chromatin was put aside at -20 ⁰C to be used as a 2% input
control. The expected chromatin yield was DNA fragments of 150-900 base pairs in
length. 2 antibodies were used from the immunoprecipitation reaction including 2µg of
DAXX-specific (S-20, Santa Cruz Biotechnology, Santa Cruz, CA) or 2µg of nonspecific
rabbit IgG provided by the kit. Antibodies were added to separate tubes for each
experimental condition which was diluted in 400µL of 1X ChIP buffer. The chromatin
mixture + antibody was then allowed to rotate overnight at 4oC.
The following day, ChIP samples were spun down at 1200 RPM and 30µL of
Protein G magnetic beads were added to each reaction. Tubes were then rotated for 2
hours at 4oC. Tubes were spun down at 1200 RPM for 1 min and placed in a magnetic
rack for 2 minutes. The supernatant was removed without taking up any beads and the
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samples were washed with low salt buffer (1x ChIP Buffer) 3X then high salt buffer [(1x
ChIP Buffer and 5M NaCl] 1X. 150µL of ChIP elution buffer was then added to each
sample and incubated on a shaker set to 300 RPM and 65oC for 30 minutes. To all the
experimental samples including the 2% input, 6µL of 5M NaCl and 2µL of Proteinase K
were added to each tube and incubated on the shaker again for 4 hours. Following the
incubation, 600µL of DNA binding reagent A was added to each tube. The solution was
then added to the provided DNA purification columns and spun at 14,000 RPM for 1
minute. The supernatant was discarded and the tubes were washed with 700µL of wash
reagent 2X. The spin column was then put in a new 1.5 mL tube and 50µL of DNA
elution reagent was added to each tube and allowed to incubate at room temperature
for 5 minutes. Quantification of DAXX enrichment was then quantified by RT-PCR using
ChIP specific primers designed to recognize AP-1 binding sites upstream of gene
coding regions. These genes included SOX2, OCT4, NOTCH4, NANOG, and
ALDH1A1. The primer sequences are provided in Table 4.
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MAMMOSPHERE FORMING ASSAY.
3 X 105 cells were plated in 6 cm2 tissue culture dishes and allowed to adhere
overnight. The next day cells were transfected with the appropriate plasmid DNA or
siRNA and allowed to incubate for two days at 37oC with 5% CO2 conditions. Cells were
then washed with PBS 2X and phenol red-free RPMI supplemented with EtOH or 5nM
E2 was added to the appropriate plate based on experimental condition. Cells were
allowed to propagate for 3 days. After this growth period cells were trypsinized and
harvested in PBS. The number of live cells were determined using the Countess
Automated Cell Counter (Life Technologies, Carlsbad, CA) by Trypan Blue staining. 5 X
104 cells were then seeded in a 6-well non-adherent plate coated in mammosphere
forming media [(196mL DMEM/F12 (Life Technologies), 4g methyl cellulose (Sigma
Aldrich, St. Louis, MO), 10mL B27 (Life Technologies), 1μL recombinant EGF (Sigma
Aldrich)]. These plates were then set in the incubator and allowed to propagate for 7
days at 37oC and 5% CO2. Following this period, pictures of the mammospheres were
taken at 20X magnification using a Nikon Diashot TMD Fluorescence Phase Contrast
Inverted microscope (Nikon, Tokyo, Japan). 6mL of PBS were added to each well to
dissolve the mammosphere media. The PBS-mammosphere media solution was then
spun down at 1200 RPM for 5 minutes 4oC, the supernatant was aspirated off and the
mammosphere pellet was resuspended in 1 mL of PBS and deposited into a 2mL tube.
These tubes were then spun at 1200 RPM for 5 minutes. The PBS was aspirated off
and the pellet was again resuspended in 1mL of PBS. 50µL of the mammosphere
solution was then deposited into a 96-well, flat bottom plate with the addition of 200µL of
PBS. Picture were taken at 4X using the same microscope to generate the 20X images.
The mammosphere forming efficiency (% MFE) was determined by counting the
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number of spheres greater than 50µM, with % MFE= (number of spheres counted X
dilution factor)/ (5 X 104) X 100.
RNA SEQUENCING AND PATHWAY ANALYSIS.
1 X 106 MCF-7 cells were seeded in 10 cm2 tissue culture dishes. The next day
cells were transfected with SCBi or DAXXi siRNA for 2 days. Following this, cells were
washed 2X with PBS and phenol-red free RPMI containing 5nM E2 was added to each
dish. This experiment was done two independent times. Total RNA was extracted using
the RNeasy mini Kit (Qiagen, Germantown, MD). Total RNA (3µg) per sample was then
submitted to the University of Chicago Genomics Facility where an RNA-library was
prepared. RNA sequencing was then conducted using the Illumina HiSeQ instrument
was conducted. Raw data was then prepared and analyzed. Quality control was run
using Trimmomatic [424] and FastQC [425]. The alignment and quantification were
done using Kallisto, due to its high efficiency compared to other aligners [426]. The
differential gene analysis was run using the Bioconductor R package DESeq2 [427].
Any manual filtering and the comparison of output from DESeq2 was done using code
Python scripts. Filtering cutoffs of significant genes include Fragments Per Kilobase of
transcript per Million mapped reads (FPKM) ≥ 10, fold change values ≥ 1.5 and p-value
≤ .05. Python code was also written to create heat maps of the data. Pathway analysis
was conducted using the Metascape pathway analysis software pathway, with pathway
enrichment being plotted by p-value for the number of genes in a given Gene Ontology
(GO) pathway.
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BISULFITE SEQUENCING.
3 X 105 MCF-7 cells were seeded onto 6 cm2 tissue culture dishes and allowed to
adhere overnight. Cells were then transfected with the appropriate siRNA (SCBi,
DAXXi, DNMT1i) for 2 days. Following this, cells were washed 2X with PBS and phenol
red-free RPMI supplemented with EtOH or 5nM E2 was added to the appropriate plate
and allowed to propagate for 1 day. Total DNA from each experimental condition was
then extracted using the Qiagen DNeasy® Blood and Tissue Kit (Qiagen, Germantown,
MD. DNA was then converted to bisulfite-treated DNA using the EZ DNA MethylationGold Kit (Zymo Research) following the manufacturer’s protocol. First CT conversion
reagent was prepared by adding 900µL of nuclease free water to 300µL of M-dilution
buffer and 50µL of M-dissolving buffer. This solution was then added to a tube of CT
Conversion Reagent. The activated solution was vortexed for 10 minutes at high speed.
130µL of CT Conversion Reagent was added to 20µL of 500ng of DNA total in a PCR
tube. The PCR tube was then incubated on thermocycler using the following conditions:
98oC for 10 minutes, 64oC for 2.5 hours, 4oC until ready to use. The resulting solution
was added to 600µL of M-binding buffer and then added to the Zymo-Spin™ IC column.
The tube was then spun at 12,000 RPM for 1 minute and the flow-through was
discarded. 100µL of M-Wash Buffer was added to the column and the tube was spun at
12,000 RPM for 1 minute. The flow through was discarded. 200µL of M-Desulphonation
buffer was added to each column, and the reaction was allowed to incubate at room
temperature for 20 minutes. The tube was then spun at 14,000 RPM for 1 minute.
Following which, 200µL of M-Wash buffer was added to each column and the tube was
spun at 12,000 RPM for 1 minute. This was done 2X. The column was then placed in a
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fresh tube and 10µL of M-Elution buffer was added to the column. Tubes were
incubated at room temperature for 5 minutes. The tubes were spun at 14,000 RPM for 1
minute. The Bisulfite-converted DNA was then amplified via PCR using SOX2-promoter
specific primers (Forward: 5’-AAAGATTTTAATAAGAGAGTGGAAGGAA-3’, Reverse:
5’- CCAAAACCCAAAAAAATAATTTTAAC-3’, which were generated using the
MethPrimer free to use software [428]. The PCR was run using the EpiMark® Hot Start
Taq DNA Polymerase enzyme kit (New England BioLabs, Ipswich, MA) and the
following reaction conditions: 95oC 30 seconds, 35 cycles (95oC 20 seconds, 54oC 45
seconds, 68oC 30 seconds), 68oC 5 minutes. The reaction mix consisted of 5µL of PCR
buffer, 10mM dNTPs, 10µM of forward and reverse primer, 500ng of bisulfite converted
DNA and 0.125µL of enzyme for a total of 25µL reaction. The PCR product was then
cleaned and purified using the UltraClean® PCR Clean-Up Kit (Mo Bio Laboratories,
Carlsbad, CA) and sequenced by Sanger Sequencing by ACGT Inc. The methylation
status was then determined by reading the DNA sequence.
EXTREME LIMITING DILUTION ASSAY IN VIVO.
The protocol for this animal study was approved by Loyola University Chicago’s
Institutional Animal Care and Use Committee (IACUC). T150 cm2 tissue culture flasks of
MCF-7 cells were transfected with SCBi or DAXXi siRNA for 2 days. Cells were
trypsinized and injected into the left mammary fat pad of female, ovariectomized FoxN1
nu/nu athymic nude mice (Harlan Sprague-Dawley, Madison, WI) with 5 animals/ cell
dilution and experimental condition used. Cells were injected at varying dilutions
including 10,000, 100,000 or 1,000,000 cells/animal. Animals were also implanted with
a silastic-release capsule containing E2, allowing for a slow, sustained release of E2 that
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mimics post-menopausal levels (83.8pg/mL) for up to 8 weeks [429]. Cells were
implanted into nude mice at a 1:1 ratio with Matrigel® (Corning). Animals were also
tagged an ear tag allowing for tracking of tumor growth for the total experiment. After 8
weeks, the number of mice that developed tumors-designated as having a tumor area
greater than or equal to 40mm2 were counted as mice-bearing tumors. The estimated
frequency of TICs based on the number of tumors that formed at each cell dilution was
determined using Extreme Limiting Dilution Analysis (ELDA) software from Walter Eliza
Hall Institute of Medical Research (http://bioinf.wehi.edu.au/software/elda/).
STATISTICAL ANALYSIS.
All experiments were conducted in triplicate at a minimum and repeated three
independent times, with results reported as Mean ± Standard Deviation (S.D.).
Comparisons between experimental groups were performed using ANOVA with a posthoc Tukey’s test using Graphpad Prism 6 software. All graph figures were generated
using Graphpad Prism 6. The Kaplan-Meier curve for the ELDA experiment was
generated using Graphpad and statistical differences between the two experimental
groups was calculated by the Log-rank, Mantel-Cox test. A power analysis was initially
performed to determine the number of mice needed for the in vivo studies, which was
determined to be 5 animals/group. Differences in TIC-frequency between SCBi and
DAXXi MCF-7 tumors were calculated by the Chi-squared test. Linear regression was
used to determine the estimated half-life of DAXX for each individual CHX chase
experiment. All three half-life calculations were then pooled together for each group and
statistical differences between groups was determined by ANOVA. P-values <0.05 were
considered statistically significant for all experiments.

CHAPTER 3
HYPOTHESIS AND SPECIFIC AIMS
Although ER+ breast cancer is considered the subtype with the best prognosis,
the 20-year survival rate in these patients is below that of TNBC [33]. This decrease in
overall survival is thought to be due to the high rates of resistance and recurrence
following ET [54-55, 338]. Specifically, nearly 50% of patients treated with ET will
develop resistance to one or more therapies over the course of treatment [54, 55]. This
is thought to be due, in part, to the persistence of TICs following ER inhibitory therapies
[13, 269]. As these TICs express low levels of the ER, they are intrinsically resistant to
ET, thus they remain within the tissue and overtime can promote regeneration of a
heterogeneous, more aggressive, tumor [13, 255, 269, 288, 296-297].
TICs in ER+ breast cancer have been shown to require NOTCH signaling for their
survival, and activation of the ER prevents NOTCH activation [338-341]. This suggests
that ETs select for TICs by preventing ER restriction of NOTCH signaling. Based on
this, therapeutics that inhibit NOTCH signaling including GSIs were investigated for their
efficacy to prevent TIC-survival when combined with ET [338-340]. Specifically inhibition
of NOTCH4 signaling was shown to inhibit TIC survival in cell lines and PDX models
[340]. These promising findings have not however resulted in clinical approval as GSI
therapies are associated with side effects which include gastrointestinal toxicity and skin
cancer [347]. Thus, there remains a critical need for new therapies capable of inhibiting
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TIC-survival to improve outcomes in ER+ breast cancer. Recently, Albain et. al.
conducted a biomarker clinical trial with the goal of identifying novel therapeutic targets
to prevent TIC-survival [430, ClinTrials.gov Identifier: NCT00756717]. The study
schema is depicted in Figure 7A. Briefly, biopsies were taken at diagnosis (day 0) prior
to treatment, day 14 following ET (tamoxifen or AI), and then at definitive surgery at day
25 following ET plus a GSI (MK-0752). Global gene expression was conducted by
Affymetrix microarray on RNA from tumor specimen taken at the three time points. A
number of gene transcripts including DAXX were upregulated at day 25 in response to
GSI treatment when compared to day 0 (Figure 7B). As GSIs are known to inhibit TIC
survival, two investigators in Dr. Osipo’s lab (Dr. Andrei Zlobin and Debra Wyatt) tested
if DAXX was required for MCF-7 TIC-survival as assessed by the mammosphere
forming assay. They found that GSI significantly inhibited TIC-survival, but interestingly
GSI-mediated restriction of TIC-survival required DAXX expression [340]. Specifically,
loss of DAXX by siRNA transfection resulted in a recovery in mammosophere formation
under GSI-treated conditions, but only when cells were treated with a form of ET (i.e.
estrogen deprivation) (Figure 7C-7D). This suggests that DAXX expression is regulated
by NOTCH, and independently of NOTCH signaling, DAXX may restrict TIC-survival
(Figure 7).
To further explore the possibility of DAXX regulation of TIC-survival, this
investigator conducted preliminary experiments exploring the relationship between TICsurvival and DAXX. Two ER+ breast cancer cell lines (MCF-7 and T47D) were used for
these studies. Initial studies indicated that these cells were sensitive to ET therapy, as
growth was inhibited under E2 deprivation experiments, mimicking ET by AI therapy
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(Figure 8A). An inverse relationship between cell proliferation and TIC-survival was
observed. Specifically, mammosphere forming efficiency increased when the ER was
inhibited, in agreement with previous reports (Figure 8B) [338-340]. High DAXX protein
expression was found to require E2-mediated ER activation in these cells, as under ET
conditions, DAXX protein expression is low (Figure 8C). This phenomenon appears to
be specific to ER+ breast cancer, as ER- TNBC cells show no changes of DAXX protein
levels under 0 or 5 nM E2 conditions (Figure 8D). As the ER is known to inhibit TICsurvival [338-341], these initial findings suggest it may be through stabilization of DAXX.
How the ER inhibits TIC-survival is not yet fully understood, and a better understanding
would elucidate new potential drug targets. One mechanism the ER is thought to
determine cell-fate breast cells is by inducing genome wide epigenetic modifications,
leading to global changes in gene expression [293, 294]. Genes shown to be highly
expressed by human SCs and TICs include pluripotency genes like SOX2, OCT4 and
NANOG, which are also restricted by the ER [289-292]. Additionally, the epigenetic
modifier DNMT1 has been shown to inhibit expression of these genes, and loss of its
activity is associated with increased efficiency of pluripotent cell formation [295]. One
nuclear protein shown to recruit DNMT1 to gene promoters, leading to epigenetic
silencing of their expression, is DAXX [390]. Thus, one hypothesis is that the ER
restricts TIC-survival by stabilizing DAXX, allowing it to recruit DNMT1 to TICassociated genes, leading to silencing of their expression. This is supported by
preliminary data demonstrating DAXX protein levels inversely correlate with NOTCH4
protein levels and activation, which are known to be required for TIC-survival (Figure 8C
& 8E) [338-341].
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Finally, a therapeutic strategy for increasing DAXX levels would be of clinical
significance if it is in fact shown to inhibit TIC-survival in ER+ breast cancer. The
question is how can we increase a marker that seems to be dependent on ER
activation, without stimulating cells that are dependent on ER activation for growth? PEs
have been reported to modestly activate the ER without stimulating breast cancer cell
proliferation [340, 405]. This ER activation by specific PEs appears to be ER isoform
specific, with some PEs having a higher affinity for ERα and others for ERβ [396]. Thus
we hypothesize that PEs are sufficient to increase DAXX without stimulating ER+ breast
cancer total cell proliferation when given in combination with ET. We expect that this will
result in ET inhibiting total tumor cell proliferation, and the PE inhibiting TIC-survival.
Ultimately improving the long term outcome in the treatment of ER+ breast cancer.
Hypotheses: The ER restricts TIC-survival by maintaining expression of DAXX,
allowing it to regulate TIC-associated transcript expression through DNMT1. Further,
PEs that stabilize DAXX, in combination with ET, will restrict TIC-survival.
Specific Aim 1: Determine if the ER restricts TIC-survival by maintaining DAXX levels
Specific Aim 2: Determine if DAXX, through DNMT1, restricts TIC-survival by
regulating transcript expression of TIC-associated genes
Specific Aim 3: Determine if PEs are sufficient to increase DAXX and restrict TICsurvival in combination with ET
These studies will determine if the ER inhibits TIC-survival through DAXX in ER+
breast cancer. This would be a novel, unreported mechanism, as to how the ER
prevents TIC-survival. Further, these experiments will elucidate the mechanism by
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which DAXX restricts TIC-survival, identifying potential drug targets. This is of clinical
significance, as current therapeutics that limit TIC-survival (GSIs) are associated with
severe side-effects and thus cannot be used in their current formulations [346]. Thus,
positive results from these experiments would possibly identify a new target with
reduced side effect profiles. Finally, if DAXX is shown to be a bonafide suppressor of
TIC-survival, the outlined experiments will illustrate the efficacy of DAXX promoting
agents in restricting TIC-survival in ER+ breast cancer. Taken together, these aims will
identify a new drug target in restricting TIC-survival, its mechanism in doing so, and
potential therapeutics to be used in a clinical setting.
Here, to our knowledge for the first time, we demonstrate that DAXX protein
stability is dependent on E2-mediated ER activation and ETs that inhibit the ER
destabilize DAXX. We illustrate that DAXX is necessary and sufficient for the restriction
of TIC-survival, thus agents that increase DAXX protein would hypothetically decrease
TICs. We demonstrate that DAXX inhibits TIC-survival through inhibition of
pluripotent/stem genes and NOTCH signaling, as it binds to the promoter of these
genes and appears to be required for their epigenetic silencing by DNMT1. As DAXX is
dependent on ER activation for protein expression, partial agonists of the ER,
specifically PEs, were investigated and shown to increase DAXX protein levels. Further
experiments demonstrated a subset of these PEs were sufficient to restrict TIC-survival,
without inducing total cell proliferation. Thus, in combination with ETs that do not affect
ER ligand binding, such as AIs, PEs represent a novel therapy to restrict TIC-survival
without causing tumor growth. Overall this study elucidates a mechanism by which the
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ER restricts TIC-survival, and provides a potential therapeutic to maintain this under ET
conditions.

FIGURE 7. IDENTIFICATION OF DAXX VIA BIOMARKER CLINICAL TRIAL. A.
Outline of the biomarker clinical trial setup. B. Gene transcripts indicated to be
upregulated following GSI therapy in patients, determined from by microarray analysis
of patients’ samples comparing days 1 and day 25 of the trial. C-D. MCF-7 cells were
transfected with non-specific or DAXX-specific siRNA for 2 days. Following which cells
were grown in phenol red-free (Estrogen-) or regular (Estrogen+) RPMI media for 3
days. Cells were then trypsinized and placed in mammosphere media supplemented
with vehicle DMSO or GSI. Cells were allowed to propagate for 7 days and were
imaged and counted. C. Representative images at 20X were taken. D. %MFE was
determined and compared for each group based on images taken at 4X.
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FIGURE 8. DAXX PROTEIN LEVELS ARE DEPENDENT ON ER ACTIVATION AND
INVERSELY CORRELATE WITH TIC-SURVIVAL. A. MCF-7 and T47D cells were
grown in 0 (EtOH) vs. 5 nM E2 conditions for 7 days. Increase in cell number was then
determined by cell counts. Statistically differences within each cell group were
determined by One-way ANOVA, comparing Fold increase in 0 nM vs. 5 nM E2. B.
MCF-7 cells were grown in 0 vs. 5 nM E2 conditions for 3 days and then plated in
mammosphere media for 7 days. Spheres were then counted and %MFE was
determined. Statistical significance in %MFE was determined by One-way ANOVA
comparing 0 nM E2 to 0.5 and 5 nM E2 %MFE. C. MCF-7 and T47D cells were grown
in 0 (E2-) or 5 (E2+) nM E2 conditions for 3 days, following which total protein lysate
was isolated and DAXX and NOTCH4 protein levels were determined by Western Blot
Analysis. β-ACTIN was used as a loading control. D. MDA-MB-231 (231) and MDA-MB468 (468) cells were grown in E2-free (ethanol) or 5nM E2 conditions for 3 days.
Lysates were harvested and proteins subjected to Western blotting to detect DAXX
protein levels. E. MCF-7 and T47D cells were grown in 0 or 5 nM E2 conditions for 3
days, RNA was the isolated and converted to cDNA. Transcript levels of Notch gene
targets, Deltex, Hes1, and Hey1were measured by RT-PCR using HPRT as an
endogenous control. 0 nM E2 transcript levels were standardized to 1.0 and compared
to 5 nM E2 transcript levels. The results of all figures are means ± SDs of three
independent experiments. #= P< 0.05, $= P< 0.01, @= P< 0.001.
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FIGURE 9. WORKING HYPOTHESIS OF INVESTIGATION. A. Working hypothesis
based on known findings and new findings that will be addressed in the Specific Aims.
B. Novel therapeutic strategy based on new findings.

CHAPTER 4
RESULTS

SPECIFIC AIM 1
Determine if the ER restricts TIC-survival by maintaining DAXX levels
The following sub-aims will test Specific Aim 1:
Aim 1A: Determine if ER activation is required for DAXX expression in breast cancer
cells
Aim 1B: Determine if DAXX is required for ER restriction of TIC-survival and frequency
Aim 1C: Determine if DAXX is sufficient to restrict TIC-survival
Aim 1A: Determine if ER activation is required for DAXX expression in ER+ breast
cancer cells
Our preliminary data demonstrate that DAXX protein levels inversely correlate
with TIC-survival and NOTCH activation in both patient samples (Figure 7) and breast
cancer cell lines (Figure 8A-8D). As both TIC-survival and NOTCH signaling are known
to be increased by ET in ER+ breast cancer, we wanted to determine how this relates to
DAXX protein levels. Specifically, we wanted to determine if both passive (0nM E2) and
active (5nM E2 + 100nM fulvestrant) inhibition of the ER resulted in depletion of DAXX,
and if so, why this occurred [338-341].
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ER ACTIVATION INCREASES DAXX LEVELS BY STABILIZATION OF THE
PROTEIN
MCF-7 and T47D cells were grown under passive ER inhibitory conditions (0nM
E2), conditions of ER activation (5nM E2) or conditions of active inhibition of the ER
(5nM E2 + 100nM fulvestrant) for 3 days to match previous studies by Simões et. al.
[340]. Total protein was isolated from these cells and levels of ERα, DAXX, and
NOTCH4 protein were determined by Western Blot analysis. As depicted in Figure 10,
in MCF-7 and T47D cells, expression of DAXX protein requires ER activation as both
passive and active inhibition of the ER resulted in a decrease in DAXX protein (Figure
10A). Further, this protein expression inversely correlates with NOTCH4 protein levels
(Figure 10A). As these data suggest that DAXX requires ER activation to be expressed,
we next wanted to determine how the ER regulates DAXX protein levels. A primary
mechanism by which the ER regulates expression of markers is through transcriptional
modulation [92]. We hypothesized that DAXX may be a classical ER-responsive gene
and thus expression of its transcript increases under conditions of ER activation. To test
this, we performed RT-PCR on cDNA converted from RNA of MCF-7 and T47D cells
grown in 0 or increasing concentration of E2 (0.5-50nM) for 3 days. As a control, a
known ER-responsive gene, PS2 (TFF1), was used to assess ER activity [431]. As
expected, increasing levels of E2 resulted in a concentration-dependent increase of PS2
transcript levels, until a supra-concentration of 50nM E2 was used (Figure 10B).
Unexpectedly, DAXX transcript levels did not significantly change in response to ER
activation (Figure 10B). It was concluded based on these results that ER activation was
not required for expression of DAXX transcripts. An alternative hypothesis is that

104

activation of the ER regulates DAXX at the protein level, and thus under ET conditions
DAXX protein is decreased. We first tested this hypothesis by measuring DAXX protein
levels in the presence or absence of MG132, a proteasome inhibitor. As illustrated in
Figure 10C, under passive ET (0nM E2) vehicle conditions, DAXX protein levels are low,
in agreement with our preliminary data from both MCF-7 and T47D cells (Figures 8C,
10C). Conversely, when the proteasome is inhibited by MG132, the differences in DAXX
protein levels when comparing 0nM vs. 5nM E2 conditions were abolished in both cell
lines (Figure 10C). This suggests that the ER regulates DAXX at the protein level, and
under ET conditions, DAXX protein may be destabilized. We sought to further test this
hypothesis through CHX pulse-chase experiments.
ER ACTIVATION INCREASES DAXX LEVELS BY STABILIZATION OF THE
PROTEIN
In order to determine the correct time interval to quantify DAXX stability, MCF-7
cells were grown under 5nM E2 for 3 days and compared to cells grown in 0nM E2 for 1,
2 or 3 days. Total protein lysate was then isolated and total DAXX protein levels were
compared (Figure 11A). These experiments indicated that depletion of the DAXX
protein occurs between 1-2 days of ET, thus CHX experiments were conducted after
MCF-7 cells were grown in their respective conditions for 1 day, and then CHX was
added (Figure 11A). Based on Western Blot analysis, passive or active inhibition of the
ER is associated with a relatively short half-life of DAXX, predicted to be ~26 hours (1.7
+ 24 hours) for both groups using linear regression modeling (Figure 11B). Conversely,
activation of the ER significantly increased the half-life and thus the stability of the
DAXX protein to ~34 hours (Figure 11B). Shorter time intervals (0-4 hours) were used to
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more accurately estimate the half-life of DAXX under passive and active ER-inhibitory
conditions (Figure 11C). Each independent experiment was graphed and a best-fit line
was determined by linear regression analysis (Figure 11D). The DAXX half-life for each
independent experiment was then compared between the 3 groups via a Two-way
ANOVA, indicating a statistically significant longer half-life of DAXX under ER activated
conditions compared to ET conditions (Figure 11E). Together these results indicate that
ER activation stabilizes DAXX protein, and conditions that inhibit ER activation, such as
ET, result in destabilization and depletion of DAXX in ER+ breast cancer cells.

FIGURE 10. ER ACTIVATION REGULATES DAXX AT THE PROTEIN LEVEL. A. 1X106
MCF-7 and T47D cells were grown in 0nM E2 (EtOH), 5nM E2 or 5nM E2 + 100nM
Fulvestrant (Fulv) conditions for 3 days in 10cm2 tissue culture dishes. Following this,
total protein lysate was isolated and ERα, DAXX and NOTCH4 protein levels were
determined by Western Blot analysis. β-ACTIN was used as a loading control. B. 3X105
MCF-7 and T47D cells were grown in 0, 0.5, 5 or 50 nM E2 conditions for 3 days, RNA
was the isolated and converted to cDNA. Transcript levels of DAXX and PS2 (TFF1) were
measured by RT-PCR using HPRT as an endogenous control. 0 nM E2 transcript levels
were standardized to 1.0 and compared to all E2-treated groups in terms of transcript
levels. The results of all figures are means ± SDs of three independent experiments. #=
P< 0.05, $= P< 0.01, @= P< 0.001. C. 1X106 MCF-7 and T47D cells were grown in 0 or
5 nM E2 conditions for 3 days. During the last 12 hours, vehicle (DMSO) or MG132 at a
final concentration of 10 uM was added to the appropriate plate. Total protein lysate was
isolated and protein levels of DAXX were determined by western blot using β-ACTIN was
used as a loading control.

106

FIGURE 11. ER ACTIVATION STABILIZES DAXX PROTEIN. A. 1X106 MCF-7 cells
were grown in 0nM E2 for 0, 1, 2 or 3 days. Total protein lysate was extracted and DAXX
protein levels were determined by Western Blot Analysis using β-ACTIN as an
endogenous control. B. 1X106 MCF-7 cells were grown in 0nM E2, 5nM E2, or 5nM E2 +
100nM fulvestrant. CHX was then added to new experimental medium at a final
concentration of 10µM. Cells were incubated with CHX for their respective times and total
protein lysate was then isolated. DAXX protein levels were then determined by Western
Blot Analysis, using β-ACTIN as an endogenous control. C. Due to the rapid
destabilization of DAXX under ER-inhibitory conditions, shorter time intervals were used,
the number of cells and the methods were the same as those used to generate Figure
11B. D. DAXX levels for each independent Western blot were measured for density using
ImageJ relative to the loading control β-ACTIN. These were then plotted to form a
degradation curve modeled by a best-fit linear regression line. E. The estimated half-lives
based on each independent CHX experiment (3 total) were averaged together and
compared between groups by Two-way ANOVA @= P< 0.05.
Aim 1B: Determine if DAXX is required for ER restriction of TIC-survival and
frequency
Activation of the ER is known to restrict TIC-survival and activity in ER+ breast
cancer [338-340]. We have shown that the expression of the DAXX protein requires ER
activation (Figure 11) and its protein levels inversely correlate with NOTCH activation
and TIC-survival (Figure 8). We hypothesized that ER-mediated restriction of TICs
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requires DAXX. We tested this by artificially depleting DAXX by siRNA and determining
if this altered TIC-survival and frequency in ER+ breast cancer cells. We hypothesized
under ER activated conditions, loss of DAXX would cause an increase in TIC-survival
and frequency, similar to ET conditions. Additionally, we investigated if DAXX is still
required to inhibit TIC-survival in ER+ breast cancer cell lines that have been treated
with different forms of ET long term and have developed resistance. This is due to
reports that in both cell lines and patient samples, long term ET can alter the
relationship between the ER and cancer cell growth [432, 433]. Specifically, E2 can
induce apoptosis in cells and patient samples [432, 433]. Three cell lines were used to
test this. The MCF-7/5C cell line, derived from MCF-7 cells exposed to LTED to mimic
long term AI therapy, a tamoxifen resistant MCF-7 cell line, derived from MCF-7 cells
exposed long term to the SERM, 4-hydroxytamoxifen (MCF-7/TAMR), and a fulvestrant
resistant cell line, derived from MCF-7 cells exposed long term to the SERD, fulvestrant
(MCF-7/FULR).
ER-MEDIATED RESTRICTION OF NOTCH AND TIC-SURVIVAL REQUIRES DAXX
MCF-7 and T47D cells at a density of 3X105 were transfected with SCBi siRNA
or a pool of 4 DAXX-specific siRNAs and then grown in 0nM E2, 5nM E2, or 5nM E2 +
100nM fulvestrant conditions for 3 days to match our preliminary data and previous
reports by Simões et. al. [340]. A portion of these cells had their total protein isolated
and both DAXX and NOTCH4 protein levels were determined by Western Blot analysis.
As depicted in Figure 12A, DAXX protein expression requires ER activation, and it is
effectively knocked down in DAXXi conditions (Figure 12A). Interestingly, loss of DAXX
is associated with an increase in NOTCH4 protein levels under conditions of ER
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activation, suggesting DAXX is required for ER restriction of NOTCH4 protein
expression (Figure 12A). Cells at a density of 5X104 from each group were also seeded
in mammosphere medium in three independent experiments to quantify TIC-survival. As
shown in Figure 12B, when DAXX is low under ET conditions, TIC-survival is high,
regardless of transfection conditions (Figure 12B). Further, TIC-survival is restricted
when the ER is activated by 5nM E2, and this is lost when DAXX is depleted by siRNA
(Figure 12B). These findings suggest that DAXX is required for ER-mediated restriction
of NOTCH4 expression and TIC-survival, and therapies such as ET that deplete DAXX
allow for both to persist. To confirm that NOTCH4 protein levels correlated with levels of
NOTCH signaling, we quantified the expression of NOTCH target genes within these
groups by RT-PCR. Total RNA was isolated from a portion of these cells and the
transcript levels of PS2, DAXX, and known NOTCH targets (DELTEX, HES1, and
HEY1) were quantified [312]. Both MCF-7 and T47D cells responded to ER activation
and siRNA transfection as predicted, namely E2-treated groups had higher PS2
transcript levels and DAXXi-treated groups had lower DAXX transcript levels (Figure
12C-D). Further, expression of all NOTCH target genes correlated with NOTCH4 protein
levels, with high expression of the gene targets occurring under ET conditions, as well
as DAXXi transfected cells grown in E2-supplemented media (Figure 12D). These
results suggest that DAXX is required for ER-mediated restriction of NOTCH signaling
and TIC-survival, and therapies that inhibit the ER allow for them to increase.
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FIGURE 12. DAXX IS REQUIRED FOR ER RESTRICTION OF NOTCH AND TICSURVIVAL. 3X105 MCF-7 and T47D cells were transfected with SCBi or DAXXi for 2
days and then grown in 0 nM E2, 5 nM E2, or 5 nM E2 + 100 nM fulvestrant for 3 days. A.
A portion of these cells had their total protein lysate was extracted and DAXX and
NOTCH4 protein levels were determined by Western Blot Analysis using β-ACTIN as an
endogenous control. B. 5X104 MCF-7 and T47D were plated in mammosphere media and
allowed to propagate for 7 days. Following which mammospheres were counted to
determine %MFE. Representative images were taken at 20X magnification for each
group. C&D. A portion of these cells had their total RNA isolated and converted to cDNA.
Transcript levels of PS2, DAXX and NOTCH targets were determined by RT-PCR using
HPRT as an internal control. Transcript expression levels of SCBi 0 nM E2 cells were
used as the relative control and set to 1.0. All other groups were then compared to this.
The results of all figures are means ± SDs of three independent experiments. All groups
were compared by to SCBi 0 nM E2 conditions by Two-Way ANOVA to determine
statistical significance #= P< 0.05, $= P< 0.01, @= P< 0.001.
As we used a pool of 4 DAXX-specific siRNA experiments, we next tested the
efficacy of each individual siRNAs to knockdown DAXX to confirm there were no offtarget effects in terms of TIC-survival. MCF-7 cells were transfected with either SCBi,
the pool of all 4 DAXX siRNAs (Pool) or each individual siRNA labeled A-D (Figure 13).
This was done under only ER-activated conditions (5nM E2) as this is the only condition
we hypothesized would result in a change in TIC-survival based on our results in Figure
12. As depicted in Figure 13A, DAXX levels were decreased by the pool and each
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individual DAXX-specific siRNA (Figure 13A). This loss of DAXX was associated with an
increase in TIC-survival in all DAXXi groups compared to SCBi transfected cells (Figure
13B). Due to the increased efficacy in DAXX knockdown, and its improved effects on
TIC-survival recovery, the DAXXi pool was used in all subsequent knockdown
experiments unless otherwise noted.

FIGURE 13. EFFECTS OF DAXX KNOCKDOWN ARE REPRODUCIBLE ACROSS
INDIVIDUAL SIRNA SEQUENCES. 3X105 MCF-7 cells were transfected with SCBi, all
DAXX siRNAs (pool), or each sequence individually (designated A-D) for 2 days and then
grown in 5 nM E2 for 3 days. A. A portion of these cells had their total protein lysate was
extracted and DAXX protein levels were determined by Western Blot Analysis using βACTIN as an endogenous control. B. 5X104 MCF-7 were plated in mammosphere media
and allowed to propagate for 7 days. C. Representative images taken at 20X
magnification. Following which mammospheres were counted to determine %MFE. The
results of (B) are means ± SDs of three independent experiments. All groups were
compared by One-Way ANOVA to SCBi conditions to determine statistical significance
$= P< 0.01, @= P< 0.001.
LOSS OF DAXX HAS NO EFFECT ON TOTAL CELL SURVIVAL
To determine if these changes in cell survival following DAXX knockdown were
specific to TICs and not due to changes in total cell viability, fold increase in total live
cells and their relative amounts in each cell cycle were quantified. Both MCF-7 and
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T47D were transfected with SCBi or DAXXi siRNA and grown in 2D bulk culture for 7
days in 0nM E2, 5nM E2, or 5nM E2 + 100nM fulvestrant growth conditions. Following
which, cells were counted and relative % in each cell cycle stage was determined. As
expected, ER activation by E2 caused a significant increase in total cell viability in both
cell lines when comparing 5nM E2 to 0nM E2. However, DAXX knockdown had little
effect on cell viability when comparing SCBi to DAXXi transfected cells (Figure 14A).
Further, cell cycle analysis indicated an increased number of cells in S-phase in
response to 5nM E2, but again little effect was observed when comparing SCBi vs.
DAXXi when comparing 0 and 5nM E2 treatment conditions (Figure 14B). This suggests
that DAXX regulates the survival of TIC, but has no effect on total cell survival or
proliferation. Thus the therapeutic targeting of DAXX will hypothetically have little effect
on total tumor cell growth.
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FIGURE 14. DAXX STATUS HAS LITTLE EFFECT ON BULK CELL PROLIFERATION.
MCF-7 and T47D cells were transfected with non-specific (SCBi) or a pool of DAXX siRNA
sequences (DAXXi) for 2 days. Cells were grown in 0 (ethanol), 5nM E2, or E2 + 100nM
fulvestrant (FUL) for 7 days. A. Cells were removed from their plates with trypsin, the
solution was quenched with growth media containing 0nM E2, and the pellet was resuspended in growth medium containing 0nM E2. Cells were stained with trypan blue and
the number of live cells was determined using an Invitrogen Countess Cell Counter. Fold
increase in live cells were determined using the equation Fold increase in live cells= (Total
live cells counted/100,000 cells originally plated). B. A subset of cells were isolated from
their growth plates with trypsin, quenched with growth medium containing 0nM E2 and
fixed in 70% ethanol overnight. Cells were then treated with RNAse A for 15 minutes and
stained with propidium iodide for 1 hour. Stages of cell cycle were then assessed by flow
cytometry. The results of both figures are means ± SDs of three independent experiments.
All groups were compared by Two-Way ANOVA to SCBi 0 nM E2 conditions to determine
statistical significance *= P< 0.05, @= P< 0.001.

ER-MEDIATED RESTRICTION OF TIC FREQUENCY IN VIVO REQUIRES DAXX
We have demonstrated that ER-mediated restriction of both NOTCH signaling
and TIC-survival requires DAXX expression in ER+ breast cancer cells in vitro, we next
wanted to determine whether these findings could be translated to an in vivo setting. We
tested this using an ELDA. MCF-7 cells were grown in 2D bulk culture and transfected
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with SCBi or DAXXi for 2 days. Following this, cells were isolated, washed, and
resuspended in 100% Matrigel®. Cells were injected at 3 dilutions including 1X106,
1X105 or 1X104 cells/mouse and were injected into the mammary fat pad of female
ovariectomized athymic mice. This was done under conditions where the animals were
also implanted with silastic-release capsules containing E2, allowing for a slow,
sustained release of E2 that mimics post-menopausal levels (83.8 pg/mL) to maintain
ER activation for 8 weeks [429]. DAXX knockdown was confirmed by isolation of a
subset of these cells prior to implantation and running Western Blot analysis for DAXX
protein expression (Figure 15A). Following 8 weeks, animals were euthanized and
tumors were isolated and their frequency within each group and total volume was
documented (Figure 15B). Overall tumor frequency was higher in DAXX-depleted cells
across all cell dilutions, suggesting an increased ability of these cells to recapitulate
tumor formation in vivo (Figure 15B). Tumors were measured weekly and the date of
appearance of a palpable tumor was documented for each cell dilution and transfection
group. Comparison of transfection groups across all cell dilution groups indicated a
significantly longer tumor-free rate in control vs. DAXX-depleted tumors (Figure 15C).
Based on tumor frequency for each group, the TIC-frequency was calculated using an
ELDA software [302]. This analysis indicated that under control ER activated conditions,
the TIC-frequency is roughly 1/589,536 cells (Figure 15D). Interestingly, when DAXX is
depleted under ER activated conditions, the TIC-frequency increases to 1/65,072 cells
(Figure 15D). This is a 9-fold increase in TIC-frequency when DAXX is depleted, which
we have shown occurs under ET conditions. As TICs are thought to be a primary
contributor to cancer recurrence in ER+ breast cancer, we used KMplotter software to
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determine whether DAXX RNA expression levels are associated with recurrence free
survival (RFS) in patients with ER+ breast cancer [13, 269, 434]. Following ET, high
DAXX RNA transcript levels are associated with a significantly longer recurrence-free
survival in patients with ER+ breast cancer, which is in agreement with the %tumor-free
survival plot of our animal experiment (Figures 15C & 15E). Together these findings
suggest that ER-mediated restriction of TIC frequency requires DAXX, and that loss of
DAXX upon ET treatment, results in an increased TIC-frequency and risk of cancer
recurrence.
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FIGURE 15. ER REQUIRES DAXX TO RESTRICT TIC-FREQUENCY IN VIVO. MCF-7
cells were transfected with SCBi or DAXXi for 2 days, following which cells were isolated
and used for an in vivo ELDA. A. A small subset of cells used for in vivo experiments had
their total protein isolated. The lysate was then quantified for DAXX levels by Western
Blot Analysis to confirm knockdown using β-ACTIN as a loading control. B. After 8 weeks,
tumors from each transfection and cell dilution group were isolated and frequency and
volume were recorded. These are depicted in tabular form with representative photos. C.
Tumors were measured in vivo weekly for each cell dilution and transfection group. The
formation of palpable tumors was recorded by date and graphed on a tumor-free survival
curve. Transfection groups across all cell dilutions were compared by the Log-rank
(Mantel-Cox) Test to determine statistically significant differences in tumor-free survival
between transfection groups. D. Tumor frequency for each cell dilution and transfection
group was deposited into an ELDA software to tabulated TIC-frequency for each
transfection group [301]. The lower, estimated and upper TIC-frequency are represented
in the table. These numbers are read as 1/number in terms of TIC-frequency. Estimated
TIC-frequency was compared between transfection groups by the Chi squared test. E.
Using the KMplotter software, recurrence free survival was compared in patients with ER+
breast cancer stratified for high vs. low DAXX RNA expression following ET [433].
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IN ET RESISTANT CELLS, DAXX IS ALSO REQUIRED TO RESTRICT TICSURVIVAL
To determine the role of DAXX in ER+ breast cancer cells resistant to long term
ET, three distinct MCF-7 cells-derived by exposing them to long term estrogen
deprivation (MCF-7/5C-LTED), 4-hydroxytamoxifen treatment (MCF-7/TAMR), or
fulvestrant treatment (MCF-7/FULR) were used. We first wanted to determine if cell
viability is altered in all three cells lines following long term ET in response to ER
activation and inhibition as this has been reported in some cases [432, 433]. Total cell
growth was assessed in the presence or absence of E2 following SCBi or DAXXi
transfection. As indicated in Figure 16, total cell growth varies between the three ET
resistant cell lines under conditions of ER activation or inhibition. The LTED MCF-7/5C
cells were resistant to both passive and active ER inhibition, but now have decreased
viability in response to 5nM E2, which was expected as these cells have been shown to
undergo apoptosis in response to E2 (Figure 16A) [432]. Further, there is a recovery in
total cell growth when DAXX is depleted, suggesting DAXX is required for E2-mediated
growth inhibition (Figure 16A). The MCF-7/TAMR line was insensitive to E2 treatment or
ER inhibition regardless of DAXX depletion (Figure 16B). Thus, these cells are resistant
to both forms of ER inhibition, but are also insensitive to ER activation. Finally, the
MCF-7/FULR line grew under all conditions, but had the most significant growth in
response to E2 treatment. Overall this suggests resistance to distinct forms of ET may
alter ER function and sensitivity to ET by distinct mechanisms. To ascertain whether
DAXX levels may contribute to these distinct phenotypes, DAXX levels under 3 days of
passive ER inhibition (0nM E2), ER activation (5nM E2), or active ER inhibition (5nM E2
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+ 100nM fulvestrant) were measured by Western Blot analysis in all three ET resistant
cell lines, using the parental MCF-7 from which they were derived as a control
(designated by “WT”). As indicated in Figure 16D, MCF-7/5C cells have a similar effects
to parental MCF-7s in terms of DAXX protein expression (Figure 16D). Specifically E2mediated ER activation is required for expression of the DAXX protein. This would
suggest that the ER in MCF-7/5C is functionally similar to the MCF-7 parental line in
terms of stabilization of DAXX protein, however more experiments are needed to
confirm this. This is also somewhat consistent in the MCF-7/FULR line, as DAXX levels
are low in the absence of E2 and increase in the presence of 5 nM E2 (Figure 16D). The
major difference however is that under active ER inhibition with fulvestrant, DAXX is still
expressed, albeit in modest amounts. One hypothesis for this is that the ER is able to
escape fulvestrant and is still partially active under these conditions. This is supported
by the total cell growth assay indicating an increased growth under E2 + fulvestrant
conditions, but less than that of E2 alone (Figure 16C). Finally, the MCF-7/TAMR cells
that demonstrated no changes in growth regardless of ER inhibition/activation
conditions (Figure 16B) also had little differences in DAXX expression (Figure 16D).
Together, this suggests that growth of MCF-7/TAMR cells is independent of E2mediated ER activation and DAXX expression. To determine if these findings in bulk
cells correlate to TIC-survival, all three ET-resistant cell lines were transfected with
SCBi or DAXXi siRNA for two days. Cells were then grown in 0nM E2, 5nM E2, or 5nM
E2 + 100nM fulvestrant for 3 days to match experiments conducted to generate Figure
12. A subset of these cells were used for Western Blot analysis to confirm DAXX
knockdown. This demonstrated that DAXX knockdown was successful in all three ET-
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resistant cell lines (Figure 17A). Based on results from mammosphere formation, MCF7/5C cells displayed a similar phenotype to their parental MCF-7 in that ET (0nM E2 or
fulvestrant) increased TIC-survival (Figure 17B). These are also conditions when DAXX
levels are relatively low in MCF-7/5C (Figure 17A) similar to their parental MCF-7s
(Figure 12A). Additionally similar to the parental MCF-7s, E2 inhibited MCF-7/5C TICsurvival, and this inhibition was reversed upon DAXX depletion (Figure 17B). However,

FIGURE 16. ET RESISTANT MCF-7 LINES RESPOND DIFFERENTLY TO ER
INHIBITION AND ACTIVATION IN TERMS OF CELL GROWTH AND DAXX LEVELS.
MCF-7/5C (A), MCF-7/TAMR (B), and MCF-7/FULR (C) cells were transfected with nonspecific (SCBi) or a pool of DAXX siRNA sequences (DAXXi) for 2 days. Cells were grown
in 0 (ethanol), 5nM E2, or E2 + 100nM fulvestrant (FUL) for 7 days. Cells were removed
from their plates with trypsin, the solution was quenched with growth media containing
0nM E2, and the pellet was re-suspended in growth medium containing 0nM E2. Cells
were stained with trypan blue and the number of live cells was determined using an
Invitrogen Countess Cell Counter. Fold increase in live cells were determined using the
equation Fold increase in live cells= (Total live cells counted/100,000 cells originally
plated). D. 1X106 cells from parental MCF-7 (WT) and their long term ET conterparts were
plated and grown in 0 nM E2, 5 nM E2, or 5 nM E2 + 100 nM fulvestrant for 3 days. Total
protein was isolated and total lysate was run via Western Blot Analysis to determine DAXX
protein levels β-ACTIN was used as a loading control. The results of figures A-C are
means ± SDs of three independent experiments. All groups were compared to SCBi 0
nM E2 growth conditions by Two-Way ANOVA to determine statistical significance #= P<
0.05, $= P< 0.01 @= P< 0.001.
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because MCF-7/5C viability is decreased by 5nM E2 (Figure 16A), it cannot be
determined if this decrease in TIC-survival is due to DAXX-mediated restriction of TICs
or due to decreased viability of these cells as E2 induced apoptosis (Figure 16A). MCF7/TAMR cells exhibit a different phenotype from their parental MCF-7 cells as neither
total cell growth nor DAXX levels were altered by ER activation or inhibition (Figure 16B
& 16D). This trend extended to TIC-survival as similar % MFE was observed across
conditions of ER activation or inhibition (Figure 17C). Interestingly, DAXX knockdown
was sufficient to increase TIC-survival, suggesting DAXX can still regulate TICs,
however DAXX protein stability is no longer regulated by the ER (Figure 17C). The
MCF-7/FULR cell line exhibited a similar trend in terms of TIC-survival when compared
to the parental MCF-7. Namely, TIC-survival was relatively high under 0nM E2
conditions, and this was inhibited under E2-supplemented conditions (Figure 17D). This
E2-mediated restriction of TIC-survival was again dependent on DAXX as depletion of
DAXX resulted in a recovery of %MFE (Figure 17D). Interestingly, under 5nM E2 +
100nM fulvestrant conditions, when DAXX expression is modest, but less than E2-only
conditions (Figure 16D), TIC-survival is also modestly inhibited (Figure 17D). This
inhibition is lost however when DAXX is depleted by siRNA (Figure 17D). Together
these findings would suggest that DAXX is still able to restrict TIC-survival in these
cells, as their %MFE directly correlates with the amount of DAXX expressed in each
given condition (Figure 17D). Overall, DAXX is still required to restrict TIC-survival in the
three ET resistant MCF-7 lines, however it is the difference in DAXX protein expression
in response to ER activity that seems to account for differences in TIC-survival.
Ultimately this suggests that DAXX still potentially remains a suitable target in both ET
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sensitive and resistant breast cancers, however the mechanism of targeting DAXX may
change.

FIGURE 17. DAXX MAINTAINS TIC-RESTRICTION IN ET RESISTANT MCF-7 CELL
LINES. MCF-7/5C, MCF-7/TAMR, and MCF-7/FULR cells were transfected with nonspecific (SCBi) or a pool of DAXX siRNA sequences (DAXXi) for 2 days. Cells were grown
in 0 (ethanol), 5nM E2, or E2 + 100nM fulvestrant (FUL) for 3 days. A. A subset of cells
had their total protein isolated and the lysate was quantified for DAXX protein levels by
Western Blot Analysis using β-ACTIN as a loading control. 5X104 MCF-7/5C (B), MCF7/TAMR (C), and MCF-7/FULR (D) cells were plated in mammosphere media and allowed
to propagate for 7 days. Mammospheres were then counted and %MFE was determined.
The results of figures B-D are means ± SDs of three independent experiments All groups
were compared to SCBi 0 nM E2 growth conditions by Two-Way ANOVA to determine
statistical significance #= P< 0.05, $= P< 0.01 @= P< 0.001.

Aim 1C: Determine if DAXX is sufficient to restrict TIC-survival
We have demonstrated that DAXX is required for ER inhibition of both NOTCH
signaling and TIC-survival. Further we have found that DAXX may be a positive
prognostic marker as higher DAXX expression is associated with a longer recurrence
free survival (Figure 15E). Additionally as DAXX is shown to be required for ER to inhibit
expression of NOTCH gene-targets, it may be a direct inhibitor of NOTCH signaling
(Figure 12D). This would be of clinical significance as NOTCH signaling inhibitors such
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as GSIs have been shown to reduce TIC-survival and activity, but their use
therapeutically is limited due to their side effect profile [338-341, 347]. Thus to
investigate whether DAXX is sufficient to inhibit NOTCH signaling and TIC-survival,
DAXX was ectopically expressed in MCF-7 and T47D cells using a mammalian
expression vector. Following transfection, NOTCH levels, expression of its downstream
gene targets and TIC-survival were assessed. We hypothesized that NOTCH signaling
and TIC-survival would decrease due to forced overexpression of DAXX, specifically
under ET conditions, overall rendering it a potential drug target in ER+ breast cancer.
DAXX IS SUFFICIENT TO INHIBIT NOTCH SIGNALING AND TIC-SURVIVAL
First, to determine transfection efficiency of ER+ breast cancer cell lines, MCF-7
cells were transfected with a GFP-labeled SUMO-1 vector for 2 days and expression of
GFP was determined by FACS. These results are represented in Figure 18 and
demonstrate a transfection efficiency of ~70% (Figure 18). MCF-7 and T47D cells were
transfected with an empty vector (EV) or a human DAXX cDNA-containing vector
(DAXX) under control of pCMV6 promoter for 2 days. Cells were then propagated in 0
or 5nM E2 medium for 3 days to match experiments conducted in Figure 12. 5 X 104
cells from each experimental group were then plated in mammosphere medium to
assess TIC-survival in vitro. A portion of these cells were isolated for total protein
extraction to confirm DAXX overexpression and protein levels of NOTCH4 by Western
Blot analysis. As depicted in Figure 19A, high DAXX protein expression is dependent on
ER activation under control conditions, and we were able to successfully overexpress
DAXX when cells were transfected with a DAXX-containing vector (Figure 19A).
Interestingly under ET conditions, ectopic expression of DAXX is sufficient to decrease
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NOTCH4 protein levels, suggesting it may fact be sufficient to decrease NOTCH4
signaling. This was supported by RT-PCR experiments from a subset of these cells,
indicating that expression of NOTCH target genes was decreased when the ER is
activated by 5nM E2, or under ET conditions when DAXX is overexpressed (Figure
19B). This confirms that DAXX is sufficient to repress NOTCH4 signaling, a pathway
required for TIC-survival [338-340]. Three independent experiments were plated in
mammosphere medium for MCF-7 and T47D cells to determine if these effects on
NOTCH signaling correlated with % MFE. As illustrated in Figure 19C, ET results in
relatively high TIC-survival, which is inhibited by ER activation (Figure 19C). Further,
overexpression of DAXX, specifically under ET conditions, results in a decrease in TICsurvival (Figure 19B). This suggests that DAXX is sufficient to inhibit TIC-survival under
ET conditions. These findings are of therapeutic significance, as ET is known to be
effective at reducing total ER+ breast cancer cell survival as previously reported and
demonstrated in our own total cell growth assays, and has very low associated toxicity
(Figure 14) [80]. Thus, these findings indicate a dual therapeutic regiment of ET and a
DAXX-promoting agent may be effective to eliminate both bulk and TIC cells. To confirm
DAXX overexpression does not result in changes in total tumor cell growth, we
conducted a total cell growth assay under control and DAXX overexpression conditions.
1 X 105 MCF-7 and T47D cells were plated in 0 or 5nM E2 conditions for 7 days,
following which total live cell numbers were determined and fold increase in live cell
number was calculated. As demonstrated in Figure 20 from both MCF-7 and T47D cells,
E2 is sufficient to induce total cell growth, but DAXX overexpression has little effect on
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total cell growth (Figure 20). Combined with Figure 12, these results suggest that DAXX
is specifically a TIC suppressor while having little effect on bulk cell growth.

FIGURE 18. TRANSFECTION EFFICIENCY OF MCF-7 CELLS. 1X106 MCF-7 cells
were transfected with no DNA (A) or a SUMO-1 vector labeled with GFP (B) for two
days with PEI. Cells were then trypsinized and run via FACS to determine the number
of cells expressing the GFP signal.

AIM 1 Conclusions
The results from Aim 1 demonstrate that the expression of the DAXX protein
requires E2-mediated ER activation in ER+ breast cancer cells, and the ER increases
DAXX levels by increasing protein stabilization. Further in vitro and in vivo experiments
indicate DAXX is required for ER-mediated restriction of TIC-survival, thus therapies
that inhibit the ER such as ET may increase TIC-survival by depleting DAXX. DAXX is
required to restrict TIC-survival in both ET sensitive and resistant cell lines suggesting it
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may be a viable therapeutic target in patients presenting with either form of ER+ breast
cancer. However the mechanism by which ET resistant cells increase DAXX levels is
still unclear, indicating that DAXX-promoting therapies in ET resistant breast cancer
may not be beneficial. Finally, DAXX is sufficient to restrict TIC-survival under ET
condtiions without altering total cell growth. This indicates that potential therapies that
increase DAXX expression when combined with ET may be effective at reducing TICsurvival and thus prevent ER+ breast cancer recurrence.

FIGURE 19. DAXX IS SUFFICIENT FOR RESTRICTION OF NOTCH AND TICSURVIVAL. 3X105 MCF-7 and T47D cells were transfected with EV or DAXX for 2 days
and then grown in 0 nM E2 or 5 nM E2 for 3 days. A. A portion of these cells had their total
protein lysate was extracted and DAXX and NOTCH4 protein levels were determined by
Western Blot Analysis using β-ACTIN as an endogenous control. B. A portion of these
cells had their total RNA isolated and converted to cDNA. Transcript levels of PS2, DAXX
and NOTCH targets were determined by RT-PCR using HPRT as an internal control.
Transcript expression levels of SCBi 0 nM E2 cells were used as the relative control and
set to 1.0. All other groups were then compared to this. C. 5X104 MCF-7 and T47D were
plated in mammosphere media and allowed to propagate for 7 days. Following which
mammospheres were counted to determine %MFE. Representative images were taken
at 20X magnification for each group. The results of all figures are means ± SDs of three
independent experiments. All groups were compared by to EV 0 nM E2 conditions by
Two-Way ANOVA to determine statistical significance #= P< 0.05, $= P< 0.01, @= P<
0.001.
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FIGURE 20. DAXX OVEREXPRESSION HAS LITTLE EFFECT ON TOTAL TUMOR
CELL GROWTH. MCF-7 and T47D cells were transfected with EV or DAXX for 2 days.
Cells were grown in 0 nM E2 or 5nM E2, for 7 days. Cells were removed from their plates
with trypsin, the solution was quenched with growth media containing 0nM E2, and the
pellet was re-suspended in growth medium containing 0nM E2. Cells were stained with
trypan blue and the number of live cells was determined using an Invitrogen Countess
Cell Counter. Fold increase in live cells were determined using the equation Fold increase
in live cells= (Total live cells counted/100,000 cells originally plated).

FIGURE 21 AIM 1 SUMMARY FIGURE. A. What is known, namely that activation of the
ER inhibits TIC-survival, and ET that block ER actvitiy prevent this. B. New model based
on Aim 1 data in which we have shown that the ER inhibits TIC-survival by stabilizing
DAXX protein.
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SPECIFIC AIM 2

Determine if DAXX requires DNMT1 to restrict TIC-survival and repress
expression of TIC-associated genes
The following sub-aims will test Specific Aim 2:
Aim 2A: Determine the cellular localization of DAXX in ER+ breast cancer cells
Aim 2B: Determine if DAXX is necessary and sufficient to restrict transcript expression
of TIC-associated genes
Aim 2C: Determine if DNMT1 activity is required to restrict transcript expression of TICassociated genes and TIC-survival
Aim 2A: Determine the cellular localization of DAXX in ER+ breast cancer cells
Activation of the ER by E2 restricts TIC-survival and correlates with increased
expression of epithelial differentiated markers (i.e. E-cadherin), and lower expression of
mesenchymal and stem-associated markers (NOTCH4, SNAIL, SLUG, SOX2, OCT4,
NANOG) [289-292, 338-340]. How the ER maintains this expression profile to prevent
TIC-survival is not fully understood [293, 294]. However, it has been shown that the ER
determines cell fate in part by maintaining genome-wide epigenetic marks [293, 294].
Specifically, Bloushtain-Qimron et. al. reported that the methylation patterns within
differentiated vs. less differentiated cells were distinct, with SCs and TICs containing
hypomethylated DNA regions near transcriptional start sites of pluripotent genes [294].
DNMT1 has been demonstrated to negatively regulate pluripotent genes including
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SOX2, OCT4, and NANOG, and further, loss of DNMT1 activity results in an increase in
induced pluripotent stem cell formation in vitro [295]. Whether the ER uses DNMT1 to
restrict expression of these pluripotency genes has not yet been reported to our
knowledge.
DAXX is a protein we have shown to be dependent on ER-activation for
stabilization (Figure 11). We have also shown that ER activation requires DAXX to
restrict TICs, although the mechanism is not yet known (Figure 12). DAXX has been
reported to function as a transcriptional repressor in multiple diseases and cell types
[347, 382, 386-389]. This repression is not by DAXX directly binding DNA, as the
protein does not contain identifiable DNA binding motifs within its structure [383].
Rather, it is thought to associate with other DNA-binding transcription factors to form a
complex, including AP-1 and RELB [387, 388]. Once this complex forms, DAXX has
been shown to act as a repressor due to its ability to recruit epigenetic modifying
enzymes including DNMT1, histone deacetylase II and DEK [388-390]. This has been
demonstrated in another hormone-dependent disease, prostate cancer [390]. Based on
these reports and our own findings, we hypothesize that the E2-mediated ER activation
restricts TIC-associated/pluripotency gene expression through DAXX and DNMT1. To
test this hypothesis, we first needed to determine if DAXX was localized within the
nucleus of ER+ breast cancer cells and further if it is enriched at promoters of TICassociated/pluripotency genes. We accomplished this by conducting cellular
fractionation studies to determine if DAXX is concentrated within the nucleus versus the
cytoplasm and whether the localization changes upon ET treatment. We then
interrogated whether nuclear DAXX associates with the promoter regions of TIC-
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associated/pluripotency genes by chromatin immunoprecipitation (ChIP), and again
whether this is lost in response to ET.
DAXX IS LOCALIZED IN THE NUCLEUS OF ER+ BREAST CANCER CELLS
MCF-7 and T47D cells were plated at a density of 1 X 106 in 10 cm2 dishes and
grown in 0 or 5nM E2 conditions for 3 days to match previous mammosphere
experiments. Total protein or separate cytoplasmic and nuclear fractions were isolated
using a cell fractionation kit (Thermo Fisher Scientific, Waltham, MA). The relative
amounts of DAXX protein in total, cytoplasmic, and nuclear lysates were then
determined by Western Blot analysis. As shown in Figure 20, E2-mediated ER activation
is required for high DAXX protein expression in total protein lysates of MCF-7 and T47D
cells (Figure 20). Further, little cytoplasmic DAXX is detectable in either cell line under
with 0 or 5nM E2 treatments (Figure 20). Nuclear expression of DAXX however is high in
response to E2 treatment, and this is decreased in response to ET (Figure 20). Overall
this demonstrates that under conditions in which the ER is activated by E2 and TICsurvival is low, nuclear DAXX levels are high in ER+ breast cancer cells. Conversely,
under ET conditions, when TIC-survival is high, nuclear DAXX levels are low.
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FIGURE 22. DAXX IS CONCENTRATED IN THE NUCLEUS OF ER+ BREAST
CANCER CELLS. 1 X 106 MCF-7 or T47D cells were plated and grown in 0 or 5 nM E2
conditions for 3 days. Cells were then isolated and either total protein or fractionated
cytoplasmic and nuclear protein were isolated from the cells. DAXX protein levels were
then determined by Western Blot analysis using β-ACTIN as a loading control for the total
protein and cytoplasmic fraction lysates and PARP-1 was used as a loading control for
the nuclear fraction lysates.

ENRICHMENT OF DAXX AT PROMOTERS OF TIC-ASSOCIATED/PLURIPOTENCY
GENES REQUIRES ER ACTIVATION.
We have confirmed that the majority of DAXX is localized in the nucleus under
conditions of E2-mediated ER activation, and this is depleted in response to ET. As
DAXX has been shown to modulate gene expression by forming complexes at
promoters of target genes, we next wanted to test whether it formed a complex at TICassociated or pluripotency genes [390]. These included pluripotency genes such as
SOX2, OCT4, NANOG, as well as NOTCH4 [261, 279-292, 338-340]. MCF-7 or T47D
cells at a density of 6 X 106 were plated and grown under 0 or 5nM E2 conditions for 1
day. Cells were then fixed with formaldehyde and their chromatin was isolated.
Chromatin was then probed with a DAXX antibody to enrich for chromatin associated
with the protein. DAXX protein was reverse-crosslinked and the presumably DAXXassociated DNA fragments were purified. Enrichment of DAXX at the promoters for TIC-
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associated gene was determined by RT-PCR using targeted primers-flanking AP-1
consensus sites designed by Dr. Andrei Zlobin. IgG control was used as a control to
determine fold enrichment. Additionally a transcription factor desert previously
described by Clementz et. al. within the NOTCH4 gene was used as an additional
negative control (NOTCH4 Negative) [435]. Known AP-1 binding sites within the
promoters of these TIC-associated/pluripotency genes were used due to previous
reports demonstrating that AP-1 activates SOX2, OCT4, NANOG and NOTCH4
transcript expression, and DAXX has been shown to repress AP-1 driven genes [387,
435-436]. A pictorial model of the genomic regions that the TIC promoter primers
recognize are provided in Figure 22. No enrichment of DAXX was seen at the NOTCH4
transcription factor desert (Figure 23). Additionally, enrichment of DAXX at promoter
regions of TIC-associated genes was low under 0nM E2 conditions in both cell lines
(Figure 23). This was expected as nuclear levels of DAXX are low under these nonestrogenic conditions (Figure 22). Conversely, when the ER is activated by E2, there are
high amounts of DAXX enrichment at the promoter regions of NOTCH4, SOX2, OCT4,
and NANOG, all genes known to be restricted by the ER (Figure 23) [289-292, 337340]. Taking results of Figures 22 and 23 together, these findings indicate DAXX, a
known transcriptional repressor, is primarily within the nucleus under ER activated
conditions, where it forms a complex at the promoter of TIC-associated genes [383].
These are conditions when TIC-survival is relatively low (Figure 12). This phenomenon
is lost however under ET conditions, when TIC-survival increases (Figure 12).
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FIGURE 23. GENOMIC LOCATION OF AP-1 BINDING SITE-SPECIFIC PRIMERS FOR
DAXX CHIP. F= forward primer, R= reverse primer, arrow designates the predicted
location where transcription is initiated.

FIGURE 24. ER ACTIVATION REQUIRED FOR DAXX ENRICHMENT AT TICASSOCIATED GENE PROMOTERS. MCF-7 and T47D cells grown in 0 or 5 nM E2
conditions for 1 day were fixed, and their chromatin was fragmented and
immunoprecipitated by a DAXX-specific antibody (Santa Cruz DAXX S-20) or control IgG
antibody. DNA was purified and used to quantify enrichment comparing DAXX vs. IgG
immunoprecipitated chromatin samples. RT-PCR primers were designed at AP-1 sites as
DAXX is known to interact with the AP-1 [386]. The figures are developed from 3
independent experiments and include the means ± SDs. 5 nM E2 grown samples were
compared to 0 nM E2 growth conditions within the same cell type by One-Way ANOVA to
determine statistical significance @= P< 0.05.
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Aim 2B: Determine if DAXX is necessary and sufficient to restrict transcript
expression of TIC-associated/pluripotency genes
The ER is known to restrict TIC-survival, in part by inhibiting expression of
pluripotent genes including SOX2, OCT4, and NANOG as well as NOTCH signaling
[289-292, 338-340]. One way the ER is proposed to do this is through genome-wide
epigenetic modifications [294]. DAXX is reported to be a recruiter of epigenetic
modifying enzymes, and we have shown it is required for ER-mediated restriction of
TIC-survival (Figure 12) [388-390]. Furthermore, under conditions of ER activation,
DAXX forms a complex at promoter regions of TIC-associated/pluripotency genes
(Figure 23). Thus, we hypothesized that restriction of TIC-associated transcripts by the
ER requires DAXX. To test this using a unbiased, genome-wide approach, we
conducted RNA sequencing (RNA-seq) when MCF-7 cells were transfected with SCBi
or DAXXi and grown under 5nM E2 conditions to identify gene transcripts that require
DAXX. After identifying a handful of target genes, we conducted a targeted approach by
depleting DAXX by ET or siRNA and determining if this alters transcript expression of
TIC-associated/pluripotency genes by RT-PCR. Our expectation being that ET will
result in relatively high levels of TIC-associated/pluripotency gene transcripts, E2
treatment will reduce this, and DAXX knockdown under E2 treatment conditions will
result in a recovery in expression of TIC-associated/pluripotency transcripts.
Additionally, as we have shown DAXX is sufficient to restrict TIC-survival under ET
conditions, we tested if it was also sufficient to reduce expression of TICassociated/pluripotency transcripts under ET conditions (Figure 19).
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DAXX IS NECESSARY FOR MODULATION OF NUMEROUS GENES INCLUDING
DEVELOPMENTAL PATHWAYS
MCF-7 cells were transfected with SCBi or DAXXi for 2 days, following which
they were grown in 5nM E2 for 1 day to match our ChIP studies. The RNA was then
extracted and submitted to the University of Chicago Genomics Facility for RNA-seq
analysis. This was done for two independent experiments. The subsequent results were
analyzed with the assistance of Jeffrey Ng to determine enriched pathways and specific
gene expression patterns within those pathways that were altered under DAXX
knockdown as compared to DAXX-expressing, control conditions. The total number of
genes down and upregulated by DAXX knockdown and the differences between the two
independent experiments are represented in Figure 24A. The majority of gene
transcripts shown to be altered by DAXX knockdown were upregulated. This was not
surprising as DAXX has been reported to be a transcriptional repressor (Figure 24A)
[383]. Pathway enrichment was conducted by Metascape analysis and the pathways
that were significantly up or down following DAXX knockdown are represented in
Figures 24B and 24C. Of significance in ER+ breast cancer, the top pathway shown to
be downregulated by DAXX depletion was response to antineoplastic agents,
suggesting loss of DAXX alters how breast cancer cells respond to general
chemotherapeutic agents (Figure 24B). Pathways shown to be upregulated in both
experiments by DAXX knockdown were the embryologic pathway of gastrulation, preNOTCH expression and processing, and the NOTCH signaling pathway (Figure 24C).
This confirms our previous results that DAXX is required for ER-mediated suppression
of NOTCH signaling (Figure 12), and also suggests that DAXX may be required for ER-
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mediated inhibition of developmental processes (Figure 24C). Heat maps-generated for
these pathways are represented in Figures 25A & 25B. Genes within the gastrulation
pathway that are upregulated by DAXX depletion include the pluripotency genes, SOX2,
OCT4 (POU5F1), NANOG, and KLF4, as well as mesenchymal markers SNAIL (SNAI1)
and TWIST (Figure 25A). Together, these results suggest that DAXX is required for the
ER to restrict pathways associated with pluripotency and NOTCH signaling, and thus
we took a more targeted approach to further test these initial findings.

FIGURE 25. LOSS OF DAXX CAUSES GLOBAL CHANGES IN GENE EXPRESSION
UNDER CONDITIONS OF ER ACTIVATION. MCF-7 cells first transfected with SCBi or
DAXXi were then grown in 5 nM E2 for 1 day for two independent experiments. . Total
RNA was isolated and sent for RNA sequencing analysis. Significant changes in gene
expression were determined using the cutoffs of FKPM=10, fold increase > or = 1.5, and
p< 0.05. A. Comparison of the total number of RNA transcripts that were upregulated
following DAXX depletion for 2 independent experiments are shown. B&C. Pathways that
were downregulated or upregulated using using Metscape software of all significantly
altered RNA transcripts following DAXX pool siRNA transfection compared to non-specific
SCBi tranfection of the two independent experiments are shown. Histogram represents Log10(P-value) of each pathway based on the number of genes that were enriched in a
given pathway.
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FIGURE 26. LOSS OF DAXX ENRICHES FOR EMBRYONIC AND NOTCH SIGNALING
PATHWAYS UNDER CONDTIONS OF ER ACTIVATION. MCF-7 cells first transfected
with SCBi or DAXXi were then grown in 5 nM E2 for 1 day for two independent
experiments. Total RNA was isolated and sent for RNA sequencing analysis. Significant
changes in gene expression were determined using the cutoffs of FKPM=10, fold increase
> or = 1.5, and p< 0.05. A. Changes of individual gene transcripts in the Gastrulation
pathway conducted using Metascape pathway analysis software when comparing DAXXi
to SCBi conditions. B. Changes of individual gene transcripts in both the NOTCH
processing and expression pathways using Metascape pathway analysis software.
DAXXi conditions were compared to SCBi conditions.
DAXX IS NECESSARY AND SUFFICIENT TO REPRESS TICASSOCIATED/PLURIPOTENCY GENES
MCF-7 and T47D cells were transfected in the same manner as those used to
generate Figure 12 for 2 days. The medium was then changed to 0 or 5nM E2 growth
conditions for 1 day to match the ChIP and RNA-Seq experiments. As shown in Figure
26, ET, regardless of transfection conditions, results in a relatively high transcript
expression of SOX2, OCT4, NANOG, ALDH1A1 and NOTCH4 for both cell lines (Figure
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26). As previously reported, ER is able to restrict expression of TICassociated/pluripotency genes [289-292, 338-341], however when DAXX is depleted,
ER activation is no longer sufficient to inhibit expression of these transcripts (Figure 26).
This indicates the ER requires DAXX to repress TIC-associated/pluripotency genes.
(Figure 12). To test whether DAXX is sufficient to repress expression of TICassociated/pluripotency genes, cells were transfected with EV or a DAXX-containing
vector under similar conditions that generated Figure 19. Cells were grown in 0 or 5nM
E2 for 1 day. As indicated in Figure 27, compared to ET conditions alone,
overexpression of DAXX under ET resulted in significantly lower transcript levels of TICassociated/pluripotency genes (Figure 27). This was demonstrated in both cell lines and
indicates that DAXX is sufficient to repress expression of TIC-associated/pluripotency
gene transcripts, providing correlation to TIC-survival results (Figures 19 & 27).
Together, these findings from Aim 2B indicate that DAXX is both necessary and
sufficient to repress expression of TIC-associated/pluripotency genes in ER+ breast
cancer cells. Taken together with Aim 1, these results suggest that DAXX suppresses
TIC-survival by possibly modulating gene expression, and therapies that deplete DAXX
such as ET result in gene expression associated with increased TIC-survival.
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FIGURE 27. DAXX IS REQUIRED AND SUFFICIENT TO RESTRICT EXPRESSION OF
TIC-ASSOCIATED GENE TRANSCRIPTS. A. 3 X 105 MCF-7 or T47D cells were
transfected with SCBi or DAXXi for 2 days and then grown in 0 or 5nM E2 for 1 day. Total
RNA from each experimental condition was isolated and converted to cDNA. Transcript
levels of SOX2, OCT4, NOTCH4, NANOG, and ALDH1A1 targets were determined by
RT-PCR using HPRT as an internal control. Transcript expression levels of SCBi 0nM E2
cells were used as the relative control and set to 1.0. All other groups were then compared
to this. B. 3 X 105 MCF-7 or T47D cells were transfected with EV or DAXX-containing
vector for 2 days, following which they were grown in 0 or 5nM E2 for 1 day. Total RNA
from each experimental condition was isolated and converted to cDNA. Transcript levels
of SOX2, OCT4, NOTCH4, NANOG, and ALDH1A1 targets were determined by RT-PCR
using HPRT as an internal control. Transcript expression levels of EV 0nM E2 cells were
used as the relative control and set to 1.0. All other groups were then compared to this.
The results of all figures are means ± SDs of three independent experiments. All groups
were compared by to SCBi/EV + 0nM E2 conditions by Two-Way ANOVA to determine
statistical significance #= P< 0.05, $= P< 0.01, @= P< 0.001.

Aim 2C: Determine if DNMT1 activity is required to restrict expression of TICassociated/pluripotency genes and TIC-survival
It is known that the ER restricts TIC-survival and this is thought to be, in part, by
regulating expression of NOTCH and pluripotency genes [289-292, 338-341]. We have
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shown that DAXX is a critical mediator of ER function to suppress TIC-survival and
repress TIC-associated/pluripotency genes (Figure 12 & 26). One reported mechanism
that the ER has been shown to regulate gene expression is through regulation of
epigenetic marks within the genome [294]. DAXX has been shown to recruit the
epigenetic enzyme DNMT1 to gene promoters, resulting in hypermethylation and
silencing of genes [390]. As we have shown DAXX protein expression is dependent on
ER activation, we hypothesize that the ER uses DAXX and DNMT1 to silence TICassociated gene expression. We first tested this by investigating effects of DNMT1
depletion by siRNA on TIC-survival and expression of TIC-associated genes. In
addition, we determined the effect a deoxycytidine analog (5-AZA) on TIC-survival and
gene expression. Further, to assess if DNMT1 is required for DAXX-mediated
suppression of TIC survival and repression of TIC-genes, DAXX overexpression studies
were performed in combination with DNMT1 knockdown. Finally, we determined the
effect DAXX or DNMT1 depletion by siRNA on the methylation status at the promoter of
one TIC-associated/pluripotency gene, SOX2.
DNMT1 IS REQUIRED FOR ER-MEDIATED SUPPRESSION OF TIC-SURVIVAL AND
REPRESSION OF TIC-ASSOCIATED GENE TRANSCRIPTS.
To test if DNMT1 is required for ER-mediated restriction of TIC-survival and
transcript expression, MCF-7 cells were transfected with SCBi or DNMT1-specific
(DNMT1i) siRNA. Cells were grown in 0 or 5nM E2 conditions for 1 or 3 days to quantify
transcript expression and TIC-survival, respectively. A subset of cells used for the
mammosphere assay had their total protein isolated to confirm DNMT1 knockdown. As
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indicated by Figure 27A, DNMT1 was successfully depleted in these cells and had little
effect on DAXX expression (Figure 27A). Further, E2-mediated ER activation or ER
inhibition have no effect on expression of DNMT1 protein (Figure 27A). As we have
previously indicated, ET results in relatively high % MFE, which is decreased by E2
(Figure 27B). This inhibition by E2 is reversed when DNMT1 is depleted in MCF-7 cells
(Figure 27B). This suggests that DNMT1 is required for ER-mediated restriction of TICsurvival. In addition, expression of TIC-associated/pluripotency gene transcripts was
decreased upon E2 treatment. This was reversed upon DNMT1 depletion (Figure 27C).
Together, these results suggest that similar to DAXX, DNMT1 is necessary for ERmediated suppression of TIC-survival and repression of TIC-associated gene
transcripts.
DNA METHYLATION IS REQUIRED FOR ER-MEDIATED RESTRICTION OF TICSURVIVAL AND EXPRESSION OF TIC-ASSOCIATED GENE TRANSCRIPTS.
We have demonstrated that DNMT1 is required for ER-mediated restriction of
TIC-survival and expression of their associated transcripts. To test if DNA methylation of
cytosine nucleotides was necessary to suppress TIC-survival and gene expression, 5AZA was used in MCF-7 cells. MCF-7 cells were grown in 0 or 5nM E2 in the presence
or absence of 5-AZA, following which TIC-survival and gene transcript expression were
assessed. As shown in Figure 28A, 5-AZA treatment has little effect on DAXX protein
expression (Figure 28A). Similar to DNMT1 depletion experiments, 5nM E2 is sufficient
to restrict TIC-survival and associated gene transcript expression, and this is reversed
when cells are treated with 5-AZA (Figures 28 B & C). This suggests that decreased
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cytosine methylation, a function of DNMT1, suppresses TIC-survival and represses
genes in ER+ breast cancer cells.

FIGURE 28. DNMT1 IS REQUIRED FOR ER RESTRICTION OF TIC-SURVIVAL AND
ASSOCIATED TRANSCRIPT EXPRESSION. A. 1 X 106 MCF-7 cells were transfected
with SCBi or DNMT1i for 2 days and then grown in 0 or 5nM E2 for 3 days. A. A subset of
these cells had total protein extracted and relative lysate levels of DNMT1 and DAXX
were determined by Western Blot Analysis using β-ACTIN as a loading control. B. A
subset of 5 X 104 cells were plated in mammosphere medium allowed to grow for 7 days.
Mammospheres were counted and % MFE was determined. C. 3 X 105 MCF-7 cells were
transfected with SCBi or DNMT1i for 2 days, following which they were grown in 0 or 5
nM E2 for 1 day. Total RNA from each experimental condition was isolated and converted
to cDNA. Transcript levels of SOX2, OCT4, NOTCH4, NANOG, and ALDH1A1 targets
were determined by RT-PCR using HPRT as an internal control. Transcript expression
levels of SCBi 0nM E2 cells were used as the relative control and set to 1.0. All other
groups were then compared to this. The results of B & C are means ± SDs of three
independent experiments. All groups were compared by to SCBi/EV + 0nM E2 conditions
by Two-Way ANOVA to determine statistical significance #= P< 0.05, $= P< 0.01, @= P<
0.001.
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DAXX REQUIRES DNMT1 TO RESTRICT TIC-SURVIVAL AND EXPRESSION OF
ASSOCIATED GENE TRANSCRIPTS
Either DNMT1 or DNA methylation is required for the ER to inhibit mammosphere
formation and expression of TIC-associated gene transcripts (Figures 27 & 28).
Additionally, we have shown that DAXX is sufficient to restrict TICs in response to ET
(Figure 19). To test whether DAXX requires DNMT1 to inhibit TIC-survival, Cells were
first transfected with an EV or DAXX-containing vector for 2 days. MCF-7 and T47D
cells were then transfected with SCBi or DNMT1i for 1 day and grown in 0 or 5nM E2 for
3 days. A subset of cells had their total protein isolated to determine DAXX and DNMT1
levels by Western Blot analysis. As indicated in Figure 29A, DAXX and DNMT1i
transfections were successful for their appropriate conditions (Figure 29A). The
remaining cells were plated in mammosphere medium and TIC-survival was quantified.
E2-mediated ER activation or DAXX overexpression was sufficient to reduce TICsurvival as previously shown (Figure 19). However, ectopic expression of DAXX is no
longer sufficient to inhibit mammosphere formation if DNMT1 is depleted by siRNA
(Figure 29B). This suggests DAXX requires DNMT1 to inhibit TIC-survival. In response
to ET, expression of TIC-associated/pluripotency gene transcripts were increased.
DAXX overexpression resulted in decreased expression of these gene transcripts even
under ET conditions. This decrease by DAXX overexpression was reversed upon
DNMT1 depletion (Figure 29C). Together these findings suggest that DAXX requires
DNMT1 to elicit its anti-TIC effects.
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10 uM AZA

FIGURE 29. METHYLATION ACTIVITY IS REQUIRED FOR ER RESTRICTION OF TICSURVIVAL AND ASSOCIATED TRANSCRIPT EXPRESSION. A. 1 X 106 MCF-7 cells
were grown in 0 or 5 nM E2 for 3 days, on the last day growth media was supplemented
with DMSO or 5-AZA A. A subset of these cells had total protein extracted and relative
lysate levels of DAXX were determined by Western Blot Analysis using β-ACTIN as a
loading control. B. A subset of 5 X 104 cells were plated in mammosphere media allowed
to grow for 7 days. Mammospheres were counted and % MFE was determined. C. 3 X
105 MCF-7 cells were grown in 0 or 5 nM E2 for 2 days, on the last day DMSO or 10 uM
AZA was added. Total RNA from each experimental condition was isolated and converted
to cDNA. Transcript levels of SOX2, OCT4, NOTCH4, NANOG, and ALDH1A1 targets
were determined by RT-PCR using HPRT as an internal control. Transcript expression
levels of DMSO 0 nM E2 cells were used as the relative control and set to 1.0. All other
groups were then compared to this. The results of B & C are means ± SDs of three
independent experiments. All groups were compared by to SCBi/EV + 0 nM E2 conditions
by Two-Way ANOVA to determine statistical significance #= P< 0.05, $= P< 0.01, @= P<
0.001.

DAXX OR DNMT1 IS REQUIRED FOR METHYLATION OF THE SOX2 PROMOTER
We have shown that DAXX is necessary and sufficient to restrict TICs. Further,
we have shown that DAXX requires DNMT1 to suppress TICs and repress expression
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of pluripotency genes (Figures 19 & 29). The ER has been reported to determine cell
fate based on global changes in epigenetic status at promoters of genes [294]. We
hypothesize that one possible mechanism for this is through upregulation of the DAXX
and DNMT1 complex at TIC-associated/pluripotency gene promoters. To test this, the
methylation status of one TIC-associated gene, SOX2 was assessed in response to E2
or ET treatment under conditions where DAXX or DNMT1 is depletion using siRNA.
The methylation status of the SOX2 promoter was detected by bisulfite treatment
followed by sequencing. Five independent experiments were conducted for each
condition. A pictorial representation of each individual sequencing run for each
experimental condition is represented in Figure 30. Changes in % methylation status of
CpG sites across all experiments are represented in Figure 31. Under ET conditions,
the SOX2 promoter has relatively low levels of methylated CpGs and that E2-mediated
ER activation increases methylation of CpG sites (Figures 31). However, this increases
is reversed when either DAXX or DNMT1 is depleted by siRNA, correlating with an
increase in SOX2 transcript expression (Figures 12, 27C, 31). Together this suggests
that the ER requires DAXX or DNMT1 to restrict SOX2 expression possibly through
methylation of CpG sites with its promoter.
AIM 2 Conclusions
The results of Aim 2 illustrate that under ER activated conditions, DAXX is
localized in the nucleus and forms a complex at promoters of TICassociated/pluripotency genes. This nuclear localization and promoter enrichment is lost
in response to ET, when TIC-survival is at its highest. RNA- sequencing results indicate
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that DAXX has a global effect on expression of gene transcripts when ER is activated
by E2. Further, depletion of DAXX results in an increase in expression of TICassociated/pluripotency pathways including the embryologic process of gastrulation as
well as NOTCH signaling and processing. This would suggest when DAXX is depleted
by ET, these pathways are increased, which may explain why TIC-survival and activity
increases. A more targeted approach using gene transcript-specific primers validated
RNA-seq results confirming that DAXX was required for ER-mediated restriction of TICassociated/pluripotency genes including NOTCH4. Conversely, results demonstrated
that DAXX is sufficient to repress the expression of these TIC-gene transcripts, which
correlates with previous findings that DAXX is sufficient to inhibit TIC-survival in
response to ET. The mechanism by which DAXX represses expression of TIC-gene
transcripts appears to be at least in part through DNMT1. We have shown that depletion
of DNMT1 or decreased methylation of cytosines results in increased TIC-survival and
gene transcripts when E2 activates the ER. Importantly, DAXX-mediated inhibition of
TICs requires DNMT1. Finally, we have shown through bisulfite sequencing that the
promoter of one TIC-associated gene, SOX2, is hypermethylated by E2-mediated
activation of the ER through a DAXX or DNTM1-dependent manner. Together, this
indicates that ER activation induces epigenetic changes to at least one TIC-associated
gene, affirming previous reports [293]. The mechanism for this appears to be due in part
to the localization of DAXX at the promoter sites of TIC-associated genes, where it
requires DNMT1 to inhibit gene expression. This beneficial effect of E2 is decreased by
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ET, and thus may explain why TIC-survival increases in response to therapies that
target the ER.

FIGURE 30. DAXX REQUIRES DNMT1 TO RESTRICT TIC-SURVIVAL AND
ASSOCIATED GENE TRANSCRIPT EXPRESSION. MCF-7 and T47D cells were plated
and transfected with EV or DAXX-containing vector for 2 days. Following which cells were
transfected with SCBi or DNMT1i for 1 day. Finally cells were grown in 0 or 5 nM E2 for 3
days. A. A subset of these cells had total protein extracted and relative lysate levels of
DNMT1 and DAXX were determined by Western Blot Analysis using β-ACTIN as a
loading control. B. A subset of 5 X 104 cells were plated in mammosphere media allowed
to grow for 7 days. Mammospheres were counted and % MFE was determined. C. 3 X
105 MCF-7 cells were transfected with EV/DAXX and then SCBi/DNMT1i to match A & B.
Cells were then grown in 0 or 5 nM E2 for 1 day. Total RNA from each experimental
condition was isolated and converted to cDNA. Transcript levels of SOX2, OCT4,
NOTCH4, NANOG, and ALDH1A1 targets were determined by RT-PCR using HPRT as
an internal control. Transcript expression levels of EV + SCBi + 0 nM E2 cells were used
as the relative control and set to 1.0. All other groups were then compared to this. The
results of B & C are means ± SDs of three independent experiments. All groups were
compared by to SCBi/EV + 0 nM E2 conditions by Two-Way ANOVA to determine
statistical significance #= P< 0.05, $= P< 0.01, @= P< 0.001.
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FIGURE 31. PICTORIAL REPRESENTATION SOX2 PROMOTER BISULFITE
SEQUENCING EXPERIMENTS. MCF-7 cells were grown in SCBi vs. DAXXi/DNMT1i
transfection conditions for 2 days, following which they were allowed to grown in 0 or 5
nm E2 conditions for 1 day. Cells then had their total DNA isolated and bisulfite
converted. DNA was then purified and run on PCR using bisulfite-specific PCR primers
to the SOX2 promoter region. The PCR product was purified and sent for DNA
sequencing. CpG sites that were read “T” were considered unmethylated and are
indicated in white, CpG sites that were read “C” were considered methylated and are
indicated in black.

FIGURE 32. DAXX AND DNMT1 ARE REQUIRED FOR ER INDUCTION OF SOX2
PROMOTER methylation. Cells were prepared as described in Figure 30. The results
are means ± SDs of three independent experiments. All groups were compared by to
SCBi/EV + 0 nM E2 conditions by Two-Way ANOVA to determine statistical significance
#= P< 0.05, $= P< 0.01, @= P< 0.001
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FIUGRE 33 AIM 2 SUMMARY FIGURE. A. What is known, namely that activation
of the ER inhibits TIC-associated gene expression and ETs that block ER actvitiy
prevent this. B. New model based on Aim 2 data in which we have shown that the
ER inhibits TIC-associated gene expression through DAXX and DNMT1
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SPECIFIC AIM 3

Determine if DAXX-promoting treatments using PEs will restrict TIC-survival
when combined with ET
The following sub-aims will test Specific Aim 3:
Aim 3A: Determine if PEs are sufficient to increase DAXX protein levels without
inducing total ER+ breast cancer cell proliferation when combined with ET
Aim 3B: Determine if PEs restrict TIC-survival and TIC-associated genes by increasing
DAXX protein levels when combined with ET
Aim 3C: Determine if PEs increase DAXX levels and restrict TIC-survival through ERα
and/or ERβ activity
AIM 3A: Determine if PEs are sufficient to increase DAXX protein levels without
inducing total ER+ breast cancer cell proliferation when combined with ET
Result to far have demonstrated that ER-mediated restriction of TIC-survival
requires DAXX in ER+ breast cancer cells (Figures 12 & 15). Moreover, DAXX is
sufficient to restrict TIC-survival in response to ET, and this increase in DAXX does not
induce total cell proliferation (Figures 19 & 20). Together, these findings suggest that a
therapy that increases DAXX may inhibit TICs, but will not promote bulk tumor
proliferation. Thus, a therapeutic regimen that combines ET with a DAXX-promoting
agent should block bulk tumor growth and inhibit TIC-survival to prevent tumor
recurrence.
148
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Results have shown that the protein stability of DAXX is dependent on E2mediated ER activation (Figure 11). However, because ER+ breast cancer cells are
dependent on ER activation for growth, full agonistic activation of the ER is not a viable
therapeutic option as it stimulates total breast cancer cell proliferation (Figures 8 & 10).
PEs are natural compounds found mostly in fruits and vegetables that have varying
estrogenic effects [399-340, 405]. Although these compounds have been shown to
activate expression of ER-responsive genes, a subset are reported not to stimulate
proliferation of ER+ breast cancer cells [402-406]. These paradoxical effects on the ER
by PEs compared to the natural ligand, E2 are thought to be due to differences in PE
affinity for the receptor, as well as differences in cofactor recruitment by the PE + ER
complex [396, 404]. Some forms of ET such as SERMs or SERDs alter the structure of
the ER, ligand binding and/or receptor levels, and thus we hypothesize that these would
alter the PE + ER relationship [80]. AIs, however have little effect on ER structure or
receptor availability to bind ligands, and thus PEs would potentially not alter the
beneficial effects of AIs as anti-bulk tumor agents [80]. A depiction of a therapeutic
regimen that includes a PE + each form of ET is represented Figure 32 with the KD
values included from Kuiper et al. [88]. If a PE is given as a monotherapy without ET,
we would expect the high affinity of circulating E2 to prevent the PE from interacting with
the ER (Figure 32A). In combination with a SERM, like tamoxifen, we again would
expect the higher affinity SERM to occupy the ligand-binding domain of the ER and also
prevent PE interaction with the receptor (Figure 32B). In presence of a fulvestrant, a
SERD, we would expect the degradation of the ER to prevent the PE from binding the
ligand-binding domain and activating the receptor (Figure 33C). However, under AI
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conditions, we would expect the patient to have very little circulating E2, allowing an
unbound ligand-binding domain of the ER to interact with the PE (Figure 33D). Thus, we
employed this therapeutic strategy of AI-conditions + each PE to hopefully capture the
beneficial effects of the AI to block total tumor cell growth, while also utilizing the
potential benefits of the PE.
To our knowledge, no study has investigated if PEs in combination with AIs are
able to increase DAXX levels in ER+ breast cancer, and whether this results in a
decrease in TIC-survival. We hypothesize that PEs are sufficient to increase DAXX
levels in ER+ breast cancer cells when the synthesis of the natural ligand, E2 is blocked
with an AI resulting in a suppression of TIC-survival without inducing bulk tumor cell
growth. We first tested this hypothesis by taking an exploratory approach of a number of
PEs with different structures [396]. These included the isoflavone GS, the flavone AG,
the flavonol Q, the flavanone NG, and the stillbenoid RES [396]. Structures of these
compounds are provided in Figure 33. We investigated at various concentrations if one
or more of these compounds stimulated bulk cell growth, and further if one or more
concentrations were sufficient to increase DAXX protein levels in MCF-7 and T47D
cells. Using this approach, we were able to identify a number of PEs that did not
stimulate total cell proliferation, but were able to increase DAXX protein levels in both
cell lines.
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FIGURE 34. SCIENTIFIC REASONING FOR THERAPEUTIC STRATEGY OF AI + PE.
KD for each compound expressed in nM as ERα/ERβ. A. Expected result using E2 + PE
as therapeutic strategy. B. Expected result using tamoxifen (TAM) + PE as therapeutic
strategy. C. Expected result using fulvestrant (scissors) + PE as therapeutic strategy. D.
Expected result of using AI + PE as a therapeutic strategy.

NARINGENIN (NG) AND RESERVATROL (RES) DO NOT STIMULATE BULK CELL
PROLIFERATION, BUT ARE SUFFICIENT TO INCREASE DAXX PROTEIN LEVELS
To first determine effects PEs on bulk tumor cell growth, MCF-7 and T47D cells
at a density of 1 X 105 were grown in increasing concentrations of an individual PE for 7
days, using 0nM or 5nM E2 as negative and positive controls, respectively. As indicated
in Figures 34A and 34B, GS or AG stimulated total cell growth in both cell lines (Figures
34A & 34B). This induction of growth appears to be through the ER, as the addition of
fulvestrant (100nM) prevented cell growth under the same PE-supplemented conditions
(Figures 34A & 34B). Conversely, NG, RES, or Q did not induce total cell growth in
MCF-7 and T47D cell lines (Figures 34C, 34D, 34E). A high concentration of RES
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(10µM), however was associated with a significant decrease in cell number, suggesting
it may be cytotoxic at this high concentration (Figure 32D). This cytotoxicity is most
probably due to activation of the ER, as fulvestrant prevented the RES-mediated
cytotoxicity (Figure 34D). To investigate the concentration response in terms of DAXX
protein levels, MCF-7 and T47D cells were grown in 10-1000nM conditions for 3 days,
following which total protein was isolated and DAXX protein levels were determined by
Western Blot analysis. As shown in Figure 35A, all of the PEs except Q were able to
induce expression of the DAXX protein in MCF-7 cells (Figure 35A). This differed from
T47D cells, in which only NG and RES were sufficient to induce DAXX protein
expression (Figure 35B). Differences in response to PEs when comparing MCF-7 and
T47D cells have been previously reported, thus they were not completely unexpected
[404, 407, 412]. This result may be due to differences in co-factor levels or differences
in expression of ERα to ERβ ratio [404, 412]. Overall, results from Figures 34 and 35
indicate that at least two PEs, namely NG and RES, are sufficient to induce DAXX
protein expression without inducing bulk cell proliferation. This suggests NG and RES
represent potential DAXX-promoting therapeutics in ER+ breast cancer cells (Figures
34 & 35). A 100nM concentration of NG or RES was used in subsequent experiments
as this was the lowest dose that significantly increased DAXX but did not stimulate total
cell proliferation. Further, 100nM Q was also used as a control as it had little effect on
DAXX levels or total cell proliferation.
PES REQUIRE ER ACTIVATION TO INCREASE EXPRESSION OF DAXX PROTEIN
The results of Figures 34 and 35 indicate that at least two PEs, NG and RES,
increase DAXX protein levels but do not induce proliferation. We have demonstrated
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that effects PEs on proliferation are dependent on the ER. To determine if PEs increase
expression of the DAXX protein by activating the ER, MCF-7 and T47D cells were
treated with 0nM E2, 5nM E2, or PEs at various concentrations (100nM NG, 10nM GS,
1µM AG, 100nM RES, 100nM Q). Treatment conditions using the PEs were conducted
in the presence or absence of 100nM fulvestrant to determine if induction of DAXX
protein requires the ER. The hypothesis being that PEs will increase DAXX protein
levels, and fulvestrant will block this effect. As indicated by Figure 36A, all the PEs are
capable of inducing DAXX protein expression in MCF-7 cells (Figure 36A). This effect is
reversed when the ER is inhibited by fulvestrant (Figure 36A). A similar trend is
observed in T47D cells with NG, AG, and RES, all resulting in a substantial increase in
DAXX protein levels, and reversed by fulvestrant (Figure 36B). This suggests that PEs
increase protein levels of DAXX through the ER.

FIGURE 35. STRUCTURE OF PES. Representative chemical structure of PEs A.
Genistein, B. Apigenin, C. Quercetin, D. Naringenin, E. Resveratrol.
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FIGURE 36. NG, RES, Q ARE PES THAT DO NOT INDUCE TOTAL CELL GROWTH. 1
X 105 MCF-7 or T47D cells plated and grown in 0 (ethanol), 5nM E2, increasing
concentrations of individual PEs for 7 days. This was done in the presence or absence of
100nM fulvestrant. Cells were removed from their plates with trypsin, the solution was
quenched with growth media containing 0nM E2, and the pellet was re-suspended in
growth medium containing 0nM E2. Cells were stained with trypan blue and the number
of live cells was determined using an Invitrogen Countess Cell Counter. Fold increase in
live cells were determined using the equation Fold increase in live cells= (Total live cells
counted/100,000 cells originally plated). The results of both figures are means ± SDs of
three independent experiments. All groups were compared by Two-Way ANOVA to SCBi
0nM E2 conditions to determine statistical significance #= P< 0.05. A. Genistein (GS), B.
Apigenin (AG), C. Naringenin (NG), D. Resveratrol (RES), E. Quercetin (Q).
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FIGURE 37. PES HAVE VARIABLE EFFECTS ON DAXX PROTEIN LEVELS IN ER+
BREAST CANCER CELLS. 1 X 106 MCF-7 (A) or T47D (B) cells plated and grown in
0nM (ethanol) or increasing concentrations of individual PEs for 3 days. Total protein
was isolated and the relative protein levels of DAXX were determined by Western Blot
analysis using β-ACTIN as a loading control

Aim 3B: Determine if PEs restrict TIC-survival and NOTCH by increasing DAXX
protein levels
We have demonstrated that PEs, NG and RES, are sufficient to increase DAXX
protein levels without inducing bulk cell proliferation when E2 is deprived (Figures 32 &
33). Further, the ability of PEs to increase DAXX protein levels requires the ER, as
fulvestrant treatment reversed these effects (Figures 34 & 36). Additionally, we have
demonstrated that DAXX is sufficient to restrict TIC-survival when E2 is deprived (Figure
19). Thus, we hypothesized that PEs would inhibit TIC-survival, but only when E2 is
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deprived (0nM E2). We tested this hypothesis by treatting MCF-7 and T47D cells with
0nM E2, 0nM E2 + PE, or 0nM E2 + PE + fulvestrant. Further, to determine if changes in
TIC-survival were mediated by DAXX, we conducted these experiments when DAXX
was expressed (SCBi) or depleted (DAXXi). Ultimately this strategy allows us to
determine if PEs are able to inhibit TIC-survival, and if these effects require the ER
and/or DAXX. Additionally, E2-mediated activation of the ER is known to induce
expression of markers associated with differentiated luminal cells such as E-cadherin
[47, 289], while inhibiting TIC-associated markers such as NOTCH4 [338-340]. To test if
PEs have similar effects, MCF-7 and T47D cells were treated with 0nM E2, 5nM E2, or
100nM PE for 1-7 days and then expression of E-Cadherin and NOTCH4 proteins were
detected by Western Blot. These studies were conducted in cells-expressing DAXX
(SCBi) or –depleted for DAXX (DAXXi) with the goal of determining if DAXX is required
for PE-mediated changes in protein expression of E-Cadherin or NOTCH4.
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FIGURE 38. PES REQUIRE ER TO INCREASE DAXX PROTEIN LEVELS. 1 X 106 MCF7 (A) or T47D (B) cells plated and grown in 0nM E2, optimal concentrations of individual
PEs, or each PE + 100nM fulvestrant 3 days. Total protein was isolated and the relative
protein levels of DAXX were determined by Western Blot Analysis using β-ACTIN as a
loading control. PE Concentrations: NG= 100nM, GS= 10nM, AG= 1µM, RES= 100nM,
Q= 100nM.

NG AND RES REQUIRE DAXX AND THE ER TO INHIBIT TIC-SURVIVAL
MCF-7 and T47D cells were first transfected with SCBi or DAXXi siRNA and then
maintained in their respective experimental growth conditions for 3 days to match
previous mammosphere assays. Cells were treated with either vehicle (0nM E2), 5nM
E2, or 100nM PEs (NG, RES, or Q) in the presence or absence of fulvestrant following
transfection. As indicated in Figure 37A and 37B, DAXX levels were increased by E2,
NG, or RES, while low amounts of DAXX were detected in the 0nM E2 or Q treated
groups (Figures 37A & 37B). Further, DAXX-depletion or fulvestrant treatment resulted

158

in a decrease in DAXX protein levels in the E2, NG, or RES treated groups (Figures 37A
& 37B). Cells at a density of 5 X 104 from each group were seeded in mammosphere
medium and allowed to grow for 7 days, after which mammospheres were counted. As
indicated in Figure 37C, E2 inhibited TIC-survival in MCF-7 cells, and this was reversed
when the ER was inhibited by fulvestrant (Figures 12 & 37C). The PEs, NG and RES
were able to inhibit TIC-survival, similar to levels of E2. However these effects were
reversed when the ER was antagonized by fulvestrant or when DAXX was depleted
using siRNA (Figure 37C). This suggests that suppression of TIC-survival by NG or
RES requires the ER or DAXX. Similar results were demonstrated for the T47D cell line
in which NG or RES was sufficient to inhibit TIC-survival, and this was reversed when
either the ER was inhibited by fulvestrant or the cells were depleted of DAXX by siRNA
(Figure 37D). This indicates that PEs bind the ER when cells are deprived of the natural
ligand, E2 to limit TIC-survival. Q was initially used as a control because it had little
effects on DAXX protein levels, however, surprisingly, it too was sufficient to decrease
TIC-survival compared to E2 minus conditions in both cell lines (Figure 34). This Qmediated decrease in TIC-survival was unaffected by DAXX depletion, but was
reversed by fulvestrant (Figures 37C & 37D). This suggests that Q is also sufficient to
limit TIC-survival, however, the mechanism of action is dependent on the ER and
independent of DAXX.
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FIGURE 39. PES ARE SUFFICIENT TO RESTRICT TIC-SURVIVAL THROUGH THE
ER. 3 X 105 MCF-7 or T47D were cells plated and transfected with SCBi or DAXXi for 2
days. Following this, cells were grown in vehicle, 5nM E2, or 100nM PE (NG, RES, or Q)
in the presence or absence of fulvestrant (100nM). A. A subset of cells had their total
protein isolated and DAXX protein levels were determined by Western blot analysis using
β-Actin as a loading control. B&C. MCF-7 (B) and T47D (C) cells were plated in
mammosphere media and allowed to propagate for 7 days. Mammospheres were then
counted and %MFE was determined. Histograms of (B) and (C) means ± SDs of %MFE
of three independent experiments. All groups were compared by Two-Way ANOVA to
SCBi 0nM E2 conditions to determine statistical significance $= P< 0.01, @= P< 0.001.

PES REQUIRE DAXX TO MAINTAIN EXPRESSION OF A LUMINAL MARKER
WHILE INHIBITING EXPRESSION OF A TIC-ASSOCIATED MARKER
We have demonstrated that at least two PEs, NG and RES, are sufficient to
reduce TIC-survival when cells are deprived of E2, mimicking AI therapy. This is a
significant finding because although E2 inhibits TIC-survival, it also stimulates bulk
tumor cell proliferation (Figures 8 & 12). Thus, the use of PEs to limit TIC-survival with
little effects on bulk cell proliferation would be a novel therapeutic strategy. Based on
these results, we hypothesized that PEs by inducing DAXX might be inhibiting TICsurvival through modulation of a differentiated luminal marker (E-Cadherin) or the TICassociated marker, NOTCH4 [47, 289, 338-340]. To test this, MCF-7 and T47D cells
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were treated with 0nM E2, 5nM E2, or 100nM PE for 1, 2, 3, or 7 days under DAXXexpressing (SCBi) or –depleted (DAXXi) conditions. Total protein was isolated and
levels of DAXX, E-Cadherin, and NOTCH4 were detected by Western Blot. As indicated
in Figure 38A, in MCF-7 cells, ER activation by E2 results in increased protein
expression of DAXX and E-Cadherin and decreased expression of the NOTCH4 protein
(Figure 38A). E2 deprivation, however results in an increase in NOTCH4 protein at 3
days, with a subsequent decrease in E-Cadherin and DAXX (Figure 38A). This is in
agreement with previous studies showing that the E2-mediated activation of the ER
decreases NOTCH4 and increases E-Cadherin (Figure 38A) [47, 289, 338-340]. Either
100nM NG or RES is sufficient to maintain DAXX and E-Cadherin expression for up to 7
days while limiting expression of the NOTCH4 protein (Figure 38B & 38C). This PEmediated decrease in NOTCH4 is reversed when DAXX is depleted (Figures 38B &
38C). Further, NG-mediated increase in E-Cadherin is also dependent on DAXX
expression, suggesting NG requires DAXX to promote E-Cadherin expression (Figure
38B). In contrast, Q treatment had little effects on expression of the DAXX protein.
However, Q maintained E-Cadherin expression and inhibited NOTCH4 expression but
this was independent of DAXX expression (Figure 38C). This is in agreement with
mammosphere results, as Q-mediated inhibition of TIC-survival was also independent
of DAXX expression (Figure 37). Similar results were observed in the T47D cell line
(Figure 39). E2-mediated activation of the ER was able to maintain DAXX and ECadherin expression, while preventing NOTCH4 expression (Figure 39A). When these
cells were deprived of E2, expression of DAXX and E-Cadherin decreased, while
NOTCH4 protein levels increased (Figure 39A). NG or RES treatment was able to
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maintain DAXX and E-Cadherin expression under E2 deprivation for up to 7 days, while
inhibiting NOTCH4 expression (Figures 39B & 39C). These effects appear to be
mediated at least in part through DAXX as depletion of DAXX by siRNA resulted in an
increase in NOTCH4 (Figures 39B & 39C). A modest decrease in E-Cadherin was
observed when DAXX was depleted under NG or RES treatment (Figures 39B & 39C).
However, whether this is biologically significant has yet to be determined. Q treatment
had little effects on DAXX levels, but was able to decrease NOTCH4 protein expression.

FIGURE 40. EFFECTS OF PES ON DAXX, E-CADHERIN AND NOTCH4 PROTEIN
LEVELS IN SCBI VS. DAXXI CONDITIONS IN MCF-7 CELLS. 1 X 106 MCF-7 were cells
plated and transfected with SCBi or DAXXi for 2 days. Following this, cells were grown in
0nM E2, 5nM E2 or 100nM PE for 3 days. Total protein was isolated and levels of DAXX,
NOTCH4 and E-Cadherin were determined by Western Blot Analysis using β-ACTIN as
a loading control. The following conditions were compared A. SCBi 5nM E2 vs. SCBi 0nM
E2, (B) SCBi 100nM NG vs. DAXXi 100nM NG, (C) SCBi 100nM RES vs. DAXXi 100nM
RES, and (D) SCBi 100nM Q vs. DAXXi 100nM Q.
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Aim 3C: Determine if PE-mediated DAXX protein expression and suppression of
TIC-survival is ER isoform-specific
Results so far have shown that PEs: NG, RES, or Q restrict TIC-survival under
conditions when E2 is deprived, simulating AI therapy, without inducing bulk cell
proliferation (Figures 34 & 37). These PEs require the ER to inhibit TIC-survival (Figure
37). However, what is not known is the specific ER isoform that mediates the actions of
the PEs. NG, RES, and Q have been reported to bind to ERα or ERβ isoforms, with a
higher affinity for ERβ [396]. And yet, it is unclear whether binding affinity of a PE for a
specific ER directly correlates to the activation status of the ER. For example, the
binding affinity of each PE to the specific ER isoform only partially correlated with EREdriven promoter activity (Table 2, page 68) [396]. Further these results were obtained in
non-breast cancer cells that ectopically expressed ERα or ERβ individually [396]. Thus,
they did not take into account differences in cofactor levels within different cell types nor
the ER hetero-dimerization [396, 404, 437]. In MCF-7 cells for example, NG has been
shown to preferentially act through ERβ whereas RES and Q have been shown to
activate ER signaling through ERα [406, 438, 439]. Determining the specific ER isoform
that mediates the actions of these PEs is of clinical importance as patient tumors can
differ in their ERα/ERβ ratio, however the majority of ER+ tumors express high ERα and
relatively low ERβ [440]. These findings are based on RNA, due to the lack of
antibodies that are ERβ specific [441]. Thus, using authenticated, selective ER isoform
agents, we wanted to determine which ER isoform mediated the action of PE on TICsurvival. We did this through the use of compounds that selectively activate or inhibit
ERα or ERβ. These include PPT, a selective ERα agonist, and DPN, a selective ERβ
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agonist. In addition, selective antagonists of ERα (MPP) and ERβ (PHTPP) were used
to assess the roles of ERα and/or ERβ in response to PEs [419-422]. TIC-survival was
assessed under PE and/or selective agonist/antagonist treatment conditions in cells
expressing DAXX or depleted for DAXX. The hypothesis was that NG acts through ERβ
and RES and Q act through ERα.

FIGURE 41. EFFECTS OF PES ON DAXX, E-CADHERIN AND NOTCH4 PROTEIN
LEVELS IN SCBI VS. DAXXI CONDITIONS IN T47D CELLS. 1 X 106 T47D were cells
plated and transfected with SCBi or DAXXi for 2 days. Following this, cells were grown in
0nM E2, 5nM E2 or 100nM PE for 3 days. Total protein was isolated and levels of DAXX,
NOTCH4 and E-Cadherin were determined by Western Blot Analysis using β-ACTIN as
a loading control. The following conditions were compared A. SCBi 5nM E2 vs. SCBi 0nM
E2, (B) SCBi 100nM NG vs. DAXXi 100nM NG, (C) SCBi 100nM RES vs. DAXXi 100nM
RES, and (D) SCBi 100nM Q vs. DAXXi 100nM Q.
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ACTIVATION OF EITHER ER ISOFORM INDUCES ER+ BREAST CANCER CELL
PROLIFERATION
The ratio of ERα to ERβ has been suggested to effect proliferation of ER+ breast
cancer cells [412]. Thus, we first determined if MCF-7 and T47D cells responded
differently to selective ER agonists and antagonists. MCF-7 and T47D cells were plated
at a density of 1 X 105 and allowed to propagate for 7 days in different experimental
conditions. This included the control groups of 0nM E2 and 5nM E2, 5nM E2 plus the
ERα and ERβ antagonist,100nM fulvestrant, 5nM E2 plus the selective ERα antagonist
(100nM MPP), 5nM E2 plus the selective ERβ antagonist (100nM PHTPP), the selective
ERα agonist alone (100nM PPT), or the ERβ agonist alone (100nM DPN). As shown in
Figure 40, E2 stimulates cell proliferation in both cell lines compared to control (0nM E2),
and this is inhibited when both ER isoforms are inhibited with fulvestrant (Figure 40).
However, neither the selective ERα (MPP) nor the ERβ (PHTPP) antagonist inhibited
E2-stimulated total cell proliferation, suggesting that both might be required (Figure 40A
and B). In agreement, when either selective ER agonists were used in the absence of
E2, cell proliferation was increased similar to E2 treatment alone (Figure 40A and B).
Together these preliminary findings suggest that activation of either or both ERα and
ERβ stimulate total cell growth of ER+ breast cancer cells. However, a genetic
knockdown approach would be better as these agents have potentially cross reactivity
at higher concentrations.
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A.

B.

FIGURE 42. EFFECTS OF ER ISOFORM ACTIVATION/INHIBITION ON TOTAL ER+
BREAST CANCER CELL SURVIVAL. MCF-7 (A) and T47D (B) cells were grown in
vehicle (0nM E2) vs. different combinations of ER activation/inhibition for 7 days. Increase
in cell number was then determined by cell counts. Statistically differences within each
cell group were determined by Two-way ANOVA, comparing Fold increase of all groups.
The results of all figures are means ± SDs of three independent experiments. #= P< 0.05,
$= P< 0.01, @= P< 0.001.

ACTIVATION OF EITHER ER ISOFORM INCREASES DAXX PROTEIN LEVELS,
HOWEVER PES HAVE ISOFORM SPECIFICITY
Results so far have shown that selective activation of either ER isoform
increases total cell proliferation. This is not surprising as both ERs are able to activate
ERE-driven promoter activity [396]. PEs have reported to bind to and activate one ER
isoform over another [406, 438, 439] and as such it is possible that one isoform of the
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ER mediates the action of PE on DAXX expression. Given this, we investigated if the
activity of one or both ER isoforms was required for increased DAXX protein levels in
response to E2 or PE treatments. To determine this, MCF-7 and T47D cells were treated
with 0nM E2 and 5nM E2, 5nM E2 plus the ERα and ERβ antagonist (100nM fulvestrant),
the selective ERα agonist alone (100nM PPT), ERβ agonist alone (100nM DPN), NG
alone (100nM), NG plus fulvestrant, NG plus ERα antagonist (MPP), NG plus ERβ
antagonist (PHTPP), RES alone (100nm), RES plus fulvestrant, RES plus MPP, RES
plus PHTPP, Q alone (100nm), Q plus fulvestrant, Q plus MPP, and Q plus PHTPP for
3 days and DAXX protein levels were detected by Western Blot analysis. As indicated in
Figure 41A, in MCF-7 cells either the ERα (PPT) or ERβ (DPN) agonist alone increased
DAXX protein levels similar to E2 treatment (Figure 41A). For the PEs, NG appears to
act through ERβ as PHTPP almost completely reversed NG-induced DAXX levels, while
MPP had little effects (Figure 41A). In contrast to NG, RES appears to act through ERα
as MPP treatment prevented RES-induced DAXX protein expression (Figure 41A).
Interestingly, Q treatment only modestly increased DAXX protein levels and neither of
the ER antagonists had any detectable effects (Figure 41A). The effects of the PEs on
DAXX expression were found to be similar in MCF-7 and T47D cells (Figures 41A and
41B). However, the ER agonists were less effective in increasing DAXX levels in T47D
compared to MCF-7 cells (Figure 41B). Interestingly, while NG or RES induced DAXX
expression to levels of E2 treatment in T47D cells, either fulvestrant, MPP, or PHTPP
inhibited this increase with MPP being less effective for NG and PHTPP for RES (Figure
41B). This would suggest that T47D cells possibly require either ER isoforms to
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express the DAXX protein but however the expression of each isoform may explain
these differential results [396, 404].

FIGURE 43. PES REQUIRE ER TO INCREASE DAXX PROTEIN LEVELS. 1 X 106 MCF7 (A) or T47D (B) cells plated and grown in 0 nM E2, 100 nM PPT or DPN, optimal
concentrations of individual PEs, or each PE + 100 nM fulvestrant, MPP (α) or PHTPP
(β) 3 days. Total protein was isolated and the relative protein levels of DAXX were
determined by Western Blot Analysis using β-ACTIN as a loading control. PE
Concentrations: NG= 100 nM, RES= 100 nM, Q= 100 nM

PE-MEDIATED INHIBITION OF TIC-SURVIVAL IS POTENTIALLY ER ISOFORMSPECIFIC
Results so far demonstrate that PEs increase DAXX protein levels possibly
through specific ER isoforms depending on the ER+ cell line (Figure 41). To determine if
PEs inhibit TIC-survival through specific ER isoforms, similar treatment conditions as
described in Figure 41 were conducted and mammosphere forming assays were
assessed. As shown in Figure 42A, the ERα agonist (PPT) or the ERβ agonist (DPN)
decreased mammosphere formation in MCF-7 cells compared to the –E2 group (Figure
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42A). This suggests that activation of either ERα or ERβ is sufficient to inhibit TICsurvival, which inversely correlates with DAXX levels detected in Figure 41A (Figures
41A & 42A). NG inhibits TIC-survival in MCF-7 cells, and this is reversed when ERβ is
inhibited with PHTPP (Figure 42A). RES inhibits TIC-survival through ERα as MPP
reversed this effect (Figure 42A). Interestingly, Q also appears to act through ERα to
inhibit TIC-survival, but the Q-mediated decrease in TIC-survival is most likely not due
to DAXX expression (Figures 41 & 42A). Similar results were observed with T47D cells
with the exception that RES-mediated inhibition of TIC-survival was almost completely
reversed by the ERα antagonist (MPP) and partially reversed by the ERβ antagonist
(PHTPP) (Figure 42B). This suggests that moderate to low amounts of DAXX may be
sufficient to restrict TIC-survival.
AIM 3 Conclusions
The results from Aim 3 demonstrate that the combination of AI-simulated therapy
and a subset of individual PEs (NG and RES) are sufficient to increase DAXX protein
levels without inducing total ER+ breast cancer cell proliferation. Furthermore, both of
these PEs require DAXX and ER to inhibit survival of TICs. Q was initially chosen as a
control as it did not induce total ER+ breast cancer cell proliferation nor increase
expression of the DAXX protein. Surprisingly, Q was also sufficient to inhibit TICsurvival under AI-simulated conditions. However, this was independent of DAXX
expression but required the ER. We further tested whether these PEs acted through
specific isoforms of the ER (ERα and/or ERβ). Individual PEs potentially act through
specific ER isoforms, namely NG seems to require ERβ activity and RES or Q seem to
require ERα activity. In T47D cells, a similar trend of NG requiring ERβ and RES or Q
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requiring ERα is observed. These findings suggest that a therapeutic regiment of an AI
to inhibit synthesis of E2 to inhibit total ER+ breast cancer proliferation plus a PE to
induce DAXX expression and restrict TIC-survival may offer better therapeutic
outcomes and thus should be investigated in a pre-clinical setting.

FIGURE 44. PES ACT THROUGH DIFFERENT ER ISOFORMS TO RESTRICT TICSURVIVAL. 3 X 105 MCF-7 (A) and T47D (B) were grown in 0 nM E2, 100 nM PPT or
DPN, or 100 nM PE +/- isoform-specific ER antagonists (100 nM) for 3 days. Cells were
plated in mammosphere media and allowed to propagate for 7 days. Mammospheres
were then counted and %MFE was determined. Histograms of (A) and (B) means ± SDs
of %MFE of three independent experiments. All groups were compared by Two-Way
ANOVA to 0 nM E2 conditions to determine statistical significance #= P< 0.05, $= P< 0.01,
@= P< 0.001.
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FIGURE 45 AIM 3 SUMMARY FIGURE. A. What is known, namely that PEs partial
activate the ER, that full activation of the ER inhibits TIC-survival and that one example
of ET (AI) inhibits total ER+ breast cancer cell survival. B. New model based on Aim 2
data in which we have shown that a combination therapy of an AI and a PE is sufficient
to restrict total cell survival and TIC-survival. Specifically AIs limt total cell survival and
PEs partial activate the ER to increase DAXX protein levels to subsequenctly restrict TICsurvival.

CHAPTER 5
DISCUSSION
ER+ breast cancer is the most common breast cancer subtype, accounting for
nearly 75% of all new breast cancer diagnoses [47]. Although these cancers are subdivided into Luminal A and Luminal B based on their proliferative index, both are first
treated with a therapeutic regiment that includes ET [30-35, 59-60]. This is due to these
tumors being initially dependent on ER activation for their growth [47]. Use of ET in the
treatment of ER+ breast cancer is considered a major success story in cancer therapy,
as it is one of the most effective and least toxic chemotherapies to date [80]. The clinical
problem that remains is the high rates of recurrence and resistance in a subset of
patients following ET, specifically in those with metastatic disease [54, 55]. This is
reflected in the poor 20-year survival rate in these patients, which falls below TNBC
[33]. TICs are thought to be one cell type that exists within the heterogeneous ER+
tumor that contributes to recurrence of treatment resistant breast cancer [12-13, 269270]. TIC persistence within the breast tissue following ET is thought to be due to their
low expression of the ER [288, 296-297]. Thus, TICs-retained in the breast tissue have
the ability to promote regeneration of a local-regional tumor over time or TICs remaining
in lymph nodes or distant organs promote distant recurrences [12-13, 269-270, 296297]. It has been demonstrated by multiple groups that TICs are dependent on NOTCH
signaling for their survival and therapies that inhibit the ER increase NOTCH activation
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[338-341]. Based on this, therapies such as GSIs were added in combination with ETs
to inhibit TIC-survival and total cell survival, respectively [338-341]. This therapeutic
strategy was shown to be effective in the preclinical testing, but increased
gastrointestinal and skin toxicity clinically [348, 443]. These results indicate there is
critical need for therapeutics that selectively inhibit NOTCH and TIC-survival in ER+
breast cancer, but avoid toxicities.
Albain et al. identified DAXX whose expression inversely correlated with NOTCH
activation in patients with ER+ breast cancer [60]. In subsequent experiments, it was
shown that DAXX protein expression is dependent on ER activation, and therefore is
depleted under ET conditions (Figure 11). Further, it was demonstrated that DAXX was
required for ER-mediated restriction of TIC-survival and NOTCH signaling, and under
AI-simulated conditions, DAXX was sufficient to target TICs (Figures 12-15, 18). Based
on these results, it was concluded that DAXX is a bonafide TIC suppressor in ER+
breast cancer. Furthermore, DAXX stabilizing therapeutics given in the absence of E2
such as when combined with an AI may restrict TICs and bulk ER+ breast cancer cells,
respectively. The data indicate that activation of the ER is required for DAXX protein
stabilization (Figure 11). Additionally, it was shown that partial agonists of the ER are
sufficient to increase DAXX protein levels under AI-simulated conditions (Figures 35 &
36) [88]. Importantly, a subset of these compounds did not induce total tumor cell
proliferation (Figures 34). However, this may be a risky strategy as we are still activating
the ER and therefore hypothetically, may induce proliferation of these ER+ cells.
Fortunately, a number of proteins have been shown to impact DAXX protein stability,
with pharmaceutical agents that modulate these markers already categorized and
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readily available. Elucidating a method to alter the activity of proteins that regulate
DAXX stability would thus provide a novel strategy to increase DAXX protein levels
independently of the ER.
A sumoylating protein, ubiquitin conjugating enzyme E2 I (UBC9 or UBE2I), has
been reported to regulate the cellular localization of DAXX and may also regulate its
stability in ER+ breast cancer. Gene expression of UBE2I has been shown to be
dependent on ER activation in MCF-7 cells and others have demonstrated it associates
with DAXX [443, 444]. Additionally, UBC9 activity has been illustrated to be required for
DAXX nuclear localization in MCF-7 cells, as expression of a dominant negative UBC9
resulted in cytoplasmic localization of DAXX [446]. In MCF-7 cells, we have shown that
nuclear depletion of DAXX by ET increases TIC-associated transcript expression and
ultimately TIC-survival (Figures 12, 21 & 26). Thus one hypothesis is that ER activation
increases nuclear levels of DAXX by inducing UBC9 expression. Our preliminary
findings indicate that this may be the case as we have shown that UBE2I transcript
expression is dependent in ER activation, which correlates with its protein levels in
MCF-7 and T47D cells (Appendix Figure 1A & 1B). Further, UBC9 knockdown in MCF-7
cells grown in E2 supplemented conditions resulted in nuclear depletion of DAXX after 1
day (Appendix Figure 1C). At this time point, expression of TIC-associated transcripts
are increased (Figure 26). Interestingly after 3 days, depletion of UBC9 resulted in a
decrease in total DAXX protein levels (Appendix Figure 1C), similar to what was
detected after 3 days of ET (Figure 12A). Additionally, this depletion of DAXX protein
after UBC9 knockdown correlated with an increase in TIC-survival in MCF-7 cells
(Appendix Figure 1D). Overall these findings suggests that in MCF-7 cells, UBC9 is
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required to increase nuclear DAXX protein levels, and may regulate the stability of the
DAXX protein. However, additional experiments are needed to confirm this. If this
hypothesis is correct, therapeutics that increase UBC9 activity may also increase DAXX
protein levels in ER+ breast cancer, which may restrict TIC-survival.
As mentioned in the introduction, DAXX stability has also been shown to be
regulated by Mdm2 and USP7, albeit with conflicting results. In the U2OS osteosarcoma
cell line, USP7 was demonstrated to increase DAXX stability and further it was shown
that Mdm2 promotes DAXX degradation [360]. This indicates pharmaceuticals that
increase USP7 or decrease Mdm2 activity may promote DAXX protein stability.
Conversely in ALL cell lines, inhibition of Mdm2 is associated with a decrease in DAXX
protein levels, suggesting the opposite relationship between Mdm2 and DAXX protein
stability [363]. This is an interesting finding, as Mdm2 activity has been shown to be
activated by the ER [364]. Additionally USP7 is considered a poor prognostic marker in
breast cancer [365]. Thus based on these findings, one could hypothesize that the ER
may stabilize DAXX by increasing Mdm2 activity, making it a potential therapeutic target
to inhibit TIC-survival. As inhibitors of both USP7 and Mdm2 have been described,
additional studies confirming this Mdm2-USP7-DAXX relationship in ER+ breast cancer
are needed [364, 447].
Separate findings indicate DAXX protein stability is regulated by Speckle-type
POZ protein (SPOP) and ubiquitin ligase Cullin 3 (Cul3) [448]. Kwon et al. showed in
HeLa and COS-7 cells that SPOP served as an adaptor protein for DAXX, facilitating
DAXX ubiquitylation by Cul3, ultimately leading to its degradation by the proteasome
[448]. They demonstrated that this degradation of DAXX could be abrogated under
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conditions of SPOP depletion by siRNA or by treatment with the proteasome inhibitor
MG132 [448]. This is in agreement with our findings in which we have shown that
MG132 prevented DAXX destabilization in response to ET (Figure 10). Further, this
group showed that depletion of DAXX prevented DAXX-mediated repression of ETS1
and p53-dependent genes [448]. This suggests that SPOP and Cul3 can alter gene
expression by destabilizing DAXX, and we have reported that ET alters gene
expression via the same mechanism (Figures 24-26). The exact mechanism by which
the SPOP/Cul3 complex functions to regulate DAXX in ER+ breast cancer is not fully
understood as few have investigated this relationship. However, one group reported that
the SPOP/Cul3 complex inhibits expression of ER-responsive genes [449]. One
hypothesis is that ET increases the SPOP/Cul3 complex to prevent activation of ERdependent pathways, including DAXX stabilization. Again, further studies are needed to
determine if this relationship is of therapeutic significance in ER+ breast cancer. If
SPOP and/or Cul3 activity are increased by ET, inhibitors of either of these proteins
may stabilize DAXX and result in TIC restriction.
Overall, we have shown DAXX is sufficient to restrict TIC-survival under ET
conditions, thus a therapy that is able to increase DAXX under ET conditions would be
of therapeutic significance. Specifically, it would represent a novel treatment regimen
that inhibits total cell survival by ET, while also inhibiting TIC-survival via a DAXX
stabilizing agent. This was ultimately the goal of the ET + GSI treatment regimen, but it
was not realized due to the associated side effect profiles [347, 442]. Although we have
illustrated one possibility of using partial ER agonists to stabilize DAXX, these therapies
could hypothetically induce ER+ breast cancer cell growth (Figure 37). Therapies that
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act independently of the ER, namely those that target proteins that directly regulate
DAXX stability, would avoid this potential therapeutic pitfall. Additionally, as some
patients lose ER expression over the course of therapy, an ER independent therapy
may be efficacious in a broader spectrum of the breast cancer population [66-67, 221].
Our present findings (specifically Aim 2) have also elucidated, at least in part, a
mechanism by which the ER restricts TIC-survival. Separate groups have indicated that
the ER inhibits expression of genes associated with stemness including pluripotent
genes, SOX2, OCT4, and NANOG [289-292], and restricts activation of NOTCH
signaling [338-341]. The exact mechanism by which the ER inhibits expression of these
genes was not fully understood. One reported mechanism for how the ER restricts TICs
was through genome-wide epigenetic modifications [294]. This was based on findings
that changes in genome methylation patterns in breast cells were critical for determining
cell fate [294]. Specifically, they demonstrated that healthy breast progenitor cells had a
pattern of hypomethylation near gene promoters associated with pluripotency, and TICs
had a similar pattern [294]. Again, how the ER induced these epigenetic patterns was
not definitively reported. Alternatively, previous studies indicated that DAXX can recruit
the DNA methylating enzyme DNMT1 to promoter regions of its target genes to silence
their expression [390]. Additionally, DNMT1 has been illustrated to regulate expression
of pluripotency genes such as SOX2, OCT4 and NANOG [289-292]. We have shown
that DAXX requires ER activation for its protein stability and nuclear localization
(Figures 11 & 21). Additionally, we found DAXX is required for the ER to restrict TICsurvival and NOTCH signaling (Figures 12). Thus we hypothesized the ER
epigenetically regulates the expression of TIC-associated genes through DAXX and
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DNMT1. We found that DAXX is required for ER-mediated restriction of TIC-associated
transcript expression including pluripotency genes and NOTCH4 (Figure 26). Further,
we have demonstrated DAXX is sufficient to inhibit expression of these TIC-associated
transcripts under ET-simulated conditions (Figure 26). Finally, we illustrated that DAXX
requires DNMT1 to restrict TIC-associated and TIC-survival, suggesting the ER
epigenetically regulates gene expression through DAXX and DNMT1 (Figure 29). In
support of this, we found that activation of the ER by E2 is associated with increased
methylation at the promoter of one TIC-associated gene, SOX2 (Figure 31). This
methylation is lost when DAXX or DNMT1 is depleted by siRNA (Figure 31). Given
these findings alone, one may hypothesize that increasing DNMT1 activity will decrease
expression of TIC-associated genes, and thus inhibit TIC-survival. This is supported by
experiments conducted using the LTED MCF-7/5C cell line, which has decreased
expression of DNMT1 in response to LTED (Appendix Figure 2A). In these cells, ER
activation did not restrict TIC-associated transcript expression, which we hypothesized
is due to long term depletion of DNMT1 (Appendix Figure 2C). In support of this
hypothesis, forced re-expression of DNMT1 was sufficient for ER-mediated restriction of
TIC-associated transcripts in MCF-7/5C cells (Appendix Figures 2B & 2C). These
results suggested that the DNMT1 is a restrictor of TIC-survival. And yet, in ER+ breast
cancer as a whole, this relationship between DAXX, DNMT1, and TICs appears to be
much more complex.
High expression of DNMT1 in ER+ breast cancer patients following ET is
associated with a shorter RFS (Appendix Figure 2D). On the surface, this finding
directly conflicts with our results indicating that DNMT1 offers beneficial effects in
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limiting TIC-survival (Figures 27 & 29). However there is a potential explanation. We
have shown that DNMT1 protein levels do not change under conditions of ER activation
as compared to ER inhibition in ET-sensitive breast cancer cells (Figures 27A & 29A).
Rather, we concluded it is the loss of DAXX under ET conditions that prevents the
DAXX-DNMT1-TIC relationship (Figure 29). This begs the question, when DAXX is
depleted in ER+ breast cancer, what is the function of DNMT1? Reports from other
groups indicate that DNMT1 may be recruited to other regions of the genome, leading to
pathological effects. One example of this is a study investigating Mucin 1 (MUC1), a
transmembrane glycoprotein that is overexpressed in metastatic, ET-resistant ER+
breast cancer [450]. MUC1 is proposed to induce ET-resistance through a variety of
mechanisms, however Rajabi et. al. demonstrated it may be through MUC1’s ability to
recruit DNMT1 [451]. Specifically, they reported that MUC1 recruits DNMT1 to target
genes allowing for epigenetic re-programming of ER+ breast cancer cells, ultimately
conferring ET-resistance [451]. This is very similar to the results we reported for DAXX.
They indicated MUC1 recruited DNMT1 to genes associated with luminal differentiation
including CDH1 (E-Cadherin), resulting in loss of its expression [451]. Interestingly, we
have shown that under conditions when DAXX is high, E-cadherin levels are also high
(Figures 38 & 39). Conversely, under conditions when DAXX is low, as during ET or
siRNA knockdown, E-cadherin levels begin to decrease (Figures 38 & 39). Whether this
is due MUC1 recruitment of DNMT1 is not yet known. Overall these findings suggest
that DNMT1 may be recruited to other regions of the genome under ET conditions when
DAXX is lost, leading to adverse changes in gene expression.
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The relationship between DNMT1 and ER expression in general is another issue
of clinical concern. Giacinti et. al. reported that loss of ER expression at the time of
diagnosis or during the course of ET is associated with hypermethylation of the ESR1
(ERα) promoter [66-67, 225]. One protein thought to cause this loss of ER expression in
breast cancer is DNMT1 [221-226]. This is based on reports that high DNMT1
expression is associated with a poor prognosis, and inversely correlates with ER
expression in human breast cancer samples [221-226]. These findings suggest that ET
impacts DNMT1 in a clinically negative way. Findings from our own cells exposed to ET
long term reflect this. For example, MCF-7/5C cells have been exposed to LTED, but
retain their ER expression. What’s interesting is they have lost DNMT1 expression
(Appendix Figure 2). One hypothesis based on this is MCF-7/5C cells lose DNMT1
expression in response to long term depletion of its recruiter, DAXX. This allows MCF7/5C cells to retain their ER expression, but also results in a loss in ER-mediated
restriction of TIC-associated transcript expression (Appendix Figure 2). This is in
contrast to the T47D cell line, which loses its ER expression when undergoing LTED
[452]. As we have shown DAXX is depleted under LTED conditions in T47D cells
(Figures 10 & 11), one hypothesis is loss of DAXX frees DNMT1 to epigenetically
silence the ER. Further, the MCF-7/TAMR cell line has lost its ability to regulate DAXX
protein through the ER (Figure 16). DAXX however is still able to regulate TIC-survival,
suggesting they may still express DNMT1 (Figure 17). Whether DNMT1 recruitment
patterns have changed in any of these ET-resistant cells is unknown, but these findings
warrant further investigation. If the DNMT1 recruitment patterns do change in response
to ET, another consideration is whether it is permanent. Answering this question is
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essential because if these changes in DNMT1 recruitment are irreversible, the use of
DAXX promoting therapies to restrict TICs may be lost. This would suggest such
therapies would be most effective at the start of ET, rather than following cancer
recurrence. Overall these findings indicate a need to better understand the effects ET
have on the expression/activity of DNMT1 and other epigenetic modifying enzymes. If
ET does alter DNMT1 recruitment patterns, studies determining if pathological DNMT1
activity is prevented by the addition of DAXX-stabilizing therapies would be warranted.
This may already be true in TNBC, as DNMT1 inhibitors have been shown to be
beneficial [227, 228].
Ultimately, findings from previous studies and our own results suggest that the
ER has beneficial functions in the context of ER+ breast cancer. Namely, activation of
the ER with E2 or PEs inhibits TIC-survival. Additionally, our results suggest that
complete inhibition of the ER can cause adverse consequences in a subset of patients
due to depletion of DAXX. A further discussion of the pathogenesis and clinical trends in
treatment of ER+ breast cancer may help us better understand why.
In healthy breast tissue, the ER+ cells are the minority and relatively quiescent,
making up 15-30% of the total luminal cell population [124, 125]. In ER+ breast cancer
however, these cells become highly proliferative and are able to give rise to a tumor
mass [123-125]. Why this occurs is still not fully understood [126-134]. ETs were
developed due to this association and are considered a major success story in cancer
therapy [80]. However, consideration of normal breast tissue physiology may help
explain why recurrence occurs in a subset of ER+ breast cancer patients following ET
[33, 54-55]. As mentioned in the introduction, the ER is required for proper
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differentiation of the breast tissue both during puberty and pregnancy [6-8, 110]. This is
demonstrated in non-cancerous tissue in which loss of the ER prevents differentiated
cells from populating the breast tissue [6-8, 110, 116, 121]. The loss of differentiated
cells within the breast occurs in all women during menopause, in which decreases in
systemic levels of E2 results in atrophy of the breast tissue [7]. Further, it is suggested
that breast progenitor cells are stimulated to undergo differentiation during breast
development in response to factors that include E2 [452]. Based on this, one hypothesis
is that the loss of ER signaling long term promotes cancer cells that have progenitor
properties, allowing TICs to persist, and over time, give rise to a recurrent tumor.
Thus, a paradox exists in ER+ breast cancer. On one hand, ETs are highly
effective at targeting the ER-dependent bulk breast tumor cells, and on the other, their
properties may induce an environment that enhances the survival of TICs. Our results
and the work of others suggest that this paradox may be due to multiple cell populations
that exist within a bulk tumor [338-341]. Namely there exist differentiated ER+ tumor
cells that are dependent on ER activation for their viability, and TICs, which prefer
conditions of low or lack of ER activation. This is in agreement with molecular analysis
of human specimens that indicate a high level of tumor cell heterogeneity [250-252,
265]. Why these differentiated cells or TICs respond differently to ET may be explained
by their expression levels of the ERs. It has been reported that TICs in ER+ breast
cancer express relatively low levels, and are thus intrinsically resistant to the anti-ER
effects of ET [288, 296-297]. Although we have not quantified ER expression directly,
our results suggest that these TICs express the ER. This is based on findings that ER
agonists such as E2 or PEs inhibit TIC-survival, and these properties are lost when the
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ER is blocked by fulvestrant (Figures 12 & 37). Others have reported that it is the ratio
of ERα/ERβ that may distinguish bulk tumor cells from TICs. Specifically bulk tumor
cells have been shown to express high levels of ERα and low ERβ [440], whereas TICs
are suggested to express low levels ERα and high ERβ [454]. High expression of TIC
markers including ALDH have been shown to be associated with poor prognosis and
high recurrence rates in in ER+ breast cancer [261]. However, to our knowledge, no
studies have investigated if the ratio of the ER isoforms correlates with cancer
recurrence. As ERs are directly targeted with ET, the ratio of their expression may be of
clinical significance. It is possible that the ER ratio alters how patients respond to ET, as
the ratio has been reported to change how ER+ breast cancer cells respond to ER
agonists [404, 412] This may explain why many patients, specifically with a high
ERα/ERβ ratio, respond favorably to ET without the development of recurrence and/or
resistance [80]. Conversely, patients that have an abnormal ERα/ERβ ratio may
respond differently to ET, which would explain high rates of recurrence in these
patients. Additional experiments determining if there is a correlation between recurrence
and the ERα/ERβ ratio in patient samples are warranted. If the ER ratio does correlate
with cancer recurrence, new treatment regimens may be warranted for a subset of
patients.
This discussion is not an indictment on ET which has saved lives with relatively
low toxicity [80]. Rather, based on our current understanding of breast physiology and
the trends in ER+ breast cancer outcomes, fine tuning of the treatment regimen may
dramatically improve clinical results. Until very recently, the direction of new ETs has
tended to be more severe inhibition of the ER in the treatment of ER+ breast cancer
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[455]. In the mid-20th century, highly estrogenic compounds such as diethylstilbestrol
(DES) were standard of care and shown to have clinical benefit. However, DES
treatment was also associated with thromboembolism and cardiovascular side effects
[455]. Due to this side effect profile, therapeutics in the opposite direction, namely
therapeutics that inhibit the ER were considered. This included SERMs, which decrease
ER signaling in select tissues like the breast [169-179]. Later, harsher anti-ER
therapeutics including AIs and SERDs were utilized to more effectively target the ER in
hopes of improved therapeutic efficacy [138, 207]. Again, more rigorous inhibition of the
ER may be effective in some patients, but in those that have cells within the tumor that
express low levels of the ER or an abnormal ratio of the ERs, this may not be the case.
Importantly, reports demonstrate that better inhibitors of ER function offer little improved
clinical benefit. For example, fulvestrant therapy was shown to be no more effective at
inhibiting recurrent, ET-resistant breast cancer than AIs [211]. This suggests that
therapies such as SERMs or AIs may be sufficient to target ER+ breast cancer in the
majority of patients with low risk of recurrence. However, the sub-population that has a
high risk of recurrence, perhaps due to a larger proportion of TICs within the tumor, may
not benefit from more aggressive ETs. Our data would suggest that they may benefit
from therapies that work in the opposite direction and partially activate the ER. Some
groups have begun to investigate the concept of a “pure SERM” in order to target ERdependent growth, but also maintain some of the beneficial effects of the receptor [395].
Specifically, Dr. Jordan’s group has reviewed the idea that phytoestrogens may fit this
distinction of turning on the ER, but also prevent tumor growth [395].
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We investigated this concept in our outlined experiments, and found that some
phytoestrogens fit the concept of partially activating the ER to improve treatment of ER+
breast cancer. Specifically naringenin, resveratrol and quercetin were shown to inhibit
TIC-survival without inducing total bulk cell proliferation in ER+ breast cancer cells
(Figures 35 & 37). Why phytoestrogens are able to effect TICs through the ER but not
the bulk tumor cells is still not known. A hypothesis based on the above discussion is it
may be due to the expression levels of the ER isoforms. Again, differentiated tumor
cells express high ERα [440], whereas TICs have been reported to express high ERβ
[453]. Interestingly phytoestrogen have been indicated to have a higher affinity for ERβ
vs. ERα (Table 1) [88]. Our preliminary experiments using the ER isoform-specific
antagonists agree with this for naringenin, however our preliminary studies suggest
resveratrol and quercetin may act through ERα (Figures 41 & 42). Although the
antagonists we used to develop these conclusions are reported to be highly selective for
each individual ER isoform, a genetic approach of ER isoform gene knockdown must be
done to validate these preliminary findings [420-422]. Ultimately, whether partial ER
agonists such as PEs tend to target TICs over bulk tumor cells due to their ER isoform
specificity is not yet known. Conversely, phytoestrogens binding of the ERs has been
reported to alter ER recruitment of cofactors [80, 85, 403-404]. This could explain why
PEs act differently than E2, and further why we see slight differences in MCF-7
compared to T47D cell lines in response to phytoestrogens and the selective ER
isoform antagonists (Figures 41 & 42).
A legitimate criticism of our strategy of using phytoestrogens to inhibit TICsurvival is that we are still activating the ER. This means theoretically, in some ER+
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breast cancer tumors, we could induce their proliferation. Thus, further studies are
needed in more translational models to investigate whether phytoestrogens induce ER+
breast tumor cell proliferation including heterogeneous PDX models. However, our
findings at the very least are a proof of concept that partial agonists of the ER are
relevant in terms of breast cancer therapy. Furthermore, our discussion indicates they
may be useful in preventing recurrence in a subset of the ER+ breast cancer population.
We hypothesize it is those patients with a higher proportion of TICs within their tumor.
These findings are supported by Xiong et al. who reported that selective human
estrogen receptor partial agonists (shERPAs) are effective in treating ET-resistant
cancer cells [456]. Taken together, our results and the findings of others suggest that
understanding why partial ER agonists, including phytoestrogens, are beneficial in
preventing TIC-survival and ultimately cancer recurrence is critical. We have indicated
that it is through the ability of phytoestrogens to increase DAXX in ER+ breast cancer
cells (Figure 37). The mechanism by which this occurs, and if phytoestrogens effect all
cells or a subset of the population is not yet known. Determining the mechanism by
which some phytoestrogen increase DAXX levels may be critical for improving
treatment of ER+ breast cancer. For example, if the increase of the DAXX protein is due
to differences in the ER-phytoestrogen structure or cofactor recruitment, it would allow
for the design of synthetic mimetics that induce the same effects of phytoestrogens, with
a lesser likelihood of unintended side effects. Side effects for example would include
inducing bulk cell proliferation in ER+ breast cancer.
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CONCLUSIONS
Previous studies have shown the ER restricts NOTCH signaling, expression of
pluripotency genes and TIC-survival [289-292, 338-341]. Thus, ETs that inhibit the ER
increase expression of TIC-associated pathways and their overall survival. We
investigated a mechanism by which the ER restricts TICs in the hopes of identifying a
novel therapeutic target. We have shown that DAXX is a marker whose protein stability
is dependent on ER activation and thus depleted in response to ET. Further, its
expression is required for ER-mediated restriction of TIC-associated pathways and
ultimately TIC-survival. This suggests that the ER inhibits TICs in part by increasing the
DAXX protein and therapies that block the ER, prevent this from occurring. DAXXmediated restriction of TICs appears to be through its ability to modulate gene transcript
expression. Explicitly, DAXX binds promoter regions of TIC-associated genes under
conditions of ER activation, and is required for the ER to inhibit their transcript
expression. This gene regulation is lost however under ET conditions, when the DAXX
protein is depleted. We have shown that DAXX requires the epigenetic modifier DNMT1
to elicit its effects, and loss of DAXX or DNMT1 is associated with a loss of promoter
methylation at one TIC-associated gene, SOX2. Furthermore, forced expression of
DAXX under AI-simulated conditions is sufficient to restrict TIC-associated transcript
expression, correlating with a decrease in TIC-survival. This suggested to us that a
therapeutic that is able to increase the DAXX protein under AI conditions, without
inducing total cell proliferation, may reduce TIC-survival. We showed that a subset of
PEs were sufficient to increase the DAXX protein through the ER, without inducing bulk
tumor cell proliferation. This was associated with a restriction in TIC-survival. Thus,
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therapeutics that partially activate the ER added with AIs may improve clinical
outcomes. Furthermore, as we have shown that DAXX is a bonafide suppressor of
TICs, the use of DAXX as a biomarker when testing the efficacy of these new
therapeutics may also facilitate drug development. This will allow for efficient screening
of potential pharmaceuticals, and thus will expedite the process for testing them in a
clinical trial setting.

CHAPTER 6
FUTURE DIRECTIONS
CONFIRM RESULTS USING OTHER MODELS
These studies demonstrate that DAXX is required for ER-mediated restriction of
TIC-survival and therapies that inhibit the ER deplete ER+ breast cancer cells of DAXX.
Furthermore, we have shown that under AI-simulated conditions of estrogen
deprivation, DAXX is sufficient to inhibit TIC-survival. Although these findings are clear
in MCF-7 and T47D cells, they were obtained using single clone cell lines, meaning the
ability to translate these results to human patients needs to be expanded [71].
Specifically, ER+ breast cancer tumors in humans have been shown to possess a high
degree of heterogeneity, thus testing our hypotheses in models that more accurately
reflect this would better translate to the human disease [265]. The use of PDXs are a
relatively new, powerful tool in the study of ER+ breast cancer [72]. As these tumors are
derived from patient samples, they better reflect the heterogeneity seen in the clinic,
providing us with an improved model of disease [72-75]. Dr. Robert Clarke’s group has
demonstrated the ability to use PDX tumors both in vitro and in vivo via animal
implantation in the study of ER+ breast cancer [338, 340]. Using these techniques, we
propose to investigate whether ET depletes DAXX in human PDXs, and whether DAXX
is required to inhibit the survival of TICs obtained from these samples. We hypothesize
that ET will deplete the DAXX protein in PDX samples as we have already shown in
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MCF-7 and T47D cell lines (Figure 11). We will test this by growing the PDX tumors in
immune compromised mice and once tumors are palpable, begin treatment with AIsimulated conditions (- E2-supplemented capsule + vehicle), ER activated conditions
(sialic release E2 capsule + vehicle), or active inhibition of the ER (sialic release E2
capsule + fulvestrant). The optimum time point for tumor removal will be first determined
by pilot experiments. Once this is achieved, we will treat animals with our proposed
strategies, isolate their tumors, and finally determine DAXX protein levels by Western
Blot analysis. We hypothesize that DAXX protein levels will be high in ER activated
conditions (+ E2 capsule + vehicle) and low under the two experimental ET conditions.
This would provide further evidence that ET depletes ER+ breast cancer tumors of
DAXX. Dr. Clarke’s group also illustrated the ability to culture individual tumor cells
derived from the PDXs for short-term molecular analysis [340]. To test whether DAXX is
required for ER-mediated restriction of TIC-survival, we will grow tumors in immune
compromised mice, isolate and de-bulk the tumors into single cells, and finally culture
them on lysine-coated plates. Cells will then be transfected with SCBi or DAXXi siRNA
and then grown in 0nM E2, 5nM E2, or 5nM E2 + 100nM fulvestrant for 3 days to match
our previous experiments (Figure 12). TIC-survival will then be determined using the
mammosphere assay. We hypothesize that ER activation will restrict TIC-survival in
isolated ER+ PDX cells as previously reported [340], and that DAXX knockdown will
prevent this restriction of TIC-survival. This again would provide stronger evidence that
DAXX is required for ER-mediated restriction of TICs in human samples, and therapies
that inhibit the ER, deplete these tumor cells of DAXX. Finally we will conduct an ELDA
using SCBi vs. DAXXi treated PDX cells under E2-supplemented capsule (ER activated)
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conditions. This will allow us to determine if loss of DAXX increases TIC-frequency in
heterogeneous patient-derived samples. Overall, these studies would confirm our
findings that DAXX is required for ER-mediated restriction of TIC-survival in a more
applicable, heterogeneous model of ER+ breast cancer.
Visualization of ET depletion of DAXX in vivo would also be a powerful set of
experiments to supplement our findings. First, we would generate MCF-7 cells
expressing a fluorescently tagged DAXX (Green fluorescent protein, GFP, for example).
We could then in vitro and in vivo determine if ET results in a decrease in GFP signal
within these cells over time. This additionally would allow us to visualize DAXX
expression in mammospheres. We would hypothesize that the GFP signal would be
decreased by ET both in culture and when these cells are implanted in immune
compromised mice. Cells or tumor samples could also be collected at different time
points and stained for TIC-associated markers including NOTCH4 or SOX2 by
immunofluorescence (IF). This would allow for dual staining to confirm the inverse
relationship between DAXX protein expression (GFP label) vs. TIC-associated protein
expression (NOTCH4 with mCherry label for example). Thus, these experiments would
also provide a temporal association between DAXX expression, NOTCH4 expression
and ET. Additionally, using FACS, we could separate GFP-DAXXhigh and DAXXlow cell
populations and conduct further experiments including the mammosphere assay to
determine if these cells have intrinsic differences in % MFE or tumor initiation in vivo.
These DAXX-GFP labeled cells would also be of value for our phytoestrogen
experiments and further testing of other partial ER agonists. This would allow
visualization over time to assess the ability of therapeutics to induce DAXX expression
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in vitro and in vivo in a temporal fashion. Again these samples could also be isolated at
specific time points and co-stained for TIC-markers including NOTCH4 to visually
determine the relationship between DAXX and NOTCH4 expression under conditions of
partial ER activation. Based on results so far, we hypothesize partial ER agonists such
as PEs would increase the DAXX GFP signal and decrease the NOTCH4 mCherry
signal both in vitro and in vivo. Finally, these cells could be used to screen other novel
ER agonists to provide immediate feedback as to whether a specific therapeutic is
sufficient to increase DAXX protein expression in ER+ breast cancer cells.
A legitimate criticism of these experiments is that artificial depletion of DAXX by
siRNA transfection is only transient. Although we report it lasts for at least 7 days
(Figures 38 & 39), ET can be administered for periods of up to 10 years [457]. This
indicates that our acute depletion of DAXX does not necessarily reflect what occurs
under ET conditions in patients. To better model this, complete deletion of DAXX by the
CRISPR/CAS9 system could be used to determine if permanent loss of DAXX results in
an increase of TIC-survival and activity [458]. Using these DAXX KO cells, we could
conduct the same experiments as outlined in our current study, namely
mammospheres, RT-PCR, and ELDA to determine if DAXX is required to restrict TICs.
Additionally, we could do this in combination with transfection of EV or DAXX-containing
vector. This would truly test if DAXX is sufficient to decrease TIC-associated gene
transcript expression and ultimately TIC-survival. We hypothesize that in these cells, ER
activation by E2 or PEs would no longer be sufficient to inhibit TIC-survival. Further
ectopic expression of DAXX would be associated with a decrease in TIC-survival.
Although presumably these sets of experiments would be of value to assess the role of
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DAXX in ER+ breast cancer, recent findings indicate evaluating TIC survival suggest the
CRISPR/CAS9 system may not be optimal [459]. Specifically, it has been shown that
this system inhibits healthy stem cell survival, thus it may artificially skew our results,
leading to incorrect conclusions [459]. Conversely, an inducible knockdown under
control of doxycycline for example would be an alternative strategy. In fact, this method
may be more translationally applicable as ET does not result in complete depletion of
DAXX protein (Figure 12). This again would allow for testing if loss of DAXX for longer
periods of time results in an increase of TIC-survival.
DETERMINE THE MECHANISM FOR ER STABILIZATION OF DAXX
From the standpoint of designing DAXX-promoting therapeutics, determining the
mechanism by which the ER stabilizes the DAXX protein is essential. As outlined in the
discussion, identification of the proteins that regulate DAXX stabilization and/or
degradation would elucidate new therapeutic targets to promote DAXX expression. This
is critical as it may allow for the increase in DAXX independently of the ER. A number of
proteins have been implicated in the degradation/stabilization of DAXX including Mdm2,
USP7, UBC9, SPOP and Cul3. In order to determine which have a role in ER
stabilization of DAXX protein, future studies will consider all of them.
ROLE FOR SPOP AND CULLIN 3
The SPOP/Cul3 pathway of DAXX degradation appears most enticing as reports
from others mirror our own. Specifically, it was shown that MG132 was sufficient to
inhibit the SPOP/Cul3 pathway, leading to DAXX stabilization [448]. Again we have
shown MG132 treatment is sufficient to prevent DAXX depletion by ET (Figures 10 &
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11). To ensure SPOP/CUL3 expression and interaction with DAXX in our ER+ breast
cancer cells, total protein isolation and immunoprecipitation IP experiments will be
performed under conditions of ER activation and inhibition in MCF-7 and T47D cells.
Protein levels will then be determined by Western Blot analysis. One hypothesis would
be growth in E2-supplemented conditions will result in relatively low levels of SPOP
and/or Cul3, and ET increases their protein expression. This is based on reports that
SPOP/Cul3 inhibits ER-responsive genes [449]. Conversely, an alternative hypothesis
is that E2 inhibits SPOP/Cul3 interaction with DAXX, and thus this would prevent the
adaptor protein SPOP from binding DAXX and then the Cul3 enzyme-mediated
ubiquitylation of DAXX for degradation. If this is the case, we would expect to see less
DAXX association with the SPOP/Cul3 complex under E2-supplemented conditions
compared to ET as assessed by immunoprecipitated studies. In parallel with this, the
amount of DAXX ubiquitylation will be determined by immunoprecipitated followed by
Western Blot analysis of Ubiquitin to determine if these levels change under conditions
of ER activation/inhibition. We have shown that proteasome inhibition increases DAXX
levels (Figures 10 & 11), and others have indicated ubiquitylation of DAXX induces its
degradation [448]. Given these findings, we hypothesize that under conditions of ER
inhibition, DAXX ubiquitylation will increase. Further as Kwon et al. have developed and
determined the authenticity of SPOP shRNA vectors, we would hope to obtain these for
future experiments [448]. This would allow transfection of the SPOP shRNA stably into
MCF-7 and T47D cells to determine the effects on DAXX protein level. These would
include growing transfected cells in ER activated or inhibitory conditions and
determining total DAXX protein. If the SPOP/Cul3 complex is required to deplete DAXX
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protein under ET conditions, then loss of SPOP will result in an increase in DAXX
protein levels. Further, we would also assess effects on TIC survival. This would include
conducting mammosphere and RT-PCR experiments to detect TIC-pluripotency gene
transcripts. We hypothesize that loss of SPOP will result in a decrease in TIC-survival
and TIC-associated gene expression and expression of DAXX to remain high in SPOPdepleted conditions. This would be similar to results in which DAXX overexpression
restricted TIC-survival and TIC-associated gene expression (Figures 19 & 26). Similar
experiments could be done with Cul3 knockdwon if needed, however these vectors
would need to first be authenticated. If these experiments confirm the hypotheses, this
would give rationale to use a recently described SPOP-inhibitor to determine its efficacy
as a therapeutic in ER+ breast cancer [460]. This would include in vitro and in vivo
experiments to determine if the SPOP-inhibitor is sufficient to restrict TIC-survival under
ET conditions. These experiments will be done under AI, tamoxifen and fulvestrant
conditions to determine if this is an ER-dependent or -independent mechanism to target
TICs.
ROLE FOR USP7 AND MDM2
As USP7 and Mdm2 are also reported to regulate DAXX protein levels,
experiments targeting these markers with a genetic approach will also be considered
[360, 363]. Due to conflicting reports on whether Mdm2 increases or decreases DAXX
protein, a clear hypothesis cannot be made in our ER+ breast cancer cells, thus these
experiments will be more exploratory [360, 363-365]. However, the notion that Mdm2
activity is increased by ER activation suggests Mdm2 may stabilize DAXX [365]. If we
find that Mdm2 increases DAXX stability and USP7 decreases it, a novel USP7 inhibitor
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has been recently defined and will be used for subsequent experiments [461]. If correct,
these studies will again reveal a novel therapeutic that may potentially inhibit TICsurvival downstream of ER activation.
ROLE FOR UBC9
Our preliminary studies outlined in Appendix Figure 1 as well as previous reports
suggest that UBC9 is required for the nuclear localization of DAXX (Appendix Figure 1)
[443-446]. Further, preliminary results of UBC9 knockdown by siRNA suggest that loss
of UBC9 results in a decrease in DAXX protein (Appendix Figure 1). Additional
experiments would help determine if these results are reproducible and if the hypothesis
is correct. First, as the primary function of UBC9 is addition of small ubiquitin-like
modifier (SUMO) moieties to its substrates, we will first determine if DAXX sumoylation
changes under conditions of ER activation and inhibition. This will be done by growing
cells in their respective conditions, conducting a DAXX IP, and visualizing its SUMO
status by Western Blot analysis for SUMO-1. Based on our preliminary results, we
would expect DAXX sumolyation to decrease under ET conditions, as we have shown
nuclear DAXX decreases under these conditions (Figure 21). Additionally we will
conduct mammosphere and RT-PCR experiments in cells stably transfected with a
previously categorized UBC9 dominant negative [446]. We hypothesize that UBC9
dominate negative will result in nuclear depletion of DAXX, resulting in an increase of
TIC-survival and TIC-associated gene expression. This is based on the expectation that
DAXX is will no longer be in the nucleus under ER activated conditions. If this
hypothesis is correct, the use of DAXX mutants that lack the nuclear localization signal
will be used for further experiments. These nuclear localization signals have been
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previously defined, and vectors generated containing DAXX nuclear localization signal
mutants have been described [462]. Our plan would be to use these vectors to discern if
nuclear DAXX is required to elicit its anti-TIC effects. We hypothesize that cells
transfected with DAXX nuclear localization signal mutants will lack nuclear DAXX, and
this will be associated with an increase in TIC-survival and TIC-associated gene
expression. Together with UBC9 experiments, this would suggest that UBC9 is required
for nuclear localization of DAXX, and this is required for DAXX restriction of TICs. These
experiments would be of lower priority compared to SPOP/Cul3 and Mdm2/USP7
experiments as UBC9 expression is reported to be dependent on ER activation, which
we have also indicated (Appendix Figure 1) [444]. Thus, therapeutics that increase
UBC9 are less likely to be ER independent.
Overall these experiments will hopefully elucidate one or many therapeutic
targets for the stabilization of DAXX protein independent or downstream of the ER. This
will allow for a broader ER+ breast cancer population of therapeutic efficacy and would
also be less likely to induce proliferation of ER dependent cells within the tumor.
FURTHER DETERMINE THE RELEVANCE OF DNMT1 IN ER+ BREAST CANCER
As mentioned in the discussion, our results suggest further experiments are
needed to better understand the role DNMT1 plays in ER+ breast cancer. In ETsensitive cells, we have shown DNMT1 is beneficial as it is required for DAXX to restrict
TIC-survival (Figure 29). Further, its expression is associated with methylation and low
expression of SOX2 (Figure 31). Conversely, when we investigate recurrence free
survival rates in ER+ patients following ET, high DNMT1 expression is associated with a
worse prognosis (Appendix Figure 2). We hypothesize this is due to DNMT1 no longer
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being recruited by DAXX and thus functioning abnormally. This again is supported by
reports indicating in ET-resistant cells, MUC1 has a similar function to DAXX, except it
recruits DNMT1 to genes associated with luminal cell differentiation including CDH1
[450, 451]. To further explore this, a series of experiments to test if DNMT1 promoter
enrichment patterns change in ER+ breast cancer when treated with ET long term will
be conducted.
First to determine if DAXX recruits DNMT1 to TIC-associated promoter genes,
we will conduct DNMT1 ChIP and quantify enrichment at the same regions we
investigated in Figure 23. This will allow for determination of whether DAXX and DNMT1
are co-enriched on the same sites. Further to test if DAXX is required for DNMT1
recruitment to these regions, these experiments will be conducted in SCBi and DAXXi
transfection conditions. We hypothesize under SCBi conditions, DAXX protein levels will
be high and it will be able to recruit DNMT1 to TIC-associated gene promoters. This will
be indicated by DNMT1 enrichment at the same regions quantified in Figure 23.
Conversely, when DAXX is low under ET or DAXXi conditions, we hypothesize that
DNMT1 enrichment at these regions will be decreased. This will more definitively
indicate that DAXX is required for DNMT1 recruitment to these TIC-associated
promoters. Additionally, we have shown that the methylation status of TIC-associated
genes such as SOX2 changes rapidly in response to DAXX depletion by ET or DAXXi.
To further test if DAXX epigenetically regulates gene expression, we will conduct
genome-wide methylation studies. This will allow us to determine in an unbiased
manner if loss of DAXX results in genome-wide changes in methylation of gene
promoters. We hypothesize that a number of genes will become hypo-methylated in
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response to DAXX depletion. This is based on our findings indicating that the ER
requires DAXX to restrict TICs, and previous studies suggesting the ER restricts TICs,
in part through epigenetic regulation [294]. These experiments will be done in parallel
with DNMT1 knockdown conditions. This will allow comparison of which genes have a
similar change in methylation status due to loss of DAXX or DNMT1. Overall these
studies will the determination of specific genes and pathways that are regulated by
DAXX-mediated recruitment of DNMT1. Thus, it will expand on mechanisms by which
ET modulates the genome epigenetically in ER+ breast cancer.
The overall pathological relationship between ER+ breast cancer and DNMT1 will
also be investigated, specifically in the context of what we have found in our own
experiments. To determine if DNMT1 recruitment patterns change in response to ET,
ET-sensitive cells will be treated with ET for short (days) and long (weeks to months)
periods of time. DNMT1 recruitment patterns will then be quantified by ChIP sequencing
and compared when ER is activated by E2 or when the ER is inhibited by estrogen
deprivation or fulvestrant, as well as short term ET compared to long term ET. This
strategy will determine if DNMT1 recruitment patterns change over the course of
therapy in ER+ breast cancer. We hypothesize that over time the DNMT1 recruitment
pattern will change due to depletion of DAXX. Further, we believe this will be associated
with a transition from DNMT1 enrichment at TIC-associated genes to enrichment at
differentiated luminal genes including CDH1 and ESR1. This is based on previous
reports that DNMT1 silences these genes in response to long term ET [66-67, 225,
451]. As DNMT1 expression is associated with loss of ER expression in response to ET,
determining if this is due to changes in DNMT1 recruitment patterns is of clinical
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importance [221-226]. Additionally, parallel experiments will be performed in ETresistant cell lines to determine if the DNMT1 recruitment pattern is different in ETsensitive compared to ET-resistant breast cancer. This is critical in terms of using DAXX
as a therapeutic target in ER+ breast cancer. Specifically, if the change in DNMT1
recruitment pattern is permanent in ET-resistant breast cancer, DAXX may no longer be
able to restrict TIC-survival. This information could be clinically important when using
DAXX-promoting therapeutics for patients with ER+ breast cancer.
INVESTIGATE THE ROLE OF DAXX IN ET-RESISTANT ER+ BREAST CANCER
We have demonstrated the positive effects of the DAXX protein on inhibiting TICsurvival in ET-sensitive breast cancer cell lines (Figures 12 & 19). In ET sensitive cells,
the stability of the DAXX protein is regulated by the ER (Figures 10 & 11). With this
information in mind, partial ER agonists were used to stabilize DAXX without inducing
breast cancer cell proliferation (Figure 37). However, results from ET-resistant breast
cancer cells indicate that this strategy may not be useful. Specifically, in tamoxifen
resistant MCF-7 cells (MCF-7/TAMR), it appears that the ER no longer regulates the
stability of DAXX protein. These MCF-7/TAMR cells retain high levels of the DAXX
protein regardless of ET treatments (Figures 16 & 17). Further, TIC-survival was similar
in response to ER activation or inhibition (Figure 17). However, depletion of DAXX by
siRNA was able to cause an increase in TIC-survival, suggesting DAXX is still required
to restrict TIC-survival (Figure 17). These results suggest that addtional experiments are
needed to discern if DAXX restricts TIC-survival in various ET-resistant breast cancer.
The above outlined DNMT1-focus experiments will aid in discerning whether
DAXX function remains as a TIC-suppressor or changes once cells acquire resistance
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to ET. If ET-resistance is associated with changes in DNMT1 gene-enrichment patterns,
then DAXX will unlikely be able to restrict TICs through recruitment of DNMT1.
Conversely, as DAXX still appears to regulate TIC-survival in 3 distinct ET-resistant cell
lines, the possibility that it does so through different mechanisms will be considered.
This notion is supported by preliminary results indicating that DAXX no longer inhibits
TIC-associated gene expression, but rather induces apoptosis through JNK activation in
the LTED MCF-7/LTED cell line (Appendix Figure 3). How the function of DAXX
changes from sensitive to resistant lines is unknown but will be investigated. One
hypothesis is that DAXX functions through the apoptotic pathway from which it was
initially discovered. Namely DAXX induced caspase independent apoptosis through the
FAS receptor. Future studies will include cell fractionation analysis to determine where
DAXX is localized in ET resistant, MCF-7/5C cells. If DAXX is found to be in the
cytoplasm rather than the nucleus, future experiments will be conducted to identify
potential changes in resistant compared to parental sensitive cell lines. One hypothesis
is that long term estrogen deprivation results in loss the ER-responsive gene, UBE2I
resulting in an inability to add a SUMO group to DAXX, and ultimately preventing its
localization in the nucleus [447]. This will be tested by determining UBC9 levels under
ER inhibition or activation in MCF-7/5C cells. Additionally, experiments of UBC9
overexpression will be conducted to test if this is sufficient to increase nuclear DAXX
levels in MCF-7/5C cells.
As DAXX seems to be independent of ER activation in other ET-resistant cells
(MCF-7/TAMR and MCF-7/FULR), additional studies will need to be considered. This
will include investigating expression levels and activity of markers associated with
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DAXX stability including SPOP/Cul3 and Mdm2/USP7. These experiments will be
critical because they may demonstrate an ER independent therapeutic to stabilize
DAXX. For example, the MCF-7/TAMR cell line expresses relatively high levels of
DAXX independent of the ER activity (Figure 16). One hypothesis is that these cells
have lost expression of SPOP/Cul3, thus DAXX levels remain high regardless of ER
activity. We could test this hypothesis by determining the protein levels of SPOP/Cul3 in
MCF-7/TAMR cells as well as the ubiquitylation status of DAXX under ER activation and
inhibition. Further an inducible SPOP or Cul3 containing vector would test if these
proteins are sufficient to induce DAXX degradation. Although these experiments would
not elucidate a method to target ET-resistant breast cancer through DAXX, they will
provide further evidence of the mechanism by which DAXX is stabilized. This will
potentially provide insight to develop novel therapeutics to use in combination with ET in
patients with a high risk of recurrence.
DETERMINE IF DIFFERENCES IN ER EXPRESSION EXIST WITHIN ER+ BREAST
CANCER TUMOR
Other groups have reported that TICs are intrinsically resistant to ET due to their
low or even lack of expression of the ER [288, 296-297]. The results from the current
study indicate that TICs may express the ER as their survival is inhibited by full (E2) or
partial agonists of the receptor (Figures 12, 19 & 37). This does not necessarily conflict
with previous reports, as low expression of the ER could be sufficient for TICs to
respond to ER agonists. However, it does suggest more studies are needed to
determine the ER status of TICs, and what clinical implications this has with regards to
recurrence of ER+ breast cancer. As mentioned previously, the majority of ER+ tumor
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cells tend to express high amounts of ERα and little to no detectable ERβ [440].
Conversely, one group reported TICs express high amounts of ERβ [454]. However, as
there are no available antibodies to specifically and accurately discern expression levels
of ERα and ERβ proteins, these studies need to be confirmed. As the ratio of ERα/ERβ
may change how ER+ breast cancer cells respond to ER agonists, one hypothesis is
this ratio may also change how cells respond to ER antagonism [404, 412]. If this is
correct, then patients whose tumors express a lower ERα/ERβ ratio may have a higher
risk of recurrence. Thus, these patients may benefit from a different therapeutic regimen
compared to patients whose tumor have high ERα/ERβ ratios. The data so far suggest
that a new therapeutic strategy could be the addition of a partial ER agonist such as a
phytoestrogen (Figure 37).
Future studies will be conducted to test whether a lower ERα/ERβ ratio is
associated with an increased rate of recurrence. Firstly, ERα/ERβ ratios in ET-sensitive
cells from 2-D, bulk cultures will be compared to TIC-enriched, 3-D mammospheres.
This will determine if the ERα/ERβ ratio changes in more differentiated cells compared
to stem-like TICs. The first attempt will be conducted by Western Blot analysis.
However, due to lack of authenticated antibodies-specific to ERα and ERβ, respectively,
this may challenging [441]. If Western blotting is not able to discern between ERα and
ERβ, then RT-PCR will be performed to detect levels of ERα (ESR1) and ERβ (ESR2)
RNA transcripts. Parallel experiments will be done with PDX breast cancer cells from
tumors grown in immunocompromised mice (FOXN1nu/nu, athymic, nudes). These PDX
cells will be isolated into cell cultures from mammospheres. This will provide further
rigor of testing in a heterogeneous model that better translates to the human disease. If
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these experiments yield results that suggest the ERα/ERβ ratio changes in 2-D, bulk
cells compared to 3-D TICs, then, we will conduct further analysis using human breast
cancer specimens. If possible, this will be done through immunofluorescence of human
ER+ breast tumor samples to detect both ER isoforms. Ideally, these would be samples
in which outcome data is already available, allowing correlation of ER isoform staining
with clinical outcome parameters such as recurrence free survival. One hypothesis is
patients with a lower ERα/ERβ ratio have a higher likelihood of recurrence. If this is
correct, experiments will be conducted to determine if the ERα/ERβ ratio is associated
with an increased likelihood of breast cancer recurrence. Further, we will test if tumor
recurrence can be prevented with partial ER agonists such as PEs. Ideally this would
done by sorting ER+ breast cancer cells or PDX cells based on ER expression through
FACS. This would include cells with a high, medium and low ERα/ERβ ratios. We could
then quantify TIC-survival via the mammosphere assay and in vivo TIC frequency
experiments, as well as the gene expression profile of these cells by RT-PCR. However,
due to lack of authenticated antibodies, we may have to consider other methods for
testing our hypotheses. One method would be to generate MCF-7 cell lines that express
endogenous ERα-tagged with GFP and a ERβ-tagged with mCherry using
CRISPR/Cas9 gene insertion editing. Thus, we could distinguish ERα and ERβ based
on their fluorescent signal. Another option would be to transfect ER+ breast cancer cells
with shRNA to ERα or ERβ and evaluate if changes in the ER ratio by shRNA are
associated with altered levels of TIC-survival and/or gene expression. One drawback of
this approach is the depletion of individual ER isoforms may be too extreme in this
scenario and thus may not accurately model TICs within a cell population. We will also
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test if these changes in ER ratios are associated with resistance to ET. This will be done
by conducting growth assays and cell cycle analysis of different ER ratio populations
under E2-supplemented, AI-simulated, SERM and SERD conditions.
Overall these experiments will test whether the ERα/ERβ ratio changes in TICs
and if this is associated with resistance to ETs. These future studies will also determine
if the ERα/ERβ ratio is associated with an increased risk of recurrence in patients. If the
hypotheses are correct and TICs are associated with higher ERβ and an inherent
resistance to ET, this will provide a rationale to determine how better to treat this subset
of patients to improve clinical outcomes.
DETERMINE THE MECHANISM OF PHYTOESTROGENS RESTRICTION OF TICS
TO DESIGN BETTER BREAST CANCER THERAPEUTICS
The results indicate that partial agonists such as phytoestrogens inhibit the
survival of TICs (Figure 37). The mechanism by which phytoestrogens inhibit TIC
survival without stimulating bulk cell proliferation is not known, although it is thought to
be due in part to the inability of phytoestrogens to activate the MAPK cascade [415]. It
is possible that phytoestrogens do not induce total cell proliferation like E2 due to
differences in ER cofactor recruitment. This is based on the findings that cofactor
recruitment determines the extent by which ER regulates gene expression. Also, there
reports demonstrating differences in cofactor recruitment when cells are treated with E2
compared to phytoestrogens [80, 85, 403]. To test this hypothesis, MCF-7 and T47D
cells will be treated with vehicle, E2, or each of the phytoestrogens, the ERα will be
immunoprecipitated followed by immunoblotting to detect distinct cofactors in order to
assess ERα-cofactor interactions. If we are able to identify differences in cofactor
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association with the ER, for example SRC3, we will conduct further experiments to test
whether these cofactors are required for stimulation of bulk cell proliferation. This will be
done using genetic approach. For example we will knockdown SRC3 (if it is
preferentially recruited by E2 + ER complex) under E2 conditions and determine if the
ligand is no longer sufficient to induce cell proliferation. These experiments will allow us
to better understand why phytoestrogens do not activate total cell proliferation but still
partially activate the ER.
A more clear insight of why phytoestrogens are unable to stimulate total cell
proliferation is absolutely critical in order to design pharmaceuticals for future studies.
Precise studies illustrating the structure of the phytoestrogens + ER complex and
interaction with cofactors are needed. Once we have achieved this, it will allow the
designing and testing of small molecules that mimic the beneficial effects of
phytoestrogens, but have a lesser probability of inducing pathological side effects. As
mentioned in the results, one issue with phytoestrogens is their low affinity prevents
their use as a monotherapy in breast cancer. Specifically, as E2 has a higher affinity for
the ER, it is able to outcompete phytoestrogens for the ligand binding domain of the ER,
ultimately resulting in proliferation of the bulk tumor cells [87]. This is why we conducted
our phytoestrogen experiments in AI-simulated conditions. However, if we are able to
design a molecule with a higher affinity for the ER than E2, we may be able to give such
a therapeutic as monotherapy. This is clinically advantageous as AIs are associated
with adverse side effects due to systemic E2 deprivation including bone pain and risk of
bone fractures [154]. Thus, once we understand how the phytoestrogen + ER complex
is beneficial in the context of ER+ breast cancer, we will design small molecules that
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mimic this effect and test their efficacy in cell lines and PDX models. The use of GFPlabeled DAXX cells will be extremely valuable to screen all potential drugs relatively
quickly. Once the ideal compound is identified we will test its ability to reduce TICfrequency by ELDA, the ideal treatment regimen (in conjunction with AIs or given as a
monotherapy), and finally if the therapeutic can prevent cancer recurrence in an animal
model. The recurrence model will be conducted as follows: animals will be implanted
with an E2 capsule and injected with a predetermined number of MCF-7 and/or PDX
tumor cells. Once tumors are palpable (0.20cm2 in area), animals will be treated with E2,
ET, the new drug, or the new drug + ET. Tumors will be measured weekly. We expect
the E2-treated animals to develop large tumors very rapidly. Conversely, tumors in
animals treated with ET and/or new drug-treated will regress. This is because the cells
injected into these animals are sensitive to ET. However, after the tumors regress to
undetectable levels, we will wait a long period of time (i.e. > 6 months) to determine if
tumors recur. This will quantify whether the new drug is more effective at preventing
ER+ breast cancer recurrence in vivo.
Taken together, these future studies will rigorously test a number of hypotheses
and expand on knowledge with the goal to determine mechanisms responsible for tumor
recurrence in ER+ breast cancer. Namely, they will test hypotheses in more clinically
relevant models, provide better models for our future studies, potentially identify a new
way to determine the prognosis in ER+ breast cancer and may ultimately identify a
novel therapeutic strategy to prevent breast cancer recurrence and death.
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MCF-7

APPENDIX FIGURE 1. UBC9 as a regulator of DAXX protein stability and TIC-survival.
A. 5X10^5 MCF-7 and T47D cells were plated in 6 cM dishes and allowed to adhere
overnight. Cells were then washed 3X with PBS and charcoal-stripped media containing
0 nM, 0.5 nM, 5 nM, or 50 nM E2 was added to each plate. Cells were incubated for 3
days, changing the media every day. RNA was isolated and converted to cDNA. RNA
was the isolated and converted to cDNA. Transcript levels of UBC9 (UBE2I) were
measured by RT-PCR using HPRT as an endogenous control. 0 nM E2 transcript levels
were standardized to 1.0 and compared to all E2-treated groups in terms of transcript
levels. B. 1X106 MCF-7 and T47D cells were grown in 0nM E2 (EtOH), 5nM E2 or 5nM
E2 + 100nM Fulvestrant (Fulv) conditions for 3 days in 10cm2 tissue culture dishes.
Following this, total protein lysate was isolated and UBC9 protein levels were
determined by Western Blot analysis. β-ACTIN was used as a loading control. C. 1 X
106 MCF-7 cells were plated and grown transfected with SCBi or UBC9i siRNA for 2
days. Cells were then propagated in 0 or 5 nM E2 conditions for 1 or 3 days. Cells were
then isolated and either total protein or fractionated cytoplasmic and nuclear protein was
isolated from the cells. UBC9 protein levels were then determined by Western Blot
analysis using β-ACTIN as a loading control for the total protein and cytoplasmic
fraction lysates and PARP-1 was used as a loading control for the nuclear fraction
lysates. D. 3X105 MCF-7 were transfected with SCBi or UBC9i for 2 days and then
grown in 0 nM E2 or 5 nM E2 for 3 days. 5X104 MCF-7 were plated in mammosphere
media and allowed to propagate for 7 days. Following which mammospheres were
counted to determine %MFE. The results of all figures are means ± SDs of three
independent experiments. All groups were compared by to SCBi 0 nM E2 conditions by
Two-Way ANOVA to determine statistical significance #= P< 0.05, $= P< 0.01, @= P<
0.001.
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APPENDIX FIGURE 2. DNMT1 lost in LTED MCF-7 cells and sufficient to inhibit TICassociated transcript expression. A. 1X106 MCF-7 or MCF-7/5C cells were plated in 10
cM dishes and allowed to adhere overnight. Cells were then transfected with empty
vector (EV) or a Vector containing DNMT1 (DNMT1) with PEI for 2 days. Cells were
then washed 3X with PBS and charcoal-stripped media containing 0 nM or 5 nM E2 was
added to each plate for 3 days. Total protein lysate was isolated and ERα and DNMT1
protein levels were determined by Western blot analysis using β-ACTIN as a loading
control. B. 1X10^6 MCF-7 and MCF-7/5C cells were plated in 10 cM dishes and allowed
to adhere overnight. First MCF-7/5C cells were then transfected with empty vector (EV)
or a Vector containing DNMT1 (DNMT1) with PEI for 2 days. MCF-7 and MCF-7/5C
cells were then washed 3X with PBS and charcoal-stripped media containing 0 nM or 5
nM E2 was added to each plate for 3 days. Total protein lysate was isolated and DNMT1
protein levels were determined by Western blot analysis using β-ACTIN as a loading
control. C. 3 X 105 MCF-7/5C cells were plated and grown transfected with EV or
DNMT1 vectors for 2 days. Cells were then washed with PBS 3X and propagated in 0 or
5 nM E2 conditions for 1 day. RNA was the isolated and converted to cDNA. Transcript
levels of SOX2, OCT4, NOTCH4, NANOG and ALDH1A1 (ALDH) were measured by
RT-PCR using HPRT as an endogenous control. EV 0 nM E2 transcript levels were
standardized to 1.0 and compared to all groups in terms of transcript levels. The results
of this histogram are means ± SDs of three independent experiments. All groups were
compared by to EV 0 nM E2 conditions by Two-Way ANOVA to determine statistical
significance #= P< 0.05, $= P< 0.01, @= P< 0.001. D. Using the KMplotter software,
recurrence free survival was compared in patients with ER+ breast cancer stratified for
high (top 25%) vs. low (bottom 25%) DNMT1 RNA expression following ET [433].
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APPENDIX FIGURE 3. DAXX is required for E2 induced apoptosis in LTED MCF-7
cells. 1X106 Parental MCF-7 cells and LTED MCF-7 cells (MCF-7/5C) were
transfected with SCBi or DAXXi siRNA for 2 days, following which cells were grown in 0
or 5 nM E2 conditions for 5 days. A. A subset of cells had total protein was isolated and
relative levels of PARP-1, Caspase 8, P-JNK and total JNK were determined by
Western blot analysis using β-ACTIN as a loading control. B. A separate subset of cells
were isolated for FACS analysis of apoptosis via Annexin V + 7-AAD staining. The
results of this histogram are means ± SDs of three independent experiments. All groups
were compared by to SCBi 0 nM E2 conditions by Two-Way ANOVA to determine
statistical significance @= P< 0.001 C. 5X106 were transfected with SCBi or DAXXi for
2 days. Following which cells were immediately plated in mammosphere media and
allowed to grow for 7 days. Mammospheres were then isolated and injected into nude,
female mice along with implantation of a silastic capsule containing E2. Tumors were
measured once a week for 8 weeks. Tumors were then isolated after 8 weeks.
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